Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
7bb7637540cc0f23156786006e367ff679945286d3b3b03a5702d69853cee5c4.png
simple
<table><tr><td>Treatments</td><td>Species</td><td>Duration</td><td>Metabolic disorders</td><td>Potential mechanism</td><td>Reference</td></tr><tr><td>0&#8211;250 &#956;mol/l capsaicin</td><td>3T3-L1 preadipocytes and adipocytes</td><td>24&#8211;72 h</td><td>Decreased the amount of intracellular triglycerides, GPDH activity</td><td>Inhibited the expression of PPAR&#947;, C/EBP-&#945;, and leptin</td><td>Hsu et al. [52]</td></tr><tr><td></td><td></td><td></td><td>Induced apoptosis</td><td>Induced up-regulation of adiponectin at the protein level</td><td></td></tr><tr><td></td><td></td><td></td><td>Inhibited adipogenesis</td><td></td><td></td></tr><tr><td>1 &#956;mol/l capsaicin</td><td>3T3-L1 preadipocytes</td><td>3&#8211;8 days</td><td>Prevented the adipogenesis</td><td>Increased intracellular calcium</td><td>Zhang et al. [53]</td></tr><tr><td>0.015% capsaicin</td><td>Male C57BL/6 mice</td><td>10 weeks</td><td>Decreased triglyceride levels</td><td>Decreased TRPV-1 expression in adipose tissue</td><td>Kang et al. [54]</td></tr><tr><td></td><td></td><td></td><td>Lowered fasting glucose, insulin, and leptin levels</td><td>Increased mRNA/protein of adiponectin in the adipose tissue</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Increased PPAR&#945;/PGC-1&#945; mRNA in the liver</td><td></td></tr><tr><td>10 mg/kg body weight capsaicin</td><td>Std ddY mice</td><td>2 weeks</td><td>Lower body weight</td><td>Increased oxygen consumption</td><td>Ohnuki et al. [55]</td></tr><tr><td></td><td></td><td></td><td>Markedly suppressed body fat accumulation</td><td>Stimulated the secretion of adrenalin</td><td></td></tr><tr><td></td><td></td><td></td><td>Decreased triglyceride levels</td><td></td><td></td></tr><tr><td>0.3% capsinoids</td><td>C57BL/6J mice</td><td>8 weeks</td><td>Suppressed body weight gain under the HFD</td><td>Increased energy expenditure</td><td>Saito et al. [57], Ohyama et al. [58]</td></tr><tr><td></td><td></td><td></td><td>Decreased plasma cholesterol level</td><td>Activation of fat oxidation in skeletal muscle</td><td></td></tr><tr><td></td><td></td><td></td><td>Prevented diet-induced liver steatosis</td><td>Activation lipolysis in BAT</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Increased cAMP levels and PKA activity in BAT</td><td></td></tr><tr><td>0.003%, 0.01%, and 0.03% capsaicin</td><td>wild-type and TRPV1&#8722;/&#8722; mice</td><td>16 weeks</td><td>Promoted weight loss</td><td>Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1&#945;, and PRDM-16 in BAT</td><td>Baskaran et al. [59]</td></tr><tr><td></td><td></td><td></td><td>Enhanced the respiratory exchange ratio</td><td>Increased the phosphorylation of SIRT-1</td><td></td></tr><tr><td></td><td></td><td></td><td>Countered hypercholesterolemia</td><td></td><td></td></tr><tr><td>0.01% capsaicin</td><td>wild-type and TRPV1&#8722;/&#8722; mice</td><td>26 weeks</td><td>Countered obesity</td><td>Promoted SIRT-1 expression</td><td>Baskaran et al. [60]</td></tr><tr><td></td><td></td><td></td><td>Browning of WAT</td><td>Increased the expression of PGC-1&#945;</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Facilitated PPAR&#947;&#8211;PRDM-16 interaction</td><td></td></tr><tr><td>0.01% capsaicin</td><td>wild-type and TRPV1&#8722;/&#8722; mice</td><td>24 weeks</td><td>Ameliorated abnormal glucose homeostasis</td><td>Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells</td><td>Wang et al. [49]</td></tr><tr><td></td><td></td><td></td><td>Increased GLP-1 levels in the plasma and ileum</td><td></td><td></td></tr><tr><td>640 &#956;mol/L, 2 ml/kg capsaicin</td><td>Sprague-Dawley rats</td><td>15 min</td><td>Increased superior mesenteric artery blood flow</td><td>Induced a dichotomous pattern of blood flow changes</td><td>Leung et al. [68]</td></tr><tr><td></td><td></td><td></td><td>Reduction in hydrogen gas clearance</td><td></td><td></td></tr><tr><td>0.01% capsaicin</td><td>C57BL/6J male mice</td><td>9 weeks</td><td>Reduced weight gain</td><td>Modest modulation of the gut microbiota</td><td>Shen et al. [69]</td></tr><tr><td></td><td></td><td></td><td>Improved glucose tolerance</td><td>Up-regulated the expression of <i>Muc2</i> and antimicrobial protein gene <i>Reg3g</i> in the intestine</td><td></td></tr></table>
c6ef97b3f2db6fb67474085b8a5d2a7e2f6a0dcd763fd47d1468108018b6f0cb.png
complex
<table><tr><td>Themes</td><td>Subtheme</td><td>Item</td></tr><tr><td rowspan="9">LEADERSHIP/Governance</td><td>Systematic Approach</td><td>Giving no priority to the discharge planning in heath systemLack of comprehensive plan to develop discharge planning in the ministry of healthLack of patient-centered approach in the health systemLack of systematic and comprehensive approach to the planDisregarding the holistic care in training curriculum</td></tr><tr><td>Structure</td><td>Lack of referral system and rationing of health services systemLack of structured, systematic and coordinated systemLack of comprehensive benefit packageLack of specific standards, rules, regulations on discharge planning</td></tr><tr><td>Management</td><td>Low willpower of senior managersPoor monitoring and evaluation systemPoor and inefficient management in heath systemManagers and policy makers&#8217; inaccurate comprehension of discharge planning</td></tr><tr><td>Communication</td><td>Poor inter and intra sectional contributionLack of defined interaction and communication among medical personnel to provide careWeakness in written supportive policies on discharge planning</td></tr><tr><td>Advocacy</td><td>Lack of home care system in health systemLack of powerful supportive centers (such as community-based organizations)</td></tr></table>
1f51f68348099d86990c166eb9b58073ba902d1ed6327b32d8fbf1291bec2ea4.png
complex
<table><tr><td></td><td>Treatment</td><td>DF</td><td>F-value</td><td>P-value</td><td>R-square</td></tr><tr><td rowspan="3">Emergence Holes</td><td>Depth (D)</td><td>4</td><td>19.90</td><td>&lt;0.001</td><td rowspan="3">68.53</td></tr><tr><td>Volume (V)</td><td>2</td><td>83.25</td><td>&lt;0.001</td></tr><tr><td>Error</td><td>113</td><td></td><td></td></tr><tr><td rowspan="3">Air holes</td><td>Depth (D)</td><td>4</td><td>22.51</td><td>&lt;0.001</td><td rowspan="3">71.60</td></tr><tr><td>Volume (V)</td><td>2</td><td>97.46</td><td>&lt;0.001</td></tr><tr><td>Error</td><td>113</td><td></td><td></td></tr><tr><td rowspan="3">Seed Weight</td><td>Depth (D)</td><td>4</td><td>19.00</td><td>&lt;0.001</td><td rowspan="3">56.84</td></tr><tr><td>Volume (V)</td><td>2</td><td>36.41</td><td>&lt;0.001</td></tr><tr><td>Error</td><td>113</td><td></td><td></td></tr></table>
9bb7b0c4bcdcfcd2ec4630a922264660888e7afb20800717176c56a9486d862c.png
complex
<table><tr><td></td><td></td><td colspan="4">Mcm2 immunoreactivity</td></tr><tr><td>Variable</td><td>Categorisation</td><td>n analysable</td><td>negative (&lt;40%)</td><td>positive (&#8805;40%)</td><td>p<sup>a</sup></td></tr><tr><td colspan="6"><i>Clinico-pathologic data:</i></td></tr><tr><td colspan="6">Age at diagnosis</td></tr><tr><td></td><td>&lt;65 years</td><td>47</td><td>27</td><td>20</td><td>1.000</td></tr><tr><td></td><td>&#8805;65 years</td><td>63</td><td>37</td><td>26</td><td></td></tr><tr><td colspan="6">Gender</td></tr><tr><td></td><td>male</td><td>72</td><td>39</td><td>33</td><td>0.593</td></tr><tr><td></td><td>female</td><td>57</td><td>34</td><td>23</td><td></td></tr><tr><td colspan="6">Ann Arbor Stage</td></tr><tr><td></td><td>1</td><td>15</td><td>10</td><td>5</td><td>0.342</td></tr><tr><td></td><td>2</td><td>34</td><td>15</td><td>19</td><td></td></tr><tr><td></td><td>3</td><td>23</td><td>14</td><td>9</td><td></td></tr><tr><td></td><td>4</td><td>35</td><td>22</td><td>13</td><td></td></tr><tr><td colspan="6">International prognostic index</td></tr><tr><td></td><td>0</td><td>2</td><td>2</td><td>0</td><td>0.122</td></tr><tr><td></td><td>1</td><td>48</td><td>27</td><td>21</td><td></td></tr><tr><td></td><td>2</td><td>21</td><td>14</td><td>7</td><td></td></tr><tr><td></td><td>3</td><td>20</td><td>13</td><td>7</td><td></td></tr><tr><td></td><td>4</td><td>14</td><td>4</td><td>10</td><td></td></tr><tr><td colspan="6">Bone marrow involvement</td></tr><tr><td></td><td>no</td><td>72</td><td>39</td><td>33</td><td>0.414</td></tr><tr><td></td><td>yes</td><td>35</td><td>22</td><td>13</td><td></td></tr><tr><td colspan="6">Extranodal involvement</td></tr><tr><td></td><td>no</td><td>40</td><td>27</td><td>13</td><td>0.103</td></tr><tr><td></td><td>yes</td><td>62</td><td>31</td><td>31</td><td></td></tr><tr><td colspan="6">Bulky disease</td></tr><tr><td></td><td>no</td><td>62</td><td>44</td><td>20</td><td>0.003</td></tr><tr><td></td><td>yes</td><td>35</td><td>13</td><td>22</td><td></td></tr><tr><td colspan="6">Serum levels of LDH at diagnosis</td></tr><tr><td></td><td>&lt;300 U/l</td><td>42</td><td>23</td><td>19</td><td>0.505</td></tr><tr><td></td><td>&#8805;300 U/l</td><td>41</td><td>26</td><td>15</td><td></td></tr></table>
6c99e7e0efdaeba8a0c23211b9ef0e5c22b1941d9525d0ea912676df2640243e.png
complex
<table><tr><td></td><td colspan="2">4-week exposure</td><td colspan="2">13-week exposure</td></tr><tr><td></td><td>Control</td><td>BaSO<sub>4</sub></td><td>Control</td><td>BaSO<sub>4</sub></td></tr><tr><td>BaSO<sub>4</sub> lung burden (mg)</td><td></td><td>0.84 &#177; 0.18</td><td></td><td>1.73 &#177; 0.85</td></tr><tr><td>Total cells (million)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>0.649 &#177; 0.20</td><td>0.562 &#177; 0.12</td><td>0.610 &#177; 0.20</td><td>0.836 &#177; 0.15*</td></tr><tr><td>35 days</td><td>0.580 &#177; 0.11</td><td>0.454 &#177; 0.12</td><td>ND</td><td>ND</td></tr><tr><td>Neutrophils (million)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>0.007 &#177; 0.003</td><td>0.021 &#177; 0.010*</td><td>0.016 &#177; 0.006</td><td>0.204 &#177; 0.175*</td></tr><tr><td>35 days</td><td>0.019 &#177; 0.008</td><td>0.032 &#177; 0.024</td><td>ND</td><td>ND</td></tr><tr><td>Total protein (mg/L)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>60 &#177; 4</td><td>77 &#177; 13*</td><td>52 &#177; 10</td><td>64 &#177; 13</td></tr><tr><td>35 days</td><td>81 &#177; 23</td><td>59 &#177; 13</td><td>ND</td><td>ND</td></tr><tr><td>GGT (nkat/L)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>37 &#177; 17</td><td>40 &#177; 10</td><td>41 &#177; 7</td><td>64 &#177; 13*</td></tr><tr><td>35 days</td><td>42 &#177; 12</td><td>37 &#177; 12</td><td>ND</td><td>ND</td></tr><tr><td>ALP (&#956;kat/L)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>0.83 &#177; 0.16</td><td>0.83 &#177; 0.20</td><td>0.51 &#177; 0.10</td><td>0.87 &#177; 0.21*</td></tr><tr><td>35 days</td><td>0.70 &#177; 0.09</td><td>0.70 &#177; 0.12</td><td>ND</td><td>ND</td></tr><tr><td>MCP-1 (pg/ml)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>14.0 &#177; 0.0</td><td>54.7 &#177; 14.3*</td><td>24.2 &#177; 8.4</td><td>176.7 &#177; 126.1*<sup>#</sup></td></tr><tr><td>35 days</td><td>17.3 &#177; 2.6</td><td>14.7 &#177; 1.7</td><td>ND</td><td>ND</td></tr><tr><td>CINC-1/IL-8 (pg/ml)</td><td></td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>104.2 &#177; 26.7</td><td>158.7 &#177; 22.4*</td><td>93.7 &#177; 18.7</td><td>223.8 &#177; 125.7*</td></tr><tr><td>35 days</td><td>158.8 &#177; 38.1</td><td>167.6 &#177; 41.1</td><td>ND</td><td>ND</td></tr></table>
8ade2678cfc7b5da86fa63a2b845ae395de9548ced3566148b1364670aeb3902.png
complex
<table><tr><td>Fibroblast</td><td>PD+/&#8722; rotenone (R)</td><td>Number of DEGs</td></tr><tr><td rowspan="4">MRC-5</td><td>PD38 &#8722; R to PD38 + R</td><td>1</td></tr><tr><td>PD42 &#8722; R to PD42 + R</td><td>2086</td></tr><tr><td>PD48 &#8722; R to PD48 + R</td><td>3527</td></tr><tr><td>PD52 &#8722; R to PD52 + R</td><td>319</td></tr><tr><td rowspan="6">HFF</td><td>PD22 &#8722; R to PD22 + R</td><td>1</td></tr><tr><td>PD26 &#8722; R to PD26 + R</td><td>4873</td></tr><tr><td>PD30 &#8722; R to PD30 + R</td><td>8151</td></tr><tr><td>PD34 &#8722; R to PD34 + R</td><td>6424</td></tr><tr><td>PD58 &#8722; R to PD58 + R</td><td>5726</td></tr><tr><td>PD74 &#8722; R to PD74 + R</td><td>60</td></tr></table>
442cf6b6d5ee58201439c3b679cfed00f1121ef21daf01b04f858b43d01b9549.png
simple
<table><tr><td> Groups </td><td> AUC </td><td> Sens. </td><td> Spec. </td><td> Acc.</td></tr><tr><td> 0 versus 123 </td><td> 0.945 </td><td> 0.750 </td><td> 0.959 </td><td> 0.930</td></tr><tr><td> 01 versus 23 </td><td> 0.919 </td><td> 0.886 </td><td> 0.900 </td><td> 0.872</td></tr><tr><td> 012 versus 3 </td><td> 0.970 </td><td> 0.986 </td><td> 0.818 </td><td> 0.965</td></tr></table>
a212d6d7f2c979a8b29dbe74a3bf8c9900836be8c7dd0f5cf05ea09a3374f804.png
simple
<table><tr><td>Common name</td><td>Species</td><td>LTA</td><td>LTB</td></tr><tr><td>Deer mouse</td><td>Peromyscus maniculatus</td><td>AY251294</td><td>AY282503</td></tr><tr><td>House mouse</td><td><i>Mus musculus</i></td><td>NM_010735</td><td>MMU16984</td></tr><tr><td>Rat</td><td><i>Rattus norvegicus</i></td><td>NM_080769</td><td>BX883046</td></tr><tr><td>Woodchuck</td><td><i>Marmota monax</i></td><td>AF095586</td><td>AF095587</td></tr><tr><td>Human</td><td><i>Homo sapiens</i></td><td>AY216498</td><td>AY216497</td></tr></table>
ecc28297625b78279cccf66845bb845c4406cebba12cdecd3d02c18e4b516641.png
simple
<table><tr><td>miRNA</td><td>Regulation [17]</td><td>Potential regulation mechanism [17, 18]</td><td>Class [17]</td></tr><tr><td>miR-9-5p</td><td>Up</td><td>Chromosomal gain (1q)</td><td>Late</td></tr><tr><td>miR-15b-5p</td><td>Up</td><td>Chromosomal gain (3q)</td><td>Late</td></tr><tr><td>miR-28-5p</td><td>Up</td><td>Chromosomal gain (3q)</td><td>Early continuous</td></tr><tr><td>miR-100-5p</td><td>Down</td><td>Chromosomal loss (11q)</td><td>Late</td></tr><tr><td>miR-125b-5p</td><td>Down</td><td>Chromosomal loss (11q)</td><td>Late</td></tr><tr><td>miR-149-5p</td><td>Down</td><td>DNA methylation</td><td>Early continuous</td></tr><tr><td>miR-203a-3p</td><td>Down</td><td>DNA methylation</td><td>Early continuous</td></tr><tr><td>miR-375</td><td>Down</td><td>DNA methylation</td><td>Late</td></tr></table>
2a03e4d5656225c5760b05f646cf0ad95496549d352544d36f57781ec0f665a8.png
complex
<table><tr><td> </td><td colspan="8">Period of time</td><td>Significant difference between quarters</td></tr><tr><td> </td><td colspan="2">Quarter 1</td><td colspan="2">Quarter 2</td><td colspan="2">Quarter 3</td><td colspan="2">Quarter 4</td><td> </td></tr><tr><td>Cost category</td><td>Means</td><td>(SD)</td><td>Means</td><td>(SD)</td><td>Means</td><td>(SD)</td><td>Means</td><td>(SD)</td><td> </td></tr><tr><td colspan="10">Direct healthcare costs</td></tr><tr><td> Physicians</td><td>115.00</td><td>(94.54)</td><td>139.14</td><td>(145.99)</td><td>133.33</td><td>(119.93)</td><td>135.91</td><td>(108.93)</td><td>**1 vs. 2; *1 vs. 4</td></tr><tr><td> Physiotherapist</td><td>13.57</td><td>(49.18)</td><td>19.57</td><td>(57.59)</td><td>16.98</td><td>(48.73)</td><td>19.10</td><td>(57.80)</td><td> </td></tr><tr><td> Ambulatory clinic in hospital</td><td>5.17</td><td>(20.14)</td><td>7.92</td><td>(37.99)</td><td>14.99</td><td>(84.45)</td><td>7.75</td><td>(32.38)</td><td> </td></tr><tr><td> Inpatient care</td><td>1436.71</td><td>(4175.58)</td><td>1529.02</td><td>(4774.59)</td><td>723.35</td><td>(2851.91)</td><td>959.82</td><td>(3070.25)</td><td>*2 vs. 3</td></tr><tr><td> Inpatient/outpatient rehabilitation</td><td>1238.61</td><td>(1085.16)</td><td>68.38</td><td>(405.57)</td><td>24.51</td><td>(217.36)</td><td>52.56</td><td>(365.25)</td><td>**1 vs. 2, 1 vs. 3, 1 vs. 4</td></tr><tr><td> Drugs</td><td>325.58</td><td>(178.80)</td><td>339.94</td><td>(203.90)</td><td>337.11</td><td>(200.37)</td><td>312.89</td><td>(204.51)</td><td>**4 vs. 2, 4 vs. 3</td></tr><tr><td>Sum of direct healthcare costs</td><td>3134.64</td><td>(4271.98)</td><td>2104.00</td><td>(4898.88)</td><td>1250.28</td><td>(3010.82)</td><td>1488.07</td><td>(3270.83)</td><td>**1 vs. 2, 1 vs. 3, 1 vs. 4, 2 vs. 3</td></tr><tr><td colspan="10">Direct non-healthcare costs</td></tr><tr><td> Outpatient nursing service</td><td>34.67</td><td>(162.79)</td><td>43.50</td><td>(237.95)</td><td>38.70</td><td>(181.42)</td><td>28.56</td><td>(151.73)</td><td> </td></tr><tr><td> Paid household help</td><td>96.38</td><td>(643.07)</td><td>111.01</td><td>(684.75)</td><td>109.03</td><td>(626.12)</td><td>102.05</td><td>(645.84)</td><td> </td></tr><tr><td> Informal care</td><td>35.45</td><td>(177.98)</td><td>43.72</td><td>(190.73)</td><td>46.47</td><td>(194.71)</td><td>54.74</td><td>(205.98)</td><td>**1 vs. 4</td></tr><tr><td>Sum of direct non-healthcare costs</td><td>166.49</td><td>(710.79)</td><td>198.21</td><td>(811.39)</td><td>194.20</td><td>(729.73)</td><td>185.35</td><td>(743.39)</td><td> </td></tr><tr><td>Sum of costs</td><td>3301.14</td><td>(4353.64)</td><td>2302.21</td><td>(5068.35)</td><td>1444.50</td><td>(3197.00)</td><td>1673.42</td><td>(3402.68)</td><td>**1 vs.2, 1 vs. 3, 1 vs. 4, 2 vs. 3</td></tr></table>
17d5dcb1a24fed8a7c7236f488e89d1b37937620ec521d991ead9873d0e75fc3.png
simple
<table><tr><td>Animal</td><td>Skin non-midge fed**</td><td>Skin midge fed***</td><td>Tonsil</td><td>Lips</td><td>Lung</td></tr><tr><td>Sheep VH56/ 3 dpi</td><td>Minor engorgement, with indistinct vacuolation of epidermal cells.</td><td>Mildly oedematous/focal epidermal crusts/mild dermal inflammation *(lymphocytes, plasma cells and eosinophils).</td><td>Epithelial cells markedly vacuolated. Low numbers of eosinophils in tonsil itself.</td><td>Oedematous (especially around capillaries) and inflamed* (lymphocytes, plasma cells and eosinophils). Indistinct vacuolation of lip epidermal cells.</td><td>Peribronchial connective tissue is markedly oedematous and moderately inflamed*(lymphocytes, plasma cells and eosinophils).</td></tr><tr><td>Sheep VH67/ 4 dpi</td><td>Moderate oedema around capillaries and mild engorgement, mild aggregation of plasma cells around capillaries.</td><td>Moderately oedematous, especially around capillaries, with mild engorgement. Mild aggregation of plasma cells around capillaries, low numbers of neutrophils and eosinophils. Focal collagen necrosis.Note: <i>C. sonorensis</i> were last fed on this sheep 48 h prior to collection of skin samples.</td><td>Epithelial cells markedly vacuolated. Moderate numbers of eosinophils in connective tissue just below epithelium.</td><td>Focally dense aggregates of lymphocytes and plasma cells especially around capillaries and adnexae in mid dermis, lighter inflammation in superficial dermis.</td><td>Moderate inflammation *(lymphocytes, plasma cells) of peribronchial connective tissue.</td></tr><tr><td>Sheep VH58/ 6 dpi</td><td>Mild oedema and moderate engorgement, sparse dermal inflammation *(neutrophils, lymphocytes, plasma cells)</td><td>Moderately oedematous and engorged, with focal degeneration of epidermis. Moderate to marked diffuse dermal inflammation (Figure 2a) *(lymphocytes, plasma cells, eosinophils), with scattered foci of, predominantly, eosinophils associated with collagen necrosis.</td><td>Epithelial cells vacuolated. Glassy appearance to nuclei of macrophages, lymphocytes, plasma cells in lymphoid parenchyma.</td><td>Oedematous (especially around capillaries) and inflamed *(lymphocytes, plasma cells, eosinophils) &#8211; focally markedly so. Indistinct vacuolation of epidermal cells, but also apoptosis, epidermal oedema and erosion.</td><td>Peribronchial connective tissue is moderately oedematous and moderately inflamed *(plasma cells, lymphocytes).</td></tr><tr><td>Sheep VH57/ 8 dpi</td><td>Moderate oedema with mild perivascular inflammation *(lymphocytes and plasma cells).</td><td>Markedly oedematous (dermis and epidermis). Moderate to marked diffuse dermal inflammation around capillaries *(plasma cells, lymphocytes, eosinophils, neutrophils). Some crusts of surface and dermal foci of macrophages, plasma cells, lymphocytes and eosinophils, including granulomas in superficial dermis (neutrophils and eosinophils centrally with encircling epithelioid macrophages (Figure 2b).</td><td>Epithelial cells moderately to markedly vacuolated, numerous lymphocytes and plasma cells in epidermis. Glassy appearance to nuclei of macrophages, lymphocytes and plasma cells in lymphoid parenchyma.</td><td>Moderately oedematous (especially around capillaries) and moderately inflamed *(plasma cells, lymphocytes, rarely eosinophils).</td><td>Peribronchial connective tissue moderately oedematous and moderately inflamed *(plasma cells, lymphocytes). Diffuse engorgement and congestion.</td></tr><tr><td>Sheep VH66/ 9 dpi</td><td>Minor vacuolation of deep sweat gland cells as well as mild oedema with mild perivascular inflammation *(lymphocytes and plasma cells).</td><td>Moderate perivascular oedema and engorgement with patchy haemorrhage. One capillary contained a fibrin thrombus. Moderate to marked inflammation (plasma cells, lymphocytes, eosinophils, and neutrophils).</td><td>Areas of markedly vacuolated epithelial cells. There are also areas containing large numbers of lymphocytes and plasma cells in the tonsillar epithelium.</td><td>Engorged, haemorrhagic and oedematous (especially around capillaries) with mild inflammation *(plasma cells, lymphocytes, eosinophils and macrophages). Endothelial cells in the walls of some capillaries are degenerate.</td><td>Modest peribronchial inflammation *(plasma cells lymphocytes). Mild oedema, moderate engorgement, small numbers of vessels contain fibrin thrombi.</td></tr></table>
36f3056e81180c7927e9c1834545ca05b1bd77acad7dc4065e1ad52d797a1d64.png
complex
<table><tr><td rowspan="2">Age category, y</td><td colspan="3"><i>BRCA1</i> carriers</td><td colspan="3"><i>BRCA2</i> carriers</td></tr><tr><td>No. of events</td><td>HR per unit SD increase in the ER- PRS (95% CI)</td><td><i>P</i>&#8224;</td><td>No. of events</td><td>HR per unit SD increase in the overall BC PRS (95% CI)</td><td><i>P</i>&#8224;</td></tr><tr><td>Outcome: breast cancer</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;39</td><td>4125</td><td>1.63 (1.52 to 1.74)</td><td>&#8211;</td><td>1731</td><td>1.65 (1.44 to 1.88)</td><td>&#8211;</td></tr><tr><td> 40&#8211;49</td><td>2557</td><td>1.18 (1.13 to 1.23)</td><td>4.2 &#215; 10<sup>&#8722;15</sup></td><td>1587</td><td>1.22 (1.14 to 1.31)</td><td>8.5 &#215; 10<sup>&#8722;5</sup></td></tr><tr><td> 50&#8211;59</td><td>846</td><td>1.14 (1.09 to 1.21)</td><td>.40</td><td>718</td><td>1.10 (1.02 to 1.19)</td><td>.05</td></tr><tr><td> &#8805;60</td><td>269</td><td>1.20 (1.11 to 1.29)</td><td>.33</td><td>294</td><td>1.12 (1.03 to 1.23)</td><td>.75</td></tr><tr><td> Interaction HR</td><td></td><td>0.993 (0.990 to 0.996)</td><td>3.3 &#215; 10<sup>&#8722;6</sup></td><td></td><td>0.995 (0.991 to 0.999)</td><td>.01</td></tr><tr><td> Main effect PRS</td><td></td><td>1.69 (1.50 to 1.91)</td><td></td><td></td><td>1.55 (1.29 to 1.87)</td><td></td></tr><tr><td>Outcome: ovarian cancer</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 18&#8211;49</td><td>1258</td><td>1.55 (1.42 to 1.69)</td><td></td><td>172</td><td>3.05 (2.35 to 3.97)</td><td></td></tr><tr><td> 50&#8211;59</td><td>808</td><td>1.11 (1.05 to 1.18)</td><td>1.1 &#215; 10<sup>&#8722;9</sup></td><td>227</td><td>1.52 (1.26 to 1.84)</td><td>8.2 &#215; 10<sup>&#8722;6</sup></td></tr><tr><td> &#8805;60</td><td>396</td><td>1.14 (1.06 to 1.21)</td><td>.67</td><td>232</td><td>1.21 (1.12 to 1.30)</td><td>.03</td></tr><tr><td> Interaction HR</td><td></td><td>0.992 (0.988 to 0.998)</td><td>.003</td><td></td><td>0.991 (0.979 to 1.00)</td><td>.11</td></tr><tr><td> Main effect PRS</td><td></td><td>1.83 (1.43 to 2.34)</td><td></td><td></td><td>2.48 (1.34 to 4.58)</td><td></td></tr></table>
cb8ce80fc6149d3c9af03f52f0bb3075778b8a28e18324e6bfee084838b8cb02.png
simple
<table><tr><td></td><td>Controls</td><td>Pre-RA</td><td>Univariate</td><td></td><td>Multivariate</td><td></td></tr><tr><td></td><td></td><td></td><td>OR (95 % CI)</td><td><i>p</i>-value</td><td>OR (95 % CI)<sup>a</sup></td><td><i>p</i>-value</td></tr><tr><td>Intensity, n (%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Model 1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Never</td><td>133 (44)</td><td>36 (36)</td><td>reference</td><td>-</td><td>reference</td><td>-</td></tr><tr><td>Former</td><td>59 (19)</td><td>28 (28)</td><td>1.90 (1.01&#8211;3.59)</td><td>0.047</td><td>2.48 (1.27&#8211;4.84)</td><td>0.008</td></tr><tr><td>Current</td><td>80 (26)</td><td>30 (30)</td><td>1.45 (0.81&#8211;2.56)</td><td>0.205</td><td>1.57 (0.85&#8211;2.93)</td><td>0.151</td></tr><tr><td>Model 2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Never</td><td>133 (43)</td><td>36 (35)</td><td>reference</td><td>-</td><td>reference</td><td>-</td></tr><tr><td>Current, 1&#8211;15 cig/day</td><td>39 (13)</td><td>20 (20)</td><td>1.88 (0.98&#8211;3.61)</td><td>0.059</td><td>2.16 (1.06&#8211;4.39)</td><td>0.034</td></tr><tr><td>Current, &gt;16 cig/day</td><td>41 (10)</td><td>10 (10)</td><td>0.95 (0.42&#8211;2.13)</td><td>0.905</td><td>0.97 (0.43&#8211;2.28)</td><td>0.974</td></tr><tr><td>Former, quit &#8804;10 years</td><td>27 (9)</td><td>16 (16)</td><td>2.18 (1.04&#8211;4.55)</td><td>0.039</td><td>2.79 (1.29&#8211;6.07)</td><td>0.009</td></tr><tr><td>Former, quit &gt;11 years</td><td>32 (11)</td><td>12 (12)</td><td>1.50 (0.66&#8211;3.41)</td><td>0.328</td><td>2.02 (0.84&#8211;4.89)</td><td>0.115</td></tr><tr><td>Current pipe/cigar/occasional</td><td>31 (10)</td><td>7 (7)</td><td>0.93 (0.36&#8211;2.41)</td><td>0.888</td><td>1.24 (0.46&#8211;3.34)</td><td>0.670</td></tr></table>
d95491750e89eae0ba421c4533e5feedbd50442815562cd940e410acefaeb4df.png
simple
<table><tr><td>Attribute</td><td>Number (%)</td></tr><tr><td>Age</td><td> </td></tr><tr><td>Mean Age</td><td>40.6 years</td></tr><tr><td>Standard deviation</td><td>9.1 years</td></tr><tr><td>Marital status (N = 220)</td><td> </td></tr><tr><td>Married</td><td>229 (71.5)</td></tr><tr><td>Single</td><td>45 (14.1)</td></tr><tr><td>Widowed</td><td>49 (14.4)</td></tr><tr><td>Religion (N = 316)</td><td> </td></tr><tr><td>Islam</td><td>182 (57.6)</td></tr><tr><td>Christian</td><td>134 (42.4)</td></tr><tr><td>Education (N = 300)</td><td> </td></tr><tr><td>None</td><td>8 (2.7)</td></tr><tr><td>Primary</td><td>109 (36.3)</td></tr><tr><td>Secondary</td><td>155 (51.7)</td></tr><tr><td>Post-secondary</td><td>28 (9.3)</td></tr><tr><td>Ethnicity</td><td> </td></tr><tr><td>Yoruba</td><td>284 (89.3)</td></tr><tr><td>Igbo</td><td>26 (8.2)</td></tr><tr><td>Hausa</td><td>8 (2.5)</td></tr></table>
07f0d59bf1586887f4a8d6ba37552e42016731699e2b5fb5657a68b0f92a276a.png
complex
<table><tr><td>Category</td><td>Frequency</td><td>%</td></tr><tr><td><i>Gender</i></td><td> </td><td> </td></tr><tr><td>Female</td><td>91</td><td>49.2</td></tr><tr><td>Male</td><td>94</td><td>50.8</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Age</i></td><td> </td><td> </td></tr><tr><td>&#8804;6 months</td><td>8</td><td>4.3</td></tr><tr><td>&gt;6 months</td><td>176</td><td>95.7</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Gestational age</i></td><td> </td><td> </td></tr><tr><td>&gt;38 weeks</td><td>78</td><td>42.4</td></tr><tr><td>27-34 weeks</td><td>34</td><td>18.5</td></tr><tr><td>34-38 weeks</td><td>72</td><td>39.1</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Birth weight</i></td><td> </td><td> </td></tr><tr><td>&lt;1500g</td><td>20</td><td>10.9</td></tr><tr><td>&gt;2500g</td><td>89</td><td>48.4</td></tr><tr><td>1500-2500g</td><td>75</td><td>40.8</td></tr></table>
403b93c70ee211b2bcf62a2a981aecc26e2885c046e932d2e8d16753e7d669c3.png
simple
<table><tr><td>gene</td><td>forward primer</td><td>reverse primer</td><td>probe</td></tr><tr><td>HPRT</td><td><i>5&#8242;-tgaacgtcttgctcgagatgtg-3&#8242;</i></td><td><i>5&#8242;-ccagcaggtcagcaaagaattt-3&#8242;</i></td><td><i>5&#8242;-tgggaggccatcacattgtagcc-3&#8242;</i></td></tr><tr><td>SNCA</td><td><i>5&#8242;-ccaaagagcaagtgacaaatgttg-3&#8242;</i></td><td><i>5&#8242;-agccagtggctgctgcaat-3&#8242;</i></td><td><i>5&#8242;-tgacgggtgtgacagcagtagccca-3&#8242;</i></td></tr><tr><td>5HT3AR</td><td><i>5-ggctggtgcacaagcaagac-3&#8242;</i></td><td><i>5-ggctggtgcacaagcaagac-3&#8242;</i></td><td><i>5-ctgcttggctgcgtcacctggttct-3&#8242;</i></td></tr><tr><td>5HT4R</td><td><i>5&#8242;-attccgggttgaacccttttc-3&#8242;</i></td><td><i>5&#8242;-aggtcttcggtagcgctcatc-3&#8242;</i></td><td><i>5&#8242;-acgtgccttcctcatcatcctct-3&#8242;</i></td></tr><tr><td>M3R</td><td><i>5&#8242;-cagctgcatacccaaaaccttt-3&#8242;</i></td><td><i>5&#8242;-tgaatgttttgttgcacagagcata-3&#8242;</i></td><td><i>5&#8242;-caacagcaccgtgaaccccgtgtg-3&#8242;</i></td></tr><tr><td>VIP</td><td><i>5&#8242;-aataaggcccagctccttgtg-3&#8242;</i></td><td><i>5&#8242;-cccaacctgagagcagaaggt-3&#8242;</i></td><td><i>5&#8242;-cttctcacagacttcggcatggc-3&#8242;</i></td></tr></table>
75cd19ce06927091ed2972261731e2137eec86d94a2dc274f9492afae0f5b3d8.png
simple
<table><tr><td>Property</td><td>Water</td><td>Blood</td><td>Units</td></tr><tr><td>Density <i>&#961;</i></td><td>1000</td><td>1050 [25]</td><td>kg/m<sup>3</sup></td></tr><tr><td>Specific heat <i>c</i></td><td>4190 [26]</td><td>3850 [25]</td><td>J/(kg &#183; K)</td></tr><tr><td>Thermal conductivity <i>k</i></td><td>0.61 [27]</td><td>0.53 [28]</td><td>W/(m &#183; K)</td></tr><tr><td>Thermal diffusivity <i>&#945; </i>= <i>k</i>/<i>&#961;c</i></td><td>1.4 &#215; 10<sup>-7</sup></td><td>1.3 &#215; 10<sup>-7</sup></td><td>m<sup>2</sup>/s</td></tr><tr><td>Absolute viscosity <i>&#956;</i></td><td>7 &#215; 10<sup>-4 </sup>[26]</td><td>3.5 &#215; 10<sup>-3 </sup>[29]</td><td>Pa &#183; s</td></tr><tr><td>Kinematic viscosity <i>&#957; </i>= <i>&#956;</i>/<i>&#961;</i></td><td>7 &#215; 10<sup>-7</sup></td><td>3.3 &#215; 10<sup>-6</sup></td><td>m<sup>2</sup>/s</td></tr><tr><td>Coefficient of thermal expansion <i>&#946;</i></td><td>2.1 &#215; 10<sup>-4 </sup>[26]</td><td>4.0 &#215; 10<sup>-4 </sup>[30]</td><td>K<sup>-1</sup></td></tr></table>
41e8e737c3c2d8586fb842dd88a878468e40c62c5525fe2fc04eba7482b5e129.png
simple
<table><tr><td>Source</td><td>df</td><td>SS</td><td>MS</td><td>Est. Var.</td><td>%</td></tr><tr><td>Among Pops</td><td>10</td><td>164.219</td><td>16.422</td><td>0.628</td><td>12%</td></tr><tr><td>Among Indiv</td><td>66</td><td>528.158</td><td>8.002</td><td>3.443</td><td>66%</td></tr><tr><td>Within Indiv</td><td>74</td><td>86.000</td><td>1.162</td><td>1.162</td><td>22%</td></tr><tr><td>Total</td><td>150</td><td>778.377</td><td></td><td>5.188</td><td>100%</td></tr></table>
65155ce47de619697536edb74f2ecf0acd75ea354ebc7ec8113da3fd48d472af.png
complex
<table><tr><td></td><td colspan="2"><i>Un-adjusted HRs (95% C.I.)</i></td><td colspan="2"><i>Adjusted</i><sup><i>a </i></sup><i>HRs (95% C.I.)</i></td></tr><tr><td><i>LNs extracted</i></td><td><i>Stage II</i></td><td><i>Stage III</i></td><td><i>Stage II</i></td><td><i>Stage III</i></td></tr><tr><td><underline>5 Years DSS</underline></td><td></td><td></td><td></td><td></td></tr><tr><td>Current guideline</td><td></td><td></td><td></td><td></td></tr><tr><td>&lt; 12</td><td>ref</td><td>ref</td><td>ref</td><td>ref</td></tr><tr><td>&#8805; 12</td><td>0.65 (0.40, 1.07)</td><td>1.13 (0.77, 1.64)</td><td>0.61 (0.37, 1.00)</td><td>0.97 (0.64, 1.46)</td></tr><tr><td>Quartiles</td><td></td><td></td><td></td><td></td></tr><tr><td>1-6</td><td>ref</td><td>ref</td><td>ref</td><td>ref</td></tr><tr><td>7-11</td><td>0.93 (0.60, 1.43)</td><td>1.64 (0.91, 2.94)</td><td>0.85 (0.43, 1.67)</td><td>0.87 (0.41, 1.85)</td></tr><tr><td>12-19</td><td>0.89 (0.58, 1.34)</td><td>0.97 (0.55, 1.71)</td><td>0.68 (0.35, 1.32)</td><td>0.97 (0.55, 1.70)</td></tr><tr><td>&#8805; 20</td><td>0.54 (0.35, 0.83)</td><td>1.02 (0.57, 1.82)</td><td>0.42 (0.20, 0.90)</td><td>0.74 (0.39, 1.40)</td></tr><tr><td><underline>Overall DSS</underline></td><td></td><td></td><td></td><td></td></tr><tr><td>Current guideline</td><td></td><td></td><td></td><td></td></tr><tr><td>&lt; 12</td><td>ref</td><td>ref</td><td>ref</td><td>ref</td></tr><tr><td>&#8805; 12</td><td>0.69 (0.44, 1.07)</td><td>1.09 (0.76, 1.56)</td><td>0.65 (0.42, 1.02)</td><td>0.95 (0.64, 1.40)</td></tr><tr><td>Quartiles</td><td></td><td></td><td></td><td></td></tr><tr><td>1-6</td><td>ref</td><td>ref</td><td>ref</td><td>ref</td></tr><tr><td>7-11</td><td>0.69 (0.37, 1.28)</td><td>0.84 (0.48, 1.48)</td><td>0.75 (0.40, 1.40)</td><td>0.83 (0.47, 1.47)</td></tr><tr><td>12-19</td><td>0.68 (0.38, 1.24)</td><td>1.01 (0.60, 1.70)</td><td>0.67 (0.37, 1.22)</td><td>0.94 (0.56, 1.59)</td></tr><tr><td>&#8805; 20</td><td>0.45 (0.23, 0.87)</td><td>0.94 (0.55, 1.61)</td><td>0.45 (0.23, 0.87)</td><td>0.69 (0.38, 1.26)</td></tr></table>
a6e8860ed712cfa4b2a08c6aeb01c4125584132076bc22a99bcf39cd33ba7408.png
simple
<table><tr><td> </td><td>Total (n = 1,304)</td><td>NSV (n = 806)</td><td>Rape (n = 183)</td><td>NCS (n = 315)</td><td>OR RAPE/NSV</td><td>OR NCS/NSV</td><td>OR Rape/NCS</td><td><i>&#967;</i><sup><i>2</i></sup><i>/F</i><sup>&#8224;</sup></td></tr><tr><td>Have been separated from family</td><td>284 (22.1%)</td><td>137 (17.2%)</td><td>50 (27.8%)</td><td>97 (31.2%)</td><td>1.85**</td><td>2.18**</td><td>0.85</td><td>29.38**</td></tr><tr><td>Have witnessed violent acts against family members or friends</td><td>172 (13.4%)</td><td>84 (10.5%)</td><td>37 (20.3%)</td><td>51 (16.9%)</td><td>2.17**</td><td>1.72**</td><td>1.26</td><td>16.29**</td></tr><tr><td>Had family members or friends violently killed during the war</td><td>515 (40.6%)</td><td>292 (37.3%)</td><td>96 (53.3%)</td><td>127 (41.5%)</td><td>1.92**</td><td>1.19</td><td>1.61</td><td>15.76**</td></tr><tr><td>Experienced pillage or setting your house on fire</td><td>592 (47.1%)</td><td>335 (43.1%)</td><td>116 (65.9%)</td><td>141 (46.4%)</td><td>2.56**</td><td>1.14</td><td>2.23**</td><td>30.15**</td></tr><tr><td>Experienced gunfire attacks</td><td>525 (42.3%)</td><td>276 (35.7%)</td><td>106 (59.6%)</td><td>143 (49.1%)</td><td>2.65**</td><td>1.74**</td><td>1.52</td><td>41.06**</td></tr><tr><td>Have seen somebody being killed</td><td>479 (38.1%)</td><td>245 (31.0%)</td><td>79 (51.3%)</td><td>155 (49.7%)</td><td>2.34**</td><td>2.20**</td><td>1.07</td><td>45.92**</td></tr><tr><td>Have seen dead or mutilated bodies</td><td>491 (38.4%)</td><td>250 (31.5%)</td><td>108 (59.7%)</td><td>133 (43.5%)</td><td>3.21**</td><td>1.67**</td><td>1.92*</td><td>53.79**</td></tr><tr><td>Have been injured during the war</td><td>113 (8.9%)</td><td>36 (4.5%)</td><td>41 (26.3%)</td><td>36 (11.5%)</td><td>7.56**</td><td>2.75**</td><td>2.74**</td><td>79.69**</td></tr><tr><td>Have been in prison</td><td>74 (5.7%)</td><td>6 (7.0%)</td><td>48 (26.7%)</td><td>20 (6.4%)</td><td>48.18**</td><td>9.11**</td><td>5.29**</td><td>183.22**</td></tr><tr><td>Have been enrolled in an armed group</td><td>48 (3.8%)</td><td>3 (.4%)</td><td>25 (16.0%)</td><td>20 (6.4%)</td><td>50.76**</td><td>18.22**</td><td>2.79*</td><td>95.73**</td></tr><tr><td>Have been kidnapped by an armed group</td><td>85 (6.5%)</td><td>16 (2.0%)</td><td>51 (28.0%)</td><td>18 (5.7%)</td><td>19.17**</td><td>2.99**</td><td>6.40**</td><td>165.01**</td></tr><tr><td>Have been forced to kill, injure or rape someone themselves</td><td>75 (5.9%)</td><td>25 (3.3%)</td><td>35 (22.2%)</td><td>14 (4.6%)</td><td>8.45**</td><td>1.42</td><td>5.96*</td><td>85.67**</td></tr><tr><td>Have seen someone being raped</td><td>180 (14.1%)</td><td>67 (8.4%)</td><td>56 (31.6%)</td><td>57 (18.9%)</td><td>5.08**</td><td>2.56**</td><td>1.98**</td><td>72.79**</td></tr><tr><td><i>Total traumatic exposure (mean, SD)</i></td><td>2.83 (2.43)</td><td>2.19 (1.90)</td><td>4.71 (3.05)</td><td>3.16 (2.45)</td><td>2.43**</td><td>1.01**</td><td>1.42**</td><td>86.62**</td></tr></table>
cdf13183f63b9b3bab1f52e69270b83073d111ab328e16ec3a49849e8389ed08.png
complex
<table><tr><td></td><td colspan="5">Screening or Intervention (Dependent Variable)</td></tr><tr><td></td><td>Asked about AOD use</td><td>Suggested cutting down or stopping AOD use</td><td>Referred for specialty care</td><td>Counseled for &gt; = 5 min</td><td>Asked and provided any treatment</td></tr><tr><td>Independent Variable</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td></tr><tr><td>MHI-5 Score (0&#8211;100)</td><td>1.01 [1.00&#8211;1.01]</td><td>1.01 [1.00&#8211;1.02]</td><td>0.97 [0.96&#8211;0.98]***</td><td>0.97 [0.97&#8211;0.98]***</td><td>0.98 [0.97&#8211;0.99]***</td></tr><tr><td colspan="6">PESQ Risk Flags</td></tr><tr><td> Red (vs. Green)</td><td>1.69 [1.19&#8211;2.40]**</td><td>8.89 [5.59&#8211;14.14]***</td><td>2.80 [1.73&#8211;4.54]***</td><td>3.48 [2.29&#8211;5.30]***</td><td>4.44 [3.11&#8211;6.36]***</td></tr><tr><td> Yellow (vs. Green)</td><td>1.36 [0.96&#8211;1.92]</td><td>2.37 [1.37&#8211;4.09]**</td><td>1.14 [0.61&#8211;2.14]</td><td>2.15 [1.35&#8211;3.42]***</td><td>2.03 [1.37&#8211;3.01]***</td></tr><tr><td>Age</td><td>1.25 [1.17&#8211;1.34]***</td><td>0.98 [0.88&#8211;1.11]</td><td>0.96 [0.85&#8211;1.08]</td><td>0.88 [0.80&#8211;0.97]*</td><td>0.93 [0.85&#8211;1.01]</td></tr><tr><td colspan="6">Gender</td></tr><tr><td> Female (vs. Male)</td><td>1.19 [0.93&#8211;1.52]</td><td>0.61 [0.41&#8211;0.91]*</td><td>0.81 [0.53&#8211;1.25]</td><td>0.93 [0.65&#8211;1.33]</td><td>0.81 [0.60&#8211;1.08]</td></tr><tr><td colspan="6">Race</td></tr><tr><td> Black (vs. White)</td><td>0.42 [0.27&#8211;0.66]***</td><td>1.03 [0.51&#8211;2.08]</td><td>1.00 [0.50&#8211;1.99]</td><td>0.91 [0.50&#8211;1.68]</td><td>0.80 [0.48&#8211;1.33]</td></tr><tr><td> Hispanic (vs. White)</td><td>0.40 [0.26&#8211;0.64]***</td><td>0.98 [0.49&#8211;1.97]</td><td>1.17 [0.58&#8211;2.33]</td><td>1.12 [0.62&#8211;2.01]</td><td>0.93 [0.57&#8211;1.54]</td></tr><tr><td> Multi/Other (vs. White)</td><td>0.56 [0.31&#8211;0.99]*</td><td>1.05 [0.41&#8211;2.69]</td><td>0.88 [0.32&#8211;2.38]</td><td>1.46 [0.69&#8211;3.10]</td><td>1.12 [0.58&#8211;2.13]</td></tr><tr><td colspan="6">Mother&#8217;s Education</td></tr><tr><td> At least some college (vs. less than college)</td><td>1.07 [0.81&#8211;1.41]</td><td>0.93 [0.59&#8211;1.45]</td><td>1.10 [0.69&#8211;1.76]</td><td>1.31 [0.89&#8211;1.93]</td><td>1.22 [0.88&#8211;1.69]</td></tr><tr><td colspan="6">Clinic</td></tr><tr><td> Clinic A (vs. Clinic D)</td><td>0.80 [0.52&#8211;1.26]</td><td>1.53 [0.75&#8211;3.12]</td><td>1.45 [0.68&#8211;3.10]</td><td>1.25 [0.67&#8211;2.32]</td><td>1.36 [0.81&#8211;2.30]</td></tr><tr><td> Clinic B (vs. Clinic D)</td><td>0.66 [0.43&#8211;1.02]</td><td>1.08 [0.53&#8211;2.20]</td><td>1.86 [0.92&#8211;3.76]</td><td>1.36 [0.76&#8211;2.44]</td><td>1.26 [0.76&#8211;2.08]</td></tr><tr><td> Clinic C (vs. Clinic D)</td><td>0.87 [0.54&#8211;1.40]</td><td>0.98 [0.45&#8211;2.15]</td><td>1.79 [0.87&#8211;3.69]</td><td>0.79 [0.41&#8211;1.55]</td><td>0.98 [0.56&#8211;1.70]</td></tr></table>
28038510ca983c364308fa41017f319c45fa0da2881343d8ba4f742752a645b8.png
simple
<table><tr><td>Rank</td><td>Feature description</td></tr><tr><td>1</td><td>Cumulative number of <i>30-day readmissions</i></td></tr><tr><td>2</td><td>Presence of <i>acute respiratory failure</i> ICD-9 code</td></tr><tr><td>3</td><td>Number of <i>abnormal sodium level</i> laboratory tests</td></tr><tr><td>4</td><td>Presence of <i>pneumonia (organism unspecified)</i> ICD-9 code</td></tr><tr><td>5</td><td>Number of <i>abnormal chloride level</i> laboratory tests</td></tr><tr><td>6</td><td>Presence of <i>acute kidney failure (unspecified)</i> ICD-9 code</td></tr><tr><td>7</td><td>Presence of <i>diabetes (with other specified manifestations)</i> ICD-9 code</td></tr><tr><td>8</td><td>Presence of <i>acute kidney failure (any)</i> ICD-9 code</td></tr><tr><td>9</td><td>Presence of <i>respiratory failure</i>, WKF</td></tr><tr><td>10</td><td>Presence of <i>disorders of fluid electrolyte and acid-base balance (any)</i> ICD-9 code</td></tr><tr><td>11</td><td>Presence of <i>disorders of fluid/electrolyte/acid-base</i>, WKF</td></tr><tr><td>12</td><td>Number of <i>abnormal albumin level</i> laboratory tests</td></tr><tr><td>13</td><td>Presence of <i>asphyxia and hypoxemia</i> ICD-9 code</td></tr><tr><td>14</td><td>Presence of <i>anemia of chronic illness</i> ICD-9 code</td></tr><tr><td>15</td><td>Presence of <i>hypokalemia</i> ICD-9 code</td></tr></table>
14f140b50063417e99b361fb12576a07bcde169acbd48a093629a3286191be1c.png
simple
<table><tr><td>Location</td><td>Number</td></tr><tr><td>Spleen</td><td>14</td></tr><tr><td>Liver</td><td>13</td></tr><tr><td>Kidney</td><td>2</td></tr><tr><td>Diaphragm</td><td>2</td></tr><tr><td>Pancreas</td><td>2</td></tr></table>
abd5661fc03f71373edd487ee3539ec4afbaa43274e21ea7febc6635be8fc838.png
complex
<table><tr><td rowspan="2">Measure</td><td colspan="4">Whole sample</td><td colspan="4">Males</td><td colspan="4">Females</td><td colspan="2">Mean difference (male&#8211;female)</td></tr><tr><td><i>N</i></td><td>Range</td><td>Mean</td><td>SD</td><td><i>N</i></td><td>Range</td><td>Mean</td><td>SD</td><td><i>N</i></td><td>Range</td><td>Mean</td><td>SD</td><td><i>t</i></td><td><i>p</i></td></tr><tr><td>Social isolation</td><td>2061</td><td>0&#8211;24</td><td>3.29</td><td>4.35</td><td>976</td><td>0&#8211;24</td><td>3.74</td><td>4.51</td><td>1085</td><td>0&#8211;24</td><td>2.87</td><td>4.15</td><td>4.56</td><td>&lt;0.001</td></tr><tr><td>Loneliness</td><td>2051</td><td>0&#8211;8</td><td>1.57</td><td>1.94</td><td>973</td><td>0&#8211;8</td><td>1.51</td><td>1.93</td><td>1078</td><td>0&#8211;8</td><td>1.62</td><td>1.95</td><td>&#8722;1.39</td><td>0.17</td></tr><tr><td>Depression</td><td>2063</td><td>0&#8211;9</td><td>1.81</td><td>2.97</td><td>979</td><td>0&#8211;9</td><td>1.44</td><td>2.70</td><td>1084</td><td>0&#8211;9</td><td>2.13</td><td>3.16</td><td>&#8722;5.32</td><td>&lt;0.001</td></tr></table>
753ac1208bfa11b3518f71b03f8441cfe524387a24dddbdcc3d2c40c27c5c926.png
complex
<table><tr><td rowspan="2">Tap</td><td colspan="2">Channel A</td><td colspan="2">Channel B</td><td>Doppler</td></tr><tr><td>Relative Delay (ns)</td><td>Average Power (dB)</td><td>Relative Delay (ns)</td><td>Average Power (dB)</td><td>Spectrum</td></tr><tr><td>1</td><td>0</td><td>0.0</td><td>0</td><td>&#8211;2.5</td><td>Classic</td></tr><tr><td>2</td><td>310</td><td>&#8211;1.0</td><td>300</td><td>0</td><td>Classic</td></tr><tr><td>3</td><td>710</td><td>&#8211;9.0</td><td>8900</td><td>&#8211;12.8</td><td>Classic</td></tr><tr><td>4</td><td>1090</td><td>&#8211;10.0</td><td>12,900</td><td>&#8211;10.0</td><td>Classic</td></tr><tr><td>5</td><td>1730</td><td>&#8211;15.0</td><td>17,100</td><td>&#8211;25.2</td><td>Classic</td></tr><tr><td>6</td><td>2510</td><td>&#8211;20.0</td><td>20,000</td><td>&#8211;16.0</td><td>Classic</td></tr></table>
d1f28466d378f146c3bc37971c356badbcf5c69a95cb719efd6e194a42f6664c.png
simple
<table><tr><td> </td><td>Invasive fungal rhinosinusitis with orbital complications (<i>n</i> = 35)</td><td>Bacterial rhinosinusitis with orbital complications (<i>n</i> = 65)</td><td>Adjusted odds ratio (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Nasal crust</td><td>14</td><td>1</td><td>77.78 (1.95&#8211;3095.00)</td><td>&lt;0.001</td></tr><tr><td>Oculomotor nerve involvement</td><td>34</td><td>45</td><td>15.11 (2.16&#8211;644.26)</td><td>0.001</td></tr><tr><td>Trochlear nerve involvement</td><td>33</td><td>43</td><td>5.70 (0.52&#8211;62.57)</td><td>0.10</td></tr><tr><td>Optic nerve involvement</td><td>22</td><td>17</td><td>3.77 (1.50&#8211;9.50)</td><td>0.002</td></tr><tr><td>Abducens nerve involvement</td><td>33</td><td>45</td><td>3.70 (0.40&#8211;34.57)</td><td>0.22</td></tr><tr><td>Facial swelling</td><td>10</td><td>8</td><td>2.37 (0.82&#8211;6.80)</td><td>0.10</td></tr><tr><td>Trigeminal nerve involvement</td><td>16</td><td>13</td><td>1.62 (0.77&#8211;3.42)</td><td>0.20</td></tr><tr><td>Pus in middle meatus</td><td>16</td><td>27</td><td>1.36 (0.57&#8211;3.25)</td><td>0.49</td></tr><tr><td>Swelling of middle meatus</td><td>28</td><td>31</td><td>1.29 (0.55&#8211;3.04)</td><td>0.56</td></tr><tr><td>Secretion in nasopharynx</td><td>4</td><td>10</td><td>0.56 (0.18&#8211;1.73)</td><td>0.31</td></tr><tr><td>Proptosis</td><td>27</td><td>45</td><td>0.53 (0.16&#8211;1.79)</td><td>0.30</td></tr><tr><td>Periorbital swelling</td><td>20</td><td>58</td><td>0.32 (0.12&#8211;0.83)</td><td>0.01</td></tr><tr><td>Chemosis</td><td>27</td><td>53</td><td>0.26 (0.06&#8211;1.18)</td><td>0.06</td></tr></table>
7e3e579d0cbfffcdbc81f409ee0ec5e8bee85d191ae243949ac937e896d91694.png
simple
<table><tr><td>Group</td><td>(1a) Ultramutated <i>POLE</i> mutant</td><td>(1b) Hypermutated dMMR/MSI</td><td>(2) CIN/SCNA-high, MSS</td></tr><tr><td>Mutation rate</td><td>++++</td><td>+++</td><td>+</td></tr><tr><td>Somatic copy number alterations</td><td>+/&#8722;</td><td>+</td><td>+++</td></tr><tr><td>Key molecular/genetic abnormality</td><td><i>POLE</i> EDM proofreading mutation</td><td>Defective MMR/MLH1 promoter hypermethylation</td><td>Variety of mutated cancer genes; WNT pathway activation (mostly by APC mutation/inactivation)</td></tr><tr><td>Predominant histological type</td><td>Moderately differentiated adenocarcinoma</td><td>Mucinous, or signet ring, or poorly differentiated adenocarcinoma</td><td>Moderately differentiated adenocarcinoma</td></tr><tr><td>Proportion of all colorectal carcinomas</td><td>&#8764;3 %</td><td>&#8764;13 %</td><td>&#8764;84 %</td></tr><tr><td>Prognosis</td><td>Good (more data required)</td><td>Good/poor after relapse</td><td>Good-poor (depending on other characteristics)</td></tr></table>
60409a6c747c4f6fb540b553c93c9c50d1041c4c0fe08327c9792ae63379b1cc.png
complex
<table><tr><td></td><td colspan="4"><i>N</i><sub>0</sub><i>S</i><sub>0</sub></td><td colspan="4"><i>N</i><sub>0</sub><i>S</i><sub>&#960;</sub></td></tr><tr><td></td><td>HH</td><td>LL</td><td>LH</td><td>HL</td><td>HH</td><td>LL</td><td>LH</td><td>HL</td></tr><tr><td>Obs. 1</td><td>Limited<sup>**</sup></td><td></td><td></td><td></td><td>Limited<sup>**</sup></td><td>Super<sup>*</sup></td><td>Super</td><td></td></tr><tr><td>Obs. 2</td><td>Limited<sup>**</sup></td><td>Limited<sup>**</sup></td><td></td><td>Super</td><td>Limited<sup>**</sup></td><td>Super</td><td></td><td>Limited<sup>**</sup></td></tr><tr><td>Obs. 3</td><td>Limited<sup>**</sup></td><td>Limited<sup>**</sup></td><td>Limited<sup>**</sup></td><td>Limited<sup>*</sup></td><td></td><td>Super<sup>**</sup></td><td>Super</td><td></td></tr><tr><td>Obs. 4</td><td>Limited<sup>**</sup></td><td></td><td>Limited<sup>**</sup></td><td>Limited<sup>**</sup></td><td>Limited<sup>**</sup></td><td>Super</td><td></td><td></td></tr></table>
221b3da9e5cb348697d57c9fac38be5bf988ef4562eaea777a5b929930907117.png
complex
<table><tr><td>Regimens of first-line chemotherapy</td><td>Overall</td><td colspan="2">MTB or MK infection</td></tr><tr><td></td><td></td><td>(+)</td><td>(&#8211;)</td></tr><tr><td></td><td>N = 30</td><td>N = 7</td><td>N = 23</td></tr><tr><td>Intensive regimens</td><td>26</td><td>6</td><td>20</td></tr><tr><td> FOLFOX</td><td>8</td><td>2</td><td>6</td></tr><tr><td> FOLFOX + Bmab</td><td>6</td><td>1</td><td>5</td></tr><tr><td> FOLFIRI</td><td>6</td><td>1</td><td>5</td></tr><tr><td> FOLFOX + Pmab/Cmab</td><td>2</td><td>2</td><td>0</td></tr><tr><td> FOLFIRI + Pmab/Cmab</td><td>2</td><td>0</td><td>2</td></tr><tr><td> FOLFIRI + Bmab</td><td>1</td><td>0</td><td>1</td></tr><tr><td> XELOX</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Non-intensive regimens</td><td>4</td><td>1</td><td>3</td></tr><tr><td> UFT/LV</td><td>1</td><td>1</td><td>0</td></tr><tr><td> S-1</td><td>2</td><td>0</td><td>2</td></tr><tr><td> Capecitabine</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Response rate (%)</td><td>40.0</td><td>28.6</td><td>43.5</td></tr><tr><td> CR</td><td>1</td><td>1</td><td>0</td></tr><tr><td> PR</td><td>11</td><td>1</td><td>10</td></tr><tr><td> SD</td><td>10</td><td>2</td><td>8</td></tr><tr><td> PD</td><td>7</td><td>3</td><td>4</td></tr><tr><td> NE</td><td>1</td><td>0</td><td>1</td></tr></table>
16b96a4e44db1aeaad23a92d850fb7454870e6bf92342ab55f032e7a36dd9d6f.png
complex
<table><tr><td rowspan="2">Days</td><td colspan="4">Body weight (g)</td></tr><tr><td>N30 (100 mg/kg)</td><td>N30 (50 mg/kg)</td><td>Solvent control</td><td>Control</td></tr><tr><td>0</td><td>17.0 &#177; 1.1</td><td>17.0 &#177; 1.3</td><td>16.0 &#177; 0.9</td><td>15.9 &#177; 0.7</td></tr><tr><td>5</td><td>23.7 &#177; 0.9</td><td>21.6 &#177; 1.0</td><td>22.0 &#177; 1.9</td><td>22.7 &#177; 1.3</td></tr><tr><td>10</td><td>28.5 &#177; 2.1</td><td>26.3 &#177; 0.9</td><td>26.2 &#177; 2.3</td><td>27.6 &#177; 1.0</td></tr><tr><td>14</td><td>30.1 &#177; 2.5</td><td>27.7 &#177; 1.5</td><td>27.9 &#177; 2.6</td><td>29.9 &#177; 1.6</td></tr></table>
dd413b34451d96e41b227e96434f37b228eed4f4fe2ebee94fcc2b93e8f9e8ef.png
complex
<table><tr><td colspan="5">Activity against the Isolates</td></tr><tr><td rowspan="2">Antibiotics</td><td rowspan="2">Resistance Prevalence (%)</td><td colspan="3">MIC (mg L<sup>&#8722;1</sup>)</td></tr><tr><td>Range</td><td>50%</td><td>90%</td></tr><tr><td>Ampicillin (AMP)</td><td>100.0</td><td>64 to &#8805;1024</td><td>1024</td><td>1024</td></tr><tr><td>Amoxicillin (AMO)</td><td>100.0</td><td>1 to &#8805;1024</td><td>1024</td><td>1024</td></tr><tr><td>Streptomycin Sulfate (STR)</td><td>92.3</td><td>1 to &#8805;1024</td><td>128</td><td>512</td></tr><tr><td>Trimethoprim (TRI)</td><td>98.0</td><td>8 to &#8805;1024</td><td>1024</td><td>1024</td></tr><tr><td>Chloramphenicol (CHL)</td><td>100.0</td><td>256 to &#8805;1024</td><td>1024</td><td>1024</td></tr><tr><td>Sulfonamide (SUL)</td><td>100.0</td><td>512 to &#8805;1024</td><td>1024</td><td>1024</td></tr><tr><td>Tetracycline (TET)</td><td>90.6</td><td>2 to &#8805;512</td><td>128</td><td>256</td></tr><tr><td>Oxytetracycline (OXY)</td><td>90.6</td><td>1 to &#8805;1024</td><td>256</td><td>512</td></tr><tr><td>Nalidixic Acid (NAL)</td><td>73.6</td><td>1 to &#8805;1024</td><td>512</td><td>1024</td></tr><tr><td>Erythromycin (ERY)</td><td>92.5</td><td>4 to &#8805;1024</td><td>128</td><td>512</td></tr><tr><td>Spiramycin (SPIRA)</td><td>90.6</td><td>2 to &#8805;1024</td><td>512</td><td>1024</td></tr><tr><td>Kanamycin (KAN)</td><td>54.7</td><td>1 to &#8805;1024</td><td>128</td><td>1024</td></tr></table>
a454960f6b3ff022af55b951c977c7755a7ad250fd0dbc6eaa2df157e439a97b.png
complex
<table><tr><td></td><td>Cases (n = 830)</td><td>Controls (n = 907)</td><td>P</td></tr><tr><td>Age*</td><td>43 (39&#8211;47)</td><td>41 (36&#8211;44)</td><td>&lt;0.001</td></tr><tr><td>Female</td><td>354 (43%)</td><td>407 (45%)</td><td>0.421</td></tr><tr><td>Black</td><td>353 (43%)</td><td>354 (39%)</td><td>0.207</td></tr><tr><td>HTN</td><td>371 (45%)</td><td>181 (20%)</td><td>&lt;0.001</td></tr><tr><td>MI</td><td>62 (7.5%)</td><td>14 (1.5%)</td><td>&lt;0.001</td></tr><tr><td>DM</td><td>147 (18%)</td><td>55 (6%)</td><td>&lt;0.001</td></tr><tr><td>Smoking</td><td>348 (42%)</td><td>257 (28%)</td><td>&lt;0.001</td></tr><tr><td>OC</td><td>57 (16%)</td><td>34 (8%)</td><td>&lt;0.001</td></tr><tr><td colspan="4">Migraine</td></tr><tr><td> MWA</td><td>226 (27%)</td><td>193 (21%)</td><td>0.005</td></tr><tr><td> MWoA</td><td>56 (7%)</td><td>73 (8%)</td><td>0.346</td></tr></table>
729fab2eca04a494ae3085d0ddd4e05a17c379ee43a444eed413184f30372909.png
complex
<table><tr><td rowspan="2">Characteristics, n (%)</td><td>Participants completing the SF-6D</td><td>Participants completing the EQ-5D-3L</td></tr><tr><td>(N = 1021)</td><td>(N = 1015)</td></tr><tr><td>Female</td><td>521 (51.0)</td><td>512 (50.4)</td></tr><tr><td>Age (years)</td><td></td><td></td></tr><tr><td> 21-29</td><td>190 (18.6)</td><td>194 (19.1)</td></tr><tr><td> 30-39</td><td>222 (21.7)</td><td>228 (22.5)</td></tr><tr><td> 40-49</td><td>272 (26.6)</td><td>269 (26.5)</td></tr><tr><td> 50-59</td><td>206 (20.2)</td><td>200 (19.7)</td></tr><tr><td> 60+</td><td>131 (12.8)</td><td>124 (12.2)</td></tr><tr><td>Ethnicity</td><td></td><td></td></tr><tr><td> Chinese</td><td>392 (38.4)</td><td>387 (38.1)</td></tr><tr><td> Malay</td><td>396 (38.8)</td><td>399 (39.3)</td></tr><tr><td> Indian</td><td>233 (22.8)</td><td>229 (22.6)</td></tr><tr><td>Education level</td><td></td><td></td></tr><tr><td> Primary (6 years) or less</td><td>177 (17.3)</td><td>190 (18.7)</td></tr><tr><td> Secondary (11 years)</td><td>562 (55.0)</td><td>576 (56.8)</td></tr><tr><td> Diploma/degree or higher</td><td>282 (27.6)</td><td>249 (24.5)</td></tr><tr><td>Married/partner</td><td>765 (74.9)</td><td>761 (75.0)</td></tr><tr><td>Employed or self-employed</td><td>659 (64.5)</td><td>643 (63.4)</td></tr><tr><td>General health status</td><td></td><td></td></tr><tr><td> Poor</td><td>4 (0.4)</td><td>8 (0.8)</td></tr><tr><td> Fair</td><td>70 (6.9)</td><td>99 (9.8)</td></tr><tr><td> Good</td><td>443 (43.4)</td><td>424 (41.8)</td></tr><tr><td> Very good</td><td>419 (41.0)</td><td>383 (37.7)</td></tr><tr><td> Excellent</td><td>85 (8.3)</td><td>101 (10.0)</td></tr><tr><td>Self-reported health on EQ-5D-3L VAS, Mean (SD)</td><td>84.5 (11.2)</td><td>83.0 (12.1)</td></tr></table>
13a29c9af5a704394e34d37d9de45de8fde60562d85c0cf3193e0a4d01bc39d5.png
simple
<table><tr><td>Study</td><td>Year</td><td><i>N</i></td><td>Criteria</td><td>Treatment</td><td>Findings</td></tr><tr><td>Hu et al. [6]</td><td>2006</td><td>84</td><td>Solitary brain metastasis</td><td>SRS or surgery</td><td>Stage I intrathoracic patients had better OS outcomes than stage III</td></tr><tr><td>Bonnette et al. [7]</td><td>2001</td><td>108</td><td>Brain metastasis (98 with solitary)</td><td>Surgery</td><td>Adenocarcinoma, T stage, complete resection with better outcomes</td></tr><tr><td>Rodrigues et al. [8]</td><td>2011</td><td>66</td><td>&#8804;6 intracranial lesions</td><td>Image-guided SIB RT</td><td>Presence of systemic disease, lower performance status correlated with decreased OS</td></tr><tr><td>Iwasaki et al. [9]</td><td>2004</td><td>41</td><td>Solitary brain metastasis</td><td>Resection of primary site and brain metastasis</td><td>Risk score criteria for improved OS:adenocarcinoma, node-negative, normal CEA level</td></tr><tr><td>Mussi et al. [10]</td><td>1996</td><td>52</td><td>Solitary brain metastasis</td><td>Resection of primary site and brain metastasis</td><td>No status, lobectomy associated with decreased OS. 5-year OS in patients with synchronous/metachronous lesions 6.6/19%, respectively</td></tr><tr><td>Machiarini et al.[11]</td><td>1991</td><td>37</td><td>Solitary brain metastasis. Synchronous (&lt;1 month) and metachronous included.</td><td>Resection of primary site and brain metastasis</td><td>Most frequent site of first recurrence was ipsilateral thorax (<i>n</i> = 14) and brain (<i>n</i> = 6). The receipt of adjuvant chemotherapy was strongest predictor of disease-free interval</td></tr><tr><td>Wronski et al. [12]</td><td>1995</td><td>231</td><td>Single (87%) or multiple (13%) metastatic intracranial lesions</td><td>Resection</td><td>Female gender, complete location, infratentorial location, no systemic metastases, age &lt; 60 years associated with improved OS</td></tr></table>
f7a757bc38771052098f0047c57af62d41986a61a9b7ff56ac401fc3b27ecd15.png
complex
<table><tr><td></td><td colspan="6">Average weekly doses (IU/kg)</td></tr><tr><td>Population by</td><td colspan="3">Weeks 12&#8211;24</td><td colspan="3">Weeks 37&#8211;52</td></tr><tr><td>Frequency of administration</td><td>n (%)</td><td>Mean &#177; SD</td><td>Median (Range)</td><td>n (%)</td><td>Mean &#177; SD</td><td>Median (Range)</td></tr><tr><td>3&#215; per week</td><td>158 (100.0)</td><td>103.5 &#177; 88.0</td><td>77.9 (13.3&#8211;804.0)</td><td>126 (79.8)</td><td>114.4 &#177; 130.7</td><td>90.5 (0.0&#8211;1293.6)</td></tr><tr><td>2&#215; per week</td><td>150 (100.0)</td><td>76.9 &#177; 58.5</td><td>62.2 (11.5&#8211;417.5)</td><td>131 (87.3)</td><td>79.2 &#177; 68.6</td><td>62.01 (2.5&#8211;436.5)</td></tr><tr><td>1&#215; per week</td><td>103 (100.0)</td><td>65.9 &#177; 57.8</td><td>48.8 (2.3&#8211;335.0)</td><td>88 (85.4)</td><td>80.9 &#177; 96.8</td><td>47.5 (0.0&#8211;622.6)</td></tr><tr><td>Dialysis type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Predialysis</td><td>32 (100.0)</td><td>87.7 &#177; 73.5</td><td>56.0 (19.1&#8211;335.0)</td><td>26 (81.2)</td><td>122.6 &#177; 133.3</td><td>73.2 (14.9&#8211;622.6)</td></tr><tr><td>Haemodialysis</td><td>288 (100.0)</td><td>82.3 &#177; 57.9</td><td>66.5 (2.3&#8211;396.0)</td><td>242 (84.0)</td><td>90.5 &#177; 102.6</td><td>69.0 (0.0&#8211;1293.6)</td></tr><tr><td>Peritoneal dialysis</td><td>91 (100.0)</td><td>89.8 &#177; 107.3</td><td>60.4 (12.2&#8211;804.0)</td><td>77 (84.6)</td><td>88.8 &#177; 92.4</td><td>61.9 (4.4&#8211;436.5)</td></tr><tr><td>Total</td><td>411 (100.0)</td><td>84.4 &#177; 72.7</td><td>64.8 (2.3&#8211;804.0)</td><td>345 (83.9)</td><td>92.5 &#177; 103.1</td><td>66.0 (0.0&#8211;1293.6)</td></tr></table>
639ab3402bb89d3da3862277251632a5ff0ed2e21fc23cd02b2149fc6c3820f2.png
complex
<table><tr><td>Spot no</td><td>Fold difference</td><td colspan="2">Average normalized volumes</td></tr><tr><td></td><td></td><td>HF</td><td>KF</td></tr><tr><td>102</td><td>4.9</td><td>1.474</td><td>0.301</td></tr><tr><td>94</td><td>10.1</td><td>0.337</td><td>3.404</td></tr><tr><td>101</td><td>26.7</td><td>0.121</td><td>3.220</td></tr><tr><td>105</td><td>6.8</td><td>0.452</td><td>3.090</td></tr><tr><td>103</td><td>11.0</td><td>1.516</td><td>0.138</td></tr><tr><td>86</td><td>7.6</td><td>0.358</td><td>2.738</td></tr><tr><td>83</td><td>4.6</td><td>1.506</td><td>0.330</td></tr><tr><td>96</td><td>5.0</td><td>0.442</td><td>2.215</td></tr><tr><td>90</td><td>5.4</td><td>0.484</td><td>2.633</td></tr><tr><td>99</td><td>4.6</td><td>0.601</td><td>2.786</td></tr><tr><td>129</td><td>3.8</td><td>0.441</td><td>1.692</td></tr><tr><td>125</td><td>6.1</td><td>0.524</td><td>3.219</td></tr><tr><td>145</td><td>3.5</td><td>0.666</td><td>2.324</td></tr><tr><td>148</td><td>7.7</td><td>0.283</td><td>2.180</td></tr><tr><td>144</td><td>36.9</td><td>0.074</td><td>2.725</td></tr><tr><td>110</td><td>4.8</td><td>1.343</td><td>0.280</td></tr><tr><td>104</td><td>7.7</td><td>1.508</td><td>0.196</td></tr><tr><td>116</td><td>6.1</td><td>0.430</td><td>2.616</td></tr><tr><td>135</td><td>3.1</td><td>0.663</td><td>2.026</td></tr><tr><td>122</td><td>3.7</td><td>0.738</td><td>2.698</td></tr><tr><td>35</td><td>3.6</td><td>0.599</td><td>2.163</td></tr><tr><td>27</td><td>6.8</td><td>1.537</td><td>0.226</td></tr><tr><td>39</td><td>4.2</td><td>0.566</td><td>2.363</td></tr><tr><td>46</td><td>4.9</td><td>0.659</td><td>3.250</td></tr><tr><td>38</td><td>9.8</td><td>0.374</td><td>3.662</td></tr><tr><td>16</td><td>5.3</td><td>2.011</td><td>0.381</td></tr><tr><td>10</td><td>5.3</td><td>2.046</td><td>0.389</td></tr><tr><td>19</td><td>3.3</td><td>0.576</td><td>1.925</td></tr><tr><td>24</td><td>5.0</td><td>1.465</td><td>0.290</td></tr><tr><td>18</td><td>6.9</td><td>0.362</td><td>2.506</td></tr><tr><td>65</td><td>6.5</td><td>1.664</td><td>0.257</td></tr><tr><td>56</td><td>5.2</td><td>0.469</td><td>2.455</td></tr><tr><td>73</td><td>9.2</td><td>1.553</td><td>0.169</td></tr><tr><td>69</td><td>7.2</td><td>0.364</td><td>2.635</td></tr><tr><td>71</td><td>3.2</td><td>1.307</td><td>0.410</td></tr><tr><td>48</td><td>4.2</td><td>0.717</td><td>2.991</td></tr><tr><td>45</td><td>6.1</td><td>3.287</td><td>0.538</td></tr><tr><td>52</td><td>4.5</td><td>2.628</td><td>0.589</td></tr><tr><td>55</td><td>5.2</td><td>1.772</td><td>0.341</td></tr><tr><td>51</td><td>11.1</td><td>0.235</td><td>2.618</td></tr></table>
96fb93493d85efa67820fa633499427bbafba926bdc033848950689859aad201.png
simple
<table><tr><td></td><td>Diabetic (<i>N</i> = 8)</td><td>Non-diabetic (<i>N</i> = 60)</td><td><i>p</i> value</td></tr><tr><td>Days till admission, median (range)</td><td>4 (0&#8211;49)</td><td>15 (0&#8211;49)</td><td>0.367</td></tr><tr><td>Referral, No (%)</td><td></td><td></td><td>0.088</td></tr><tr><td> Admission to hospital &gt; 1 day</td><td>7 (87.5)</td><td>49 (81.7)</td><td></td></tr><tr><td> Admission to hospital refused by patient</td><td>1 (12.5)</td><td>0 (0.0)</td><td></td></tr><tr><td> Day treatment</td><td>0 (0.0)</td><td>11 (18.3)</td><td></td></tr><tr><td>Additional hospitalization, No (%)<sup>a</sup></td><td>1 (12.5)</td><td>8 (13.6)</td><td>1.000</td></tr><tr><td>Median length of stay, days (range)</td><td>20 (4&#8211;41)</td><td>5 (1&#8211;30)</td><td>0.025</td></tr><tr><td>Complications, No (%)<sup>b</sup></td><td>5 (62.5)</td><td>10 (17.5)</td><td>0.013</td></tr><tr><td>Treatment, No (%)<sup>a</sup></td><td></td><td></td><td>0.549</td></tr><tr><td> Graft</td><td>7 (87.5)</td><td>54 (91.5)</td><td></td></tr><tr><td> Necrotectomy only</td><td>0 (0.0)</td><td>1 (1.7)</td><td></td></tr><tr><td> Conservative</td><td>1 (12.5)</td><td>4 (6.8)</td><td></td></tr><tr><td>Additional surgery, No (%)<sup>a</sup></td><td>2 (25.0)</td><td>4 (6.8)</td><td>0.147</td></tr><tr><td>Complete epithelialization after first treatment, No (%)<sup>c</sup></td><td>6 (85.7)</td><td>45 (83.3)</td><td>1.000</td></tr><tr><td>Days till complete epithelialization, median (range)</td><td>44 (17&#8211;93)</td><td>31 (10&#8211;192)</td><td>0.660</td></tr><tr><td>Take graft, No (%)<sup>d</sup></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>0.365</td></tr><tr><td> Good</td><td>6 (75.0)</td><td>48 (85.7)</td><td></td></tr><tr><td> Moderate</td><td>1 (12.5)</td><td>4 (7.1)</td><td></td></tr><tr><td> Inapplicable</td><td>1 (12.5)</td><td>4 (7.1)</td><td></td></tr></table>
feeac364f01495fcb9f4651f63409117fd05d539deeb61078e1c130645ecd815.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td><i>p</i>-value</td><td>OR (95% CI)</td><td><i>p</i>-value</td><td>OR (95% CI)</td></tr><tr><td>Age</td><td>0.011*</td><td>1.038 (1.008 ~ 1.068)</td><td>0.004*</td><td>1.048 (1.015 ~ 1.081)</td></tr><tr><td>Male sex</td><td>0.197</td><td>1.631 (0.776 ~ 3.428)</td><td>0.194</td><td>1.748 (0.753 ~ 4.060)</td></tr><tr><td>Hypertension</td><td>0.182</td><td>1.689 (0.783 ~ 3.643)</td><td></td><td></td></tr><tr><td>Diabetes</td><td>0.151</td><td>1.622 (0.838 ~ 3.140)</td><td></td><td></td></tr><tr><td>Cigarette smoking</td><td>0.036*</td><td>2.068 (1.048 ~ 4.081)</td><td>0.015*</td><td>2.764 (1.215 ~ 6.289)</td></tr><tr><td>Daily alcohol use</td><td>0.068</td><td>2.566 (0.934 ~ 7.045)</td><td>0.345</td><td>1.722 (0.558 ~ 5.317)</td></tr><tr><td>Right hemispheric involvement</td><td>0.377</td><td>1.381 (0.674 ~ 2.830)</td><td></td><td></td></tr><tr><td colspan="5">Stroke syndrome (ref. lacunar syndrome)</td></tr><tr><td> Major hemispheric</td><td>0.001*</td><td>5.070 (1.864 ~ 13.791)</td><td>0.003*</td><td>4.781 (1.711 ~ 13.356)</td></tr><tr><td> Minor hemispheric</td><td>0.698</td><td>1.334 (0.311 ~ 5.726)</td><td>0.809</td><td>1.199 (0.275 ~ 5.221)</td></tr><tr><td> Brainstem-cerebellum</td><td>0.227</td><td>1.988 (0.652 ~ 6.063)</td><td>0.294</td><td>1.831 (0.592 ~ 5.664)</td></tr></table>
401a61d0feb2513d5e2fd2a76fe201eef49061994571cc99ef17e4d9d9692f83.png
simple
<table><tr><td>Angiographic result</td><td>Total (<i>n</i> = 108) (%)</td><td>Anterior circulation (<i>n</i> = 92) (%)</td><td>Posterior circulation (<i>n</i> = 16) (%)</td></tr><tr><td>mTICI 0</td><td>8 (7.4)</td><td>4 (4.4)</td><td>4 (25)</td></tr><tr><td>mTICI 1</td><td>8 (7.4)</td><td>7 (7.6)</td><td>1 (6.3)</td></tr><tr><td>mTICI 2a</td><td>10 (9.3)</td><td>9 (9.8)</td><td>1 (6.3)</td></tr><tr><td>mTICI 2b</td><td>39 (36.1)</td><td>37 (40.2)</td><td>2 (12.5)</td></tr><tr><td>mTICI 3</td><td>43 (39.8)</td><td>35 (38.0)</td><td>8 (50)</td></tr></table>
02834ddfdf1fdccb9c880778e9df4add454e48c3a009adcba73b6210f61ae363.png
simple
<table><tr><td>Method</td><td>Phen. allowed <sup>a</sup></td><td>Input values <sup>b</sup></td><td><i>K</i><sup>c</sup></td><td>Link</td></tr><tr><td>Ref-based</td><td>Any</td><td>Beta</td><td>N/A</td><td>http://people.oregonstate.edu/~housemae/software/TutorialLondon2014</td></tr><tr><td></td><td></td><td></td><td></td><td>http://bioconductor.org/packages/release/bioc/html/minfi.html</td></tr><tr><td>Ref-free</td><td>Any</td><td>Beta</td><td>Estimated</td><td>http://cran.r-project.org/web/packages/RefFreeEWAS/index.html</td></tr><tr><td>SVA</td><td>Any</td><td>Beta or logit(beta)</td><td>Estimated</td><td>http://bioconductor.org/packages/release/bioc/html/sva.html</td></tr><tr><td>ISVA</td><td>Continuous</td><td>Beta or logit(beta)</td><td>Estimated</td><td>http://cran.r-project.org/web/packages/isva/index.html</td></tr><tr><td>EWASher</td><td>Binary</td><td>Beta</td><td>Estimated</td><td>http://research.microsoft.com/en-us/downloads/472fe637-7cb9-47d4-a0df-37118760ccd1</td></tr><tr><td>CellCDec</td><td>Not used</td><td>Beta</td><td>Input</td><td>https://github.com/jameswagner/CellCDec</td></tr><tr><td>Deconf</td><td>Not used</td><td>Beta or logit(beta)</td><td>Input</td><td>http://web.cbio.uct.ac.za/~renaud/CRAN</td></tr><tr><td>RUV</td><td>Any</td><td>Beta or logit(beta)</td><td>Estimated</td><td>https://cran.r-project.org/web/packages/ruv/index.html</td></tr></table>
35956cb7ef0639e4b58d6b4642b79608e0dc200c5f0faec47a85524cbf4be130.png
complex
<table><tr><td></td><td colspan="4">Waiting List v Community</td><td colspan="3">Comparison of Means</td><td></td><td colspan="3">ROC</td><td colspan="4">Absolute Performance Gain</td></tr><tr><td>Instruments</td><td colspan="2">Community (n = 111)</td><td colspan="2">OWL(n = 45)</td><td>Effect size #</td><td>SD.</td><td><i>t</i></td><td>RE</td><td>Area Under Curve</td><td colspan="2">Asymptotic 95% CI</td><td><i>Z</i></td><td>APG %</td><td colspan="2">95% CI</td></tr><tr><td></td><td>M</td><td>SD.</td><td>M</td><td>SD</td><td></td><td></td><td></td><td></td><td></td><td>Lower</td><td>Upper</td><td></td><td></td><td>Lower</td><td>Upper</td></tr><tr><td>AQOL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Utility Score</td><td>0.50</td><td>0.19</td><td>0.37</td><td>0.25</td><td>0.66</td><td>0.21</td><td>3.7**</td><td>1.00</td><td>**0.67</td><td>0.57</td><td>0.77</td><td>reference</td><td></td><td></td><td></td></tr><tr><td> Independent living</td><td>0.80</td><td>0.18</td><td>0.69</td><td>0.22</td><td>0.58</td><td>0.19</td><td>3.3**</td><td>0.79</td><td>*0.66</td><td>0.57</td><td>0.75</td><td>0.10</td><td>1.9</td><td>-16.6</td><td>20.5</td></tr><tr><td> Social relationships</td><td>0.84</td><td>0.15</td><td>0.76</td><td>0.26</td><td>0.24</td><td>0.19</td><td>2.4*</td><td>0.41</td><td>0.56</td><td>0.45</td><td>0.67</td><td>1.08</td><td>21.5</td><td>1.9</td><td>41.1</td></tr><tr><td> Physical senses</td><td>0.90</td><td>0.09</td><td>0.92</td><td>0.07</td><td>-0.26</td><td>0.08</td><td>-1.4</td><td>0.16</td><td>0.43</td><td>0.33</td><td>0.53</td><td>^1.97</td><td>48.5</td><td>24.4</td><td>72.7</td></tr><tr><td> Psychological wellbeing</td><td>0.81</td><td>0.11</td><td>0.67</td><td>0.23</td><td>0.88</td><td>0.15</td><td>4.9**</td><td>1.78</td><td>*0.65</td><td>0.54</td><td>0.76</td><td>0.22</td><td>4.4</td><td>-15.2</td><td>23.9</td></tr><tr><td>SF-36</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Physical function</td><td>40.8</td><td>21.0</td><td>29.8</td><td>24.9</td><td>0.50</td><td>22.2</td><td>2.8*</td><td>0.57</td><td>**0.67</td><td>0.57</td><td>0.77</td><td>-0.02</td><td>0.5</td><td>-22.7</td><td>23.8</td></tr><tr><td> Role physical</td><td>26.7</td><td>37.1</td><td>10.6</td><td>22.9</td><td>0.48</td><td>33.7</td><td>2.7*</td><td>0.53</td><td>*0.61</td><td>0.52</td><td>0.70</td><td>0.47</td><td>11.6</td><td>-12.3</td><td>35.5</td></tr><tr><td> Bodily pain</td><td>42.7</td><td>18.8</td><td>33.9</td><td>17.2</td><td>0.48</td><td>18.3</td><td>2.7*</td><td>0.53</td><td>*0.63</td><td>0.53</td><td>0.72</td><td>0.43</td><td>8.8</td><td>-11.1</td><td>28.7</td></tr><tr><td> General health</td><td>56.6</td><td>22.2</td><td>51.7</td><td>20.8</td><td>0.22</td><td>21.8</td><td>1.3</td><td>0.12</td><td>0.56</td><td>0.47</td><td>0.66</td><td>0.86</td><td>21.1</td><td>-3.0</td><td>45.2</td></tr><tr><td> Vitality</td><td>44.7</td><td>19.5</td><td>43.3</td><td>22.0</td><td>0.07</td><td>20.2</td><td>0.4</td><td>0.01</td><td>0.52</td><td>0.42</td><td>0.63</td><td>1.22</td><td>29.4</td><td>5.8</td><td>53.1</td></tr><tr><td> Social function</td><td>68.4</td><td>24.8</td><td>56.4</td><td>28.7</td><td>0.46</td><td>26.0</td><td>2.6*</td><td>0.49</td><td>*0.62</td><td>0.52</td><td>0.72</td><td>0.46</td><td>9.8</td><td>-11.2</td><td>30.9</td></tr><tr><td> Role emotional</td><td>55.1</td><td>44.6</td><td>43.0</td><td>45.9</td><td>0.27</td><td>45.0</td><td>1.5</td><td>0.17</td><td>0.57</td><td>0.47</td><td>0.67</td><td>0.81</td><td>19.9</td><td>-4.2</td><td>44.0</td></tr><tr><td> Mental health</td><td>68.3</td><td>17.9</td><td>61.3</td><td>22.3</td><td>0.36</td><td>19.2</td><td>2.1*</td><td>0.30</td><td>0.59</td><td>0.48</td><td>0.69</td><td>0.69</td><td>16.5</td><td>-6.9</td><td>39.8</td></tr><tr><td> PCS</td><td>31.8</td><td>9.3</td><td>27.8</td><td>8.1</td><td>0.44</td><td>9.0</td><td>2.5*</td><td>0.46</td><td>*0.64</td><td>0.55</td><td>0.74</td><td>0.20</td><td>5.0</td><td>-19.5</td><td>29.4</td></tr><tr><td> MCS</td><td>47.8</td><td>11.6</td><td>44.9</td><td>13.4</td><td>0.24</td><td>12.1</td><td>1.4</td><td>0.13</td><td>0.56</td><td>0.46</td><td>0.66</td><td>0.91</td><td>21.4</td><td>-1.6</td><td>44.3</td></tr><tr><td>WOMAC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Pain</td><td>41.6</td><td>20.7</td><td>54.3</td><td>21.9</td><td>-0.60</td><td>21.0</td><td>-3.4**</td><td>0.84</td><td>*0.66</td><td>0.57</td><td>0.76</td><td>0.08</td><td>1.7</td><td>-20.3</td><td>0.2</td></tr><tr><td> Stiffness</td><td>50.0</td><td>18.5</td><td>59.4</td><td>18.9</td><td>-0.51</td><td>18.6</td><td>-2.9*</td><td>0.60</td><td>*0.63</td><td>0.53</td><td>0.72</td><td>0.37</td><td>8.3</td><td>-13.5</td><td>0.3</td></tr><tr><td> Physical function</td><td>42.5</td><td>19.4</td><td>58.5</td><td>19.3</td><td>-0.82</td><td>19.4</td><td>-4.7**</td><td>1.57</td><td>**0.71</td><td>0.62</td><td>0.80</td><td>-0.38</td><td>8.1</td><td>-12.8</td><td>0.3</td></tr><tr><td> Total score</td><td>42.9</td><td>18.4</td><td>57.7</td><td>19.0</td><td>-0.79</td><td>18.6</td><td>-4.5**</td><td>1.46</td><td>**0.70</td><td>0.61</td><td>0.79</td><td>-0.28</td><td>6.0</td><td>-14.7</td><td>0.3</td></tr><tr><td>VAS (over past week)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Average pain</td><td>-43.7</td><td>23.8</td><td>-60.7</td><td>21.6</td><td>0.74</td><td>23.2</td><td>4.2**</td><td>1.26</td><td>**0.70</td><td>0.61</td><td>0.79</td><td>-0.28</td><td>6.0</td><td>-0.2</td><td>0.3</td></tr><tr><td> Pain at rest</td><td>-26.9</td><td>22.2</td><td>-41.8</td><td>22.6</td><td>0.67</td><td>22.3</td><td>3.8**</td><td>1.03</td><td>**0.70</td><td>0.61</td><td>0.78</td><td>-0.22</td><td>5.0</td><td>-0.2</td><td>0.3</td></tr><tr><td> ADL Restriction</td><td>-37.8</td><td>26.0</td><td>-51.2</td><td>23.9</td><td>0.53</td><td>25.4</td><td>3.0*</td><td>0.64</td><td>*0.65</td><td>0.56</td><td>0.74</td><td>0.18</td><td>3.9</td><td>-0.2</td><td>0.3</td></tr></table>
c5fb5efd86ad1601df2b605f8de6d98bf7b34d6354e2b810d4ed16f505024709.png
complex
<table><tr><td>Material</td><td>Fixation method</td><td>Approximate global size (mm)</td><td>Maximum deviation factor</td><td>Minimum size factor</td><td>Number of elements</td></tr><tr><td>Cement</td><td>&#8212;</td><td>2.0</td><td>0.02</td><td>0.1</td><td>107556</td></tr><tr><td>Femoral prosthesis</td><td>&#8212;</td><td>1.5</td><td>0.05</td><td>0.1</td><td>631470</td></tr><tr><td rowspan="2">Femur</td><td>Cemented</td><td>2.0</td><td>0.05</td><td>0.1</td><td>761218</td></tr><tr><td>Noncemented</td><td>2.0</td><td>0.05</td><td>0.1</td><td>792849</td></tr><tr><td rowspan="2">Total number of elements</td><td>Cemented</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>1500244</td></tr><tr><td>Noncemented</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>1424319</td></tr></table>
23c5252524d2f38184d82e56204eeef91393f735957e150eb8a4fb5703604ebc.png
simple
<table><tr><td>Facies type</td><td>Model</td><td>Nugget</td><td>Partial sill</td><td>Range (m)</td></tr><tr><td>Sand flats</td><td>Exponential</td><td>0.103</td><td>0.223</td><td>3015</td></tr><tr><td>Mixed flats</td><td>Spherical</td><td>0.186</td><td>0.065</td><td>1029</td></tr><tr><td>Mud flats</td><td>Spherical</td><td>0.099</td><td>0.295</td><td>7575</td></tr></table>
7dcb7728baf9aad94fffea14562b7373990eb5382b3e2f49866ab8d6bbc35d1d.png
simple
<table><tr><td>Variable</td><td>ACS,</td><td>No ACS,</td></tr><tr><td></td><td><i>N </i>= 128 (%)</td><td><i>N </i>= 790 (%)</td></tr><tr><td>Age (years) (mean; SD)</td><td>(56.2; 12.0)</td><td>(61.4; 12.2)</td></tr><tr><td>Male gender</td><td>78 (60.9)</td><td>362 (45.8)</td></tr><tr><td>Prior disease</td><td>60 (46.8)</td><td>119 (15.0)</td></tr><tr><td>Family history of CAD</td><td>42 (32.8)</td><td>232 (29.3)</td></tr><tr><td>Hypertension</td><td>106 (82.8)</td><td>525 (66.4)</td></tr><tr><td>Cholesterol</td><td>98 (76.5)</td><td>412 (52.1)</td></tr><tr><td>Diabetes mellitus</td><td>43 (33.6)</td><td>228 (28.8)</td></tr><tr><td>Tobacco</td><td>53 (41.4)</td><td>268 (33.9)</td></tr><tr><td>Cocaine</td><td>4 (3.1)</td><td>30 (3.8)</td></tr><tr><td>Amphetamine</td><td>7 (5.4)</td><td>21 (2.6)</td></tr><tr><td>Normal ECG</td><td>52 (40.6)</td><td>456 (57.7)</td></tr></table>
84666483f0554c459663bcfe3bd821e9570a9544a0f7e168082598ebc5e95593.png
simple
<table><tr><td>GCA Classification Criteria</td></tr><tr><td>(1) Age at onset &#8805;50 years</td></tr><tr><td>(2) A new headache</td></tr><tr><td>(3) Temporal artery abnormality such as tenderness to palpation or decreased pulsation</td></tr><tr><td>(4) Erythrocyte sedimentation rate &#8805;50 mm/h</td></tr><tr><td>(5) Abnormal artery biopsy showing vasculitis with mononuclear cell or granulomatous inflammation, usually with giant cells</td></tr></table>
df30313b621c5a954c75147e7a93c34d23e438d181b505447907e2c326f30cb1.png
simple
<table><tr><td>Items</td><td>Issues</td></tr><tr><td>Model units</td><td>&#8226; Headcounts do not reflect variation in effective workforce.&#8226; FTE measured in working hours can translate into a variable effective workforce.&#8226; FTE defined in reference to the most active physician category makes the assumption that the activity level in that category is relevant.</td></tr><tr><td>Data quality</td><td>&#8226; Routine data are useful, but provide generally limited information.&#8226; Various data sources coexist, with inconsistencies between them.&#8226; Qualitative data for in-depth understanding of trends is often lacking.</td></tr><tr><td>Categories of resources</td><td>&#8226; Computation of human resources requirements by specialty obviates professional interactions and skill mix.&#8226; Assessing skill-mix requirements is a complex task and documentation is often lacking.</td></tr><tr><td>Supply parameters</td><td>&#8226; Information other than age, sex and services volume is often unavailable.&#8226; Productivity is sensitive to the working and societal environment and is rapidly evolving.</td></tr><tr><td>Demand parameters</td><td>&#8226; Assessing the impact of new technologies, emerging pathologies and demographic changes requires a large quantity of data and expertise that are often unavailable.&#8226; Level and mode of health care utilization are sensitive to the environment and are rapidly evolving.</td></tr><tr><td>Modeling</td><td>&#8226; Deterministic models are likely to generate inaccuracies without providing a means to evaluate them.&#8226; Regression modeling with stochastic simulation can be innovative in the HRH field but background is lacking&#8226; Regular updating of data is paramount but resource-consuming.</td></tr></table>
5364dd20656d6d9dafd0e6c0358a56c1e3247e32a766b72ee059bedc0a73c6e7.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2">Control</td><td rowspan="2">Laser 0.5</td><td rowspan="2">Laser 1.0</td><td colspan="3">p value*</td></tr><tr><td>Control <i>versus</i> 0.5</td><td>Control <i>versus</i> 1.0</td><td>0.5 <i>versus</i> 1.0</td></tr><tr><td>T0</td><td>0.8&#177;0.3 100%</td><td>0.8&#177;0.3 100%</td><td>1.0&#177;0.0 93.4%</td><td>0.9266</td><td>0.0705</td><td>0.0705</td></tr><tr><td>T24</td><td>1.8&#177;0.3 100%</td><td>2.8&#177;0.3 94.9%</td><td>3.8&#177;0.3 96.8%</td><td>0.0039**</td><td>0.0039**</td><td>0.0039**</td></tr><tr><td>T48</td><td>2.8&#177;0.3 100%</td><td>3.5&#177;0.0 97.8%</td><td>4.3&#177;0.8 98.5%</td><td>0.0024**</td><td>0.0039**</td><td>0.0705</td></tr><tr><td>T72</td><td>3.0&#177;0.0 98.6%</td><td>3.8&#177;0.3 100%</td><td>4.0&#177;0.0 100%</td><td>0.0024**</td><td>0.0013**</td><td>0.0705</td></tr></table>
9a5f59dded4d63203ef315924229237167136306b4aeb7d1463a40380bfd2288.png
complex
<table><tr><td>Variable</td><td><i>N</i></td><td>%</td></tr><tr><td colspan="3">Age in years (<i>n</i> = 1533)</td></tr><tr><td> 15&#8211;19</td><td>15</td><td>1</td></tr><tr><td> 20&#8211;29</td><td>455</td><td>29.7</td></tr><tr><td> 30&#8211;39</td><td>710</td><td>46.3</td></tr><tr><td> 40&#8211;49</td><td>242</td><td>15.8</td></tr><tr><td> 50 and above</td><td>111</td><td>7.2</td></tr><tr><td colspan="3">Sex (<i>n</i> = 1549)</td></tr><tr><td> Female</td><td>1333</td><td>86.1</td></tr><tr><td colspan="3">Caregiver relationship to a child (<i>n</i> = 1546)</td></tr><tr><td> Mother</td><td>1257</td><td>81.3</td></tr><tr><td> Father</td><td>130</td><td>8.4</td></tr><tr><td> Relative</td><td>159</td><td>10.3</td></tr><tr><td colspan="3">Marital status (<i>n</i> = 1546)</td></tr><tr><td> Married</td><td>1210</td><td>78.3</td></tr><tr><td> Single, separated or divorced</td><td>179</td><td>11.5</td></tr><tr><td> Widow or widower</td><td>157</td><td>10.2</td></tr><tr><td colspan="3">Education level (<i>n</i> = 1546)</td></tr><tr><td> None or informal</td><td>170</td><td>11.0</td></tr><tr><td> Primary</td><td>285</td><td>18.4</td></tr><tr><td> Secondary</td><td>703</td><td>45.5</td></tr><tr><td> Postsecondary Diploma and above</td><td>388</td><td>25.1</td></tr><tr><td colspan="3">Employment status (<i>n</i> = 1532)</td></tr><tr><td> None</td><td>326</td><td>21.3</td></tr><tr><td> Employed in informal sector</td><td>988</td><td>64.5</td></tr><tr><td> Employed in formal sector</td><td>218</td><td>14.2</td></tr><tr><td colspan="3">Income status (<i>n</i> = 1474)</td></tr><tr><td> &lt;N18,000</td><td>914</td><td>62.0</td></tr><tr><td> N18,000&#8211;50,000</td><td>427</td><td>29.0</td></tr><tr><td> N51,000&#8211;100,000</td><td>105</td><td>7.1</td></tr><tr><td> &gt;N100,000</td><td>28</td><td>1.9</td></tr></table>
7a0ad4dca058991639e827f0ba0da8e5a8a6d397ac3edb85ca0d0a8d16a64245.png
complex
<table><tr><td>Category</td><td>Subcategory</td><td>Cases</td><td colspan="2">Monocytes(/mm<sup>3</sup>)</td><td>P value</td></tr><tr><td></td><td></td><td></td><td>&lt;545</td><td>&#8805;545</td><td></td></tr><tr><td>Gender</td><td>Male</td><td>310</td><td>115</td><td>195</td><td>0.102</td></tr><tr><td></td><td>Female</td><td>41</td><td>20</td><td>21</td><td></td></tr><tr><td>Age</td><td>&lt;50 years</td><td>268</td><td>102</td><td>166</td><td>0.418</td></tr><tr><td></td><td>&#8805;50 years</td><td>83</td><td>33</td><td>50</td><td></td></tr><tr><td>HBsAg</td><td>Negative</td><td>49</td><td>14</td><td>35</td><td>0.083</td></tr><tr><td></td><td>Positive</td><td>302</td><td>121</td><td>181</td><td></td></tr><tr><td>AFP(ng/ml)</td><td>&lt;200</td><td>161</td><td>61</td><td>100</td><td>0.463</td></tr><tr><td></td><td>&#8805;200</td><td>190</td><td>74</td><td>116</td><td></td></tr><tr><td rowspan="2">Edmonson grading</td><td>I-II</td><td>271</td><td>107</td><td>164</td><td>0.278</td></tr><tr><td>III-IV</td><td>80</td><td>28</td><td>52</td><td></td></tr><tr><td rowspan="2">Tumor size</td><td>&lt;5 cm</td><td>70</td><td>35</td><td>35</td><td>0.019</td></tr><tr><td>&#8805;5 cm</td><td>281</td><td>100</td><td>181</td><td></td></tr><tr><td rowspan="2">Surgical margin</td><td>&lt;1 cm</td><td>122</td><td>44</td><td>78</td><td>0.289</td></tr><tr><td>&#8805;1 cm</td><td>229</td><td>91</td><td>138</td><td></td></tr><tr><td rowspan="2">Liver cirrhosis</td><td>Absent</td><td>82</td><td>29</td><td>53</td><td>0.3</td></tr><tr><td>Present</td><td>269</td><td>106</td><td>163</td><td></td></tr><tr><td>PVTT</td><td>Absent</td><td>278</td><td>108</td><td>170</td><td>0.44</td></tr><tr><td></td><td>Present</td><td>73</td><td>27</td><td>46</td><td></td></tr><tr><td rowspan="2">Capsulation</td><td>Capsulated</td><td>224</td><td>92</td><td>132</td><td>0.111</td></tr><tr><td>Non-caspulated</td><td>127</td><td>43</td><td>84</td><td></td></tr><tr><td rowspan="2">Tumor number</td><td>Single</td><td>276</td><td>107</td><td>169</td><td>0.465</td></tr><tr><td>Multiple</td><td>75</td><td>28</td><td>47</td><td></td></tr><tr><td>Macrovascular invasion</td><td>Absent</td><td>261</td><td>102</td><td>159</td><td>0.391</td></tr><tr><td></td><td>Present</td><td>90</td><td>33</td><td>57</td><td></td></tr></table>
28db50cbc5213f793dbaeb8544593541f5b45dd1819587df15f36ee74364d0cf.png
complex
<table><tr><td>Collection time</td><td>AKI (renal replacement)</td><td>Mean</td><td>Std</td><td>p-value</td></tr><tr><td rowspan="2">T1 preoperative</td><td>No</td><td>1,0</td><td>,27</td><td rowspan="2">0,06</td></tr><tr><td>Yes</td><td>1,24</td><td>,43</td></tr><tr><td rowspan="2">T2 start CBP</td><td>No</td><td>,80</td><td>,21</td><td rowspan="2">0,07</td></tr><tr><td>Yes</td><td>,96</td><td>,31</td></tr><tr><td rowspan="2">T3 20 minutes after CBP start</td><td>No</td><td>,89</td><td>,21</td><td rowspan="2">0,06</td></tr><tr><td>Yes</td><td>1,05</td><td>,32</td></tr><tr><td rowspan="2">T4 OP-end</td><td>No</td><td>1,00</td><td>,26</td><td rowspan="2">0,03</td></tr><tr><td>Yes</td><td>1,22</td><td>,30</td></tr><tr><td rowspan="2">T5 24 h postoperative</td><td>No</td><td>1,26</td><td>,52</td><td rowspan="2">0,002</td></tr><tr><td>Yes</td><td>1,93</td><td>,47</td></tr><tr><td>T6 discharge(max. day 6)</td><td>No</td><td>1,28</td><td>,40</td><td>0,001</td></tr><tr><td> </td><td>Yes</td><td>2,09</td><td>,57</td><td> </td></tr></table>
8c93f57dbe550c7340e762aed892e7e90829fa26c895d24e781aa2f59411f0db.png
complex
<table><tr><td rowspan="2">Model</td><td>Standardized coefficients</td><td rowspan="2">t</td><td rowspan="2">Sig.</td><td colspan="2">95.0 % confidence interval for B</td></tr><tr><td>Beta</td><td>Lower bound</td><td>Upper bound</td></tr><tr><td>(Constant)</td><td></td><td>&#8722;12.353</td><td>&lt;0.001</td><td>&#8722;1.67</td><td>&#8722;1.21</td></tr><tr><td>Educational level of mothers</td><td>0.08</td><td>3.273</td><td>0.001</td><td>0.06</td><td>0.23</td></tr><tr><td>Appropriate complementary feeding score</td><td>0.04</td><td>1.927</td><td>0.05</td><td>&#8722;0.002</td><td>0.27</td></tr><tr><td>Diarrhoeal infection</td><td>0.10</td><td>4.499</td><td>&lt;0.001</td><td>0.14</td><td>0.35</td></tr><tr><td>Gender of child</td><td>0.05</td><td>2.209</td><td>0.03</td><td>0.012</td><td>0.209</td></tr></table>
138de02958ea49d55736c39b6f8f171e649134b3bf790cbc8034359997ee9282.png
complex
<table><tr><td>Phytochemical</td><td>Name of the tests</td><td>Observed changes</td><td>Result</td></tr><tr><td rowspan="5">Alkaloids</td><td>Mayer's test</td><td>Creamy white precipitate</td><td>&#8722;</td></tr><tr><td>Hager's test</td><td>Yellow crystalline precipitate</td><td> +</td></tr><tr><td>Wagner's test</td><td>Brown or deep brown precipitate </td><td>&#8722;</td></tr><tr><td>Dragendorff's test</td><td>Orange or orange-red precipitate</td><td>&#8722;</td></tr><tr><td>Tannic acid test</td><td>Buff color precipitate</td><td>&#8722;</td></tr><tr><td rowspan="5">Carbohydrates</td><td>Molisch's test</td><td>A red or reddish violet ring is formed at the junction of two layers and on shaking a dark purple solution is formed</td><td>+</td></tr><tr><td>Barfoed's test (general test for monosaccharides)</td><td>Red precipitate</td><td>&#8722;</td></tr><tr><td>Fehling's test</td><td>A red or brick-red precipitate</td><td>&#8722;</td></tr><tr><td>Benedict's test</td><td> </td><td>+</td></tr><tr><td>Test for combined reducing sugar</td><td>A brick-red precipitate</td><td>&#8722;</td></tr><tr><td rowspan="3">Glycosides</td><td>General test</td><td>Yellow color</td><td>&#8722;</td></tr><tr><td>Bromine water test </td><td>yellow precipitate</td><td>+</td></tr><tr><td>Test for glucoside</td><td>Production of brick-red precipitation (carried out with the hydrolyzed extract)</td><td>&#8722;</td></tr><tr><td rowspan="3">Flavonoids</td><td>Alkaline reagent test</td><td>Red color</td><td>+/&#8722;</td></tr><tr><td>Shinoda test (magnesium hydrochloride reduction test)</td><td>Green to blue color</td><td>+</td></tr><tr><td>Zinc hydrochloride reduction test</td><td>Red color after few minutes </td><td>&#8722;</td></tr><tr><td>Saponins</td><td>Frothing test</td><td>Formation of stable foam</td><td>+</td></tr><tr><td>Steroids</td><td>Libermann-Burchard's test</td><td>Greenish color</td><td>&#8722;</td></tr><tr><td rowspan="3">Tannins</td><td>Lead acetate test</td><td>A yellow or red precipitate</td><td> +</td></tr><tr><td>Ferric chloride test</td><td>Blue green color</td><td>&#8722;</td></tr><tr><td>Alkaline reagent test</td><td>Yellow to red precipitate</td><td>+</td></tr><tr><td>Terpenoids</td><td>Salkowski test</td><td>Yellow color appears at the lower layer </td><td>&#8722;</td></tr></table>
605c8918667bb688a51842ee5a12b8795b56e4be8da64ec39d63044946dee48f.png
simple
<table><tr><td></td><td>Dynesys group (<i>n</i> = 95)</td><td>PLIF group (<i>n</i> = 81)</td><td><i>p</i></td></tr><tr><td>ODI (%)<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>Pre op</td><td>57.1 &#177; 7.7</td><td>56.1 &#177; 8.1</td><td>0.391</td></tr><tr><td>Mid-term</td><td>33.5 &#177; 6.6</td><td>33.9 &#177; 7.1</td><td>0.738</td></tr><tr><td>Final</td><td>25.9 &#177; 5.7</td><td>24.9 &#177; 5.9</td><td>0.271</td></tr><tr><td>VAS<sub>back</sub> (mm)<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>Pre op</td><td>43.7 &#177; 14.5</td><td>45.3 &#177; 13.9</td><td>0.451</td></tr><tr><td>Mid-term</td><td>19.5 &#177; 11.7</td><td>18.6 &#177; 11.3</td><td>0.633</td></tr><tr><td>Final</td><td>10.6 &#177; 9.1</td><td>11.4 &#177; 8.5</td><td>0.568</td></tr><tr><td>VAS<sub>leg</sub> (mm)<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td>Pre op</td><td>51.6 &#177; 15.7</td><td>52.3 &#177; 16.3</td><td>0.752</td></tr><tr><td>Mid-term</td><td>13.2 &#177; 8.9</td><td>11.5 &#177; 8.2</td><td>0.199</td></tr><tr><td>Final</td><td>6.7 &#177; 8.3</td><td>7.1 &#177; 7.5</td><td>0.782</td></tr></table>
e1356c98cd5582097d35164c3cb6cc782c7e5f2f529e05e34151b700cfd1b218.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Morning Snack</td><td colspan="3">Lunch</td><td colspan="3">Afternoon Snack</td><td></td><td></td><td></td></tr><tr><td>Na (mg)</td><td>Na density (mg/MJ)</td><td>Energy (kJ)</td><td>Na (mg)</td><td>Na Density (mg/MJ)</td><td>Energy (kJ)</td><td>Na (mg)</td><td>Na Density (mg/MJ)</td><td>Energy (kJ)</td><td>Total Sodium (mg)</td><td>Total Energy Density (mg/MJ)</td><td>Total Energy (kJ)</td></tr><tr><td>Centre 1 <sup>a</sup></td><td>40 (0.5)</td><td>94 (4)</td><td>428 (17)</td><td>135 (82)</td><td>194 (126)</td><td>719 (134)</td><td>386 (335)</td><td>660 (478)</td><td>612 (206)</td><td>561</td><td>943</td><td>1759</td></tr><tr><td>Centre 2</td><td>50 (0.9)</td><td>113 (7)</td><td>437(25)</td><td>220 (61)</td><td>140 (52)</td><td>1614 (208)</td><td>331 (199)</td><td>537 (302)</td><td>578 (118)</td><td>601</td><td>789</td><td>2629</td></tr><tr><td>Centre 3</td><td>40 (0.7)</td><td>97 (11)</td><td>427 (66)</td><td>419 (308)</td><td>297 (164)</td><td>1333 (249)</td><td>389 (188)</td><td>586 (182)</td><td>642 (222)</td><td>848</td><td>985</td><td>2402</td></tr><tr><td>Centre 4 <sup>a</sup></td><td>166 (55)</td><td>219 (29)</td><td>936 (330)</td><td>66 (68)</td><td>151 (112)</td><td>433 (145)</td><td>154 (147)</td><td>174 (123)</td><td>824 (394)</td><td>386</td><td>560</td><td>2193</td></tr><tr><td>Centre 5</td><td>48 (1)</td><td>89 (5)</td><td>557 (32)</td><td>164 (60)</td><td>152 (24)</td><td>1093 (396)</td><td>357 (219)</td><td>516 (180)</td><td>652 (238)</td><td>569</td><td>757</td><td>2302</td></tr><tr><td>Centre 6</td><td>49 (0.7)</td><td>100 (9)</td><td>495 (53)</td><td>220 (124)</td><td>203 (154)</td><td>1205 (410)</td><td>220 (109)</td><td>482 (356)</td><td>900 (593)</td><td>489</td><td>773</td><td>2600</td></tr><tr><td>Centre 7</td><td>51 (0.8)</td><td>105 (7)</td><td>468 (34)</td><td>429 (168)</td><td>220 (110)</td><td>1415 (650)</td><td>199 (43)</td><td>292 (77)</td><td>697 (111)</td><td>679</td><td>609</td><td>2580</td></tr><tr><td>Average across centres</td><td>63 (45)</td><td>116 (46)</td><td>535 (183)</td><td>236 (139)</td><td>194 (55)</td><td>1116 (543)</td><td>291 (97)</td><td>464 (171)</td><td>701(118)</td><td>590 (146)</td><td>774 (156)</td><td>2352(453)</td></tr></table>
8f7f13b39596cbd9d15fec8f15e8dea5c062b342d4302f52d946270114c31452.png
simple
<table><tr><td>Analyte</td><td>RT (min)</td><td>[M &#8722; H]<sup>&#8722;</sup> (<i>m/z</i>)</td><td>MS<sup><i>n</i></sup> (<i>m/z</i>)</td></tr><tr><td>Paeoniflorin sulfonate (12)</td><td>2.18</td><td>543.11</td><td>121.02</td></tr><tr><td>Albiflorin (2)</td><td>3.67</td><td>525.16</td><td>121.02</td></tr><tr><td>Paeoniflorin (1)</td><td>3.90</td><td>525.16</td><td>121.02</td></tr><tr><td>Liquirtin apioside (5)</td><td>4.04</td><td>549.16</td><td>255.06</td></tr><tr><td>Liquiritin (3)</td><td>4.07</td><td>417.12</td><td>255.06</td></tr><tr><td>Isoliquiritin apioside (6)</td><td>4.26</td><td>549.16</td><td>255.06</td></tr><tr><td>Isoliquiritin (4)</td><td>4.33</td><td>417.12</td><td>255.06</td></tr><tr><td>Liquiritigenin (8)</td><td>4.56</td><td>255.06</td><td>135.01</td></tr><tr><td>Isoliquiritigenin (9)</td><td>4.91</td><td>255.06</td><td>119.05</td></tr><tr><td>Glycyrrhizic acid (10)</td><td>5.02</td><td>821.39</td><td>351.05</td></tr><tr><td>Glycyrrhetinic acid (11)</td><td>6.22</td><td>469.33</td><td>425.34</td></tr><tr><td>Ginsenoside Rb1 (IS1)</td><td>4.50</td><td>1107.59</td><td>1107.59</td></tr><tr><td>Swertiamarin (IS2)</td><td>2.77</td><td>419.11</td><td>179.05</td></tr><tr><td>Kaempferol-3-O-rutinoside (IS3)</td><td>4.16</td><td>593.15</td><td>285.04</td></tr></table>
311d76a459f2209b0837adfeac431260859846887d8f19c491b26e6db057e4da.png
simple
<table><tr><td>Strength of interaction</td><td>Definition</td></tr><tr><td>Strong</td><td>A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a substrate for that CYP by equal to or more than 5-fold (or &gt;80% decrease in clearance)</td></tr><tr><td>Moderate</td><td>A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 5-fold but equal to or more than 2-fold (or 50%&#8211;80% decrease in clearance)</td></tr><tr><td>Weak</td><td>A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 2-fold but equal to or more than 1.25-fold (or 20%&#8211;50% decrease in clearance)</td></tr></table>
ace93f5780b903de8805c8b32e7fa08b6f0fde442ecbf6ccc8f8e33d8b4df079.png
simple
<table><tr><td>Annotation category</td><td>Resource</td><td>Comments</td></tr><tr><td>Genomic</td><td>GENCODE</td><td>Variant classification and mapping to gene</td></tr><tr><td></td><td>Human DNA Repair Genes</td><td>Curated list from [40]</td></tr><tr><td>Protein</td><td>UniProt</td><td>Protein-specific annotation</td></tr><tr><td></td><td>dbNSFP</td><td>Conservation and prediction scores</td></tr><tr><td>Cancer variant</td><td>COSMIC</td><td>Catalogue of Somatic Mutations in Cancer</td></tr><tr><td>Non-cancer variant</td><td>1000 Genomes Project</td><td>Germline SNVs</td></tr></table>
9d835b69ed0dd71b599cc8e3a880a4544163419d2464e3724101fc092969f837.png
simple
<table><tr><td>Country</td><td>Sample Size SpA</td><td>Sample Size (Control)</td><td>Prevalence in Population</td><td>Prevalence in SpA</td><td>Prevalence in AS</td><td>OR AS/GP [95% CI]</td><td>Reference</td></tr><tr><td>Algeria</td><td>129 AS (ESSG and NY)</td><td>76 healthy blood donors</td><td>4%</td><td></td><td>69%</td><td>54.14 [16.09&#8211;182.18]</td><td>[17]</td></tr><tr><td>Egypt</td><td></td><td>380 normal individuals</td><td>4.7%</td><td></td><td></td><td></td><td>[18]</td></tr><tr><td>Egypt</td><td>75 SpA (ESSG) including 34 AS</td><td></td><td></td><td>58.7%</td><td></td><td></td><td>[19]</td></tr><tr><td>Egypt</td><td></td><td>100 healthy controls</td><td>1%</td><td></td><td></td><td></td><td>[20]</td></tr><tr><td>Iraq</td><td>25 AS</td><td></td><td>2.1%</td><td></td><td>84%</td><td></td><td>[21]</td></tr><tr><td>Iran</td><td>60 AS</td><td>430 healthy blood donors</td><td>3.95%</td><td></td><td>66.67%</td><td>48.59 [23.57&#8211;100.17]</td><td>[22]</td></tr><tr><td>Iran</td><td>119 AS</td><td></td><td></td><td></td><td>68.91%</td><td></td><td>[23]</td></tr><tr><td>Iran</td><td>98 AS (NY)</td><td></td><td></td><td></td><td>73.4%</td><td></td><td>[24]</td></tr><tr><td>Israel</td><td>38 AS</td><td>456 normal individuals</td><td>3%</td><td></td><td>79%</td><td></td><td>[25]</td></tr><tr><td>Jordan</td><td>22 AS (NY)</td><td></td><td></td><td></td><td>75%</td><td></td><td>[26]</td></tr><tr><td>Jordan / Qatar</td><td>129 AS</td><td>2579 healthy individuals</td><td>2.4%</td><td></td><td>72.22%</td><td>104.87 [66.21&#8211;166.11]</td><td>[12]</td></tr><tr><td>Kuwait</td><td>58 SpA (27 AS)</td><td></td><td></td><td>69.43%</td><td>82.56%</td><td></td><td>[27]</td></tr><tr><td>Kuwait</td><td>35 SpA + AS patients</td><td>544 controls</td><td>4%</td><td>25.7%</td><td></td><td>8.21 [3.44&#8211;19.60]</td><td>[28]</td></tr><tr><td>Lebanon</td><td>105 SpA (ESSG)24 AS (NY)</td><td>841 Rheumatolgy patients</td><td>1.44%</td><td>13.85%</td><td>26.32%</td><td>24.46 [7.78&#8211;68.19]</td><td>[29]</td></tr><tr><td>Morocco</td><td>46 AS + coxitis</td><td>183 healthy controls</td><td>6.16%</td><td></td><td>58.70%</td><td>22.09 [9.48&#8211;51.49]</td><td>[30]</td></tr><tr><td>Morocco</td><td>49 SpA (Amor and ESSG)</td><td></td><td></td><td></td><td>67%</td><td></td><td>[31]</td></tr><tr><td>Oman</td><td></td><td>321 healthy</td><td>0.3%</td><td></td><td></td><td></td><td>[32]</td></tr><tr><td>Qatar</td><td>119 AS (NY)</td><td></td><td></td><td></td><td>74%</td><td></td><td>[33]</td></tr><tr><td>Saudi Arabia</td><td>12 AS</td><td></td><td></td><td></td><td>66.67%</td><td></td><td>[34]</td></tr><tr><td>Syria</td><td>50 AS (NY)</td><td>217 healthy controls</td><td>1.4%</td><td></td><td>60%</td><td>105.64 [29.98&#8211;381.87]</td><td>[35]</td></tr><tr><td>Tunisia</td><td>365 AS and/or BD</td><td>124 controls</td><td>3.2%</td><td></td><td>42.9%</td><td></td><td>[36]</td></tr><tr><td>Tunisia</td><td>100 AS (NY)</td><td>100 healthy controls</td><td>3%</td><td></td><td>62%</td><td>52.75 [15.61&#8211;178.31]</td><td>[37]</td></tr><tr><td>Tunisia</td><td>50 AS (Amor / ESSG)</td><td></td><td></td><td></td><td>69%</td><td></td><td>[38]</td></tr><tr><td>Turkey</td><td>112 AS (NY)</td><td>55 controls</td><td>2.8&#8211;6.8%</td><td></td><td>70%</td><td>29.82 [9.99&#8211;89.05]</td><td>[39]</td></tr><tr><td>Turkey</td><td>216 AS (67 analyzed)</td><td></td><td></td><td></td><td>91%</td><td></td><td>[40]</td></tr><tr><td>UAE</td><td></td><td>760 healthy</td><td>6.4%</td><td></td><td></td><td></td><td>[41]</td></tr><tr><td>UAE</td><td>17 AS</td><td></td><td></td><td></td><td>56%</td><td></td><td>[42]</td></tr></table>
25fbafa7aab0ca046a620ff674d7c99028a124bb2fd863fa9d052c97271db2fe.png
simple
<table><tr><td>Covariate</td><td>Relative risk</td><td>95 % CI</td><td><i>p</i> value</td></tr><tr><td>p62</td><td>0.764</td><td>NS</td><td>0.619</td></tr><tr><td>Histological grading</td><td>1.239</td><td>NS</td><td>0.392</td></tr><tr><td>Lymph node metastases</td><td>0.794</td><td>NS</td><td>0.510</td></tr><tr><td>Tumour stage</td><td>1.647</td><td>NS</td><td>0.141</td></tr><tr><td>Distant metastases</td><td>3.176</td><td>1.453-6.940</td><td>0.004</td></tr></table>
0ff1c446ef4e99c8d57c9d329c41b8315579e3f477ca5a2eb1de1d5b37be274f.png
complex
<table><tr><td rowspan="2" colspan="2">Variables</td><td colspan="2">Syphilis</td><td>COR (95% CI)</td><td>AOR (95%CI)</td><td><i>P</i>-value</td></tr><tr><td>NR(<i>n</i> = 469)</td><td>R(<i>n</i> = 25)</td><td></td><td></td><td></td></tr><tr><td rowspan="3">Age(years)</td><td>&lt; 25</td><td>155 (96.3)</td><td>6 (3.7)</td><td>1</td><td></td><td></td></tr><tr><td>25-29</td><td>202 (94.4)</td><td>12 (5.6)</td><td>1.5 (0.563-4.180)</td><td></td><td></td></tr><tr><td>&#8805;30</td><td>112 (94.1)</td><td>7 (5.9)</td><td>1.6 (0.528-4.935)</td><td></td><td></td></tr><tr><td rowspan="2">Residence</td><td>Urban</td><td>312 (93.7)</td><td>21 (6.3)</td><td>2.6 (0.892-7.829)**</td><td>2.6 (0.845-7.982)</td><td>0.096</td></tr><tr><td>Rural</td><td>157 (97.5)</td><td>4 (2.5)</td><td>1</td><td></td><td></td></tr><tr><td rowspan="4">Education</td><td>Illiterate</td><td>57 (96.6)</td><td>2 (3.4)</td><td>1</td><td></td><td></td></tr><tr><td>Elementary</td><td>160 (95.2)</td><td>8 (4.8)</td><td>1.4 (0.294-6.909)</td><td></td><td></td></tr><tr><td>Secondary</td><td>156 (94.0)</td><td>10 (6.0)</td><td>1.8 (0.388-8.592)</td><td></td><td></td></tr><tr><td>Tertiary</td><td>96 (95.0)</td><td>5 (5.0)</td><td>1.5 (0.279-7.903)</td><td></td><td></td></tr><tr><td rowspan="5">Occupational</td><td>House wife</td><td>231 (93.9)</td><td>15 (6.1)</td><td>2.8 (0.359-21.695)</td><td></td><td></td></tr><tr><td>Health worker</td><td>17 (89.5)</td><td>2 (10.5)</td><td>5.0 (0.430-59.525)</td><td></td><td></td></tr><tr><td>Employed</td><td>128 (96.2)</td><td>5 (3.8)</td><td>1.7 (0.191-14.780)</td><td></td><td></td></tr><tr><td>Merchant</td><td>50 (96.2)</td><td>2 (3.8)</td><td>1.7 (0.151-19.632)</td><td></td><td></td></tr><tr><td>Student</td><td>43 (97.7)</td><td>1 (2.3)</td><td>1</td><td></td><td></td></tr><tr><td rowspan="2">Marital status</td><td>Married</td><td>426 (95.3)</td><td>21 (4.7)</td><td>1</td><td></td><td></td></tr><tr><td>Not cohabiting*</td><td>43 (91.5)</td><td>4 (8.5)</td><td>1.9 (0.619-5.751)</td><td></td><td></td></tr><tr><td rowspan="3">Gestational age at screening</td><td>First trimester</td><td>98 (98.0)</td><td>2 (2.0)</td><td>1</td><td></td><td></td></tr><tr><td>Second trimester</td><td>170 (94.4)</td><td>10 (5.6)</td><td>2.9 (0.619-13.423)**</td><td>3.8 (0.778-18.847)</td><td>0.099</td></tr><tr><td>Third trimester</td><td>201 (93.9)</td><td>13 (6.1)</td><td>3.2 (0.701-14.319)**</td><td>4.6 (0.959-22.340)</td><td>0.056</td></tr><tr><td rowspan="2">Gravidity</td><td>Primigravidae</td><td>153 (95.6)</td><td>7 (4.4)</td><td>1</td><td></td><td></td></tr><tr><td>Multigravidae(&#8805;2)</td><td>316 (94.6)</td><td>18 (5.4)</td><td>1.2 (0.509-3.044)</td><td></td><td></td></tr><tr><td>Frequency of</td><td>1</td><td>196 (96.1)</td><td>8 (3.9)</td><td>1</td><td></td><td></td></tr><tr><td>ANC visit</td><td>&#8805;2</td><td>273 (94.1)</td><td>17 (5.9)</td><td>1.5 (0.646-3.606)</td><td></td><td></td></tr><tr><td>Multiple sexual</td><td>Yes</td><td>41 (91.1)</td><td>4 (8.9)</td><td>2.0 (0.651-6.701)</td><td></td><td></td></tr><tr><td>Partner</td><td>No</td><td>428 (95.3)</td><td>21 (4.7)</td><td>1</td><td></td><td></td></tr><tr><td>Place of</td><td>Home</td><td>89 (93.7)</td><td>6 (6.3)</td><td>1.3 (0.464-3.502)</td><td></td><td></td></tr><tr><td>previous birth</td><td>Health institution</td><td>227 (95.0)</td><td>12 (5.0)</td><td>1</td><td></td><td></td></tr><tr><td rowspan="2">HIV</td><td>Non-reactive</td><td>429 (96.8)</td><td>14 (3.2)</td><td>1</td><td></td><td></td></tr><tr><td>Reactive</td><td>40 (79.4)</td><td>11 (21.6)</td><td>8.4 (3.859-19.786)**</td><td>10.3 (4.213-25.185)</td><td>0.001</td></tr></table>
f7db46a540812ae6b628ea46d7b8235bec6d9f85bf93c4fb242d87dbc241af09.png
simple
<table><tr><td>Food</td><td>GI</td></tr><tr><td>Gluten-free bread</td><td>230</td></tr><tr><td>Gluten-free pasta</td><td>255</td></tr><tr><td>Quinoa</td><td>186</td></tr></table>
cc42fd8d2f14155004e1695a022667621a3d9a385385268ac74617ac9969d822.png
simple
<table><tr><td>Laccase Isoform</td><td>Experimental Affinity Rank <sup>1</sup></td><td>HINT Score</td></tr><tr><td>Beta</td><td>1</td><td>430</td></tr><tr><td>Gamma</td><td>2</td><td>206</td></tr><tr><td>Delta</td><td>3</td><td>104</td></tr></table>
e5cfc6b029dc6208c9ca75c38c420660607fe0916f97ab5ee516bc7a7e090cde.png
complex
<table><tr><td>Variables</td><td>Number</td><td>All</td><td>Fish</td><td>Meat</td><td>Supplement</td><td><i>P</i><sup><i>a</i></sup></td></tr><tr><td colspan="7">Characteristics</td></tr><tr><td>Gender n (%)</td><td>415</td><td></td><td></td><td></td><td></td><td>0.546</td></tr><tr><td> Male</td><td></td><td>195 (47.0)</td><td>56 (43.8)</td><td>73 (50.3)</td><td>66 (46.5)</td><td></td></tr><tr><td> Female</td><td></td><td>220 (53.0)</td><td>72 (56.3)</td><td>72 (49.7)</td><td>76 (53.5)</td><td></td></tr><tr><td>Age (years)</td><td>415</td><td>14.6 &#177; 0.3</td><td>14.6 &#177; 0.3</td><td>14.6 &#177; 0.3</td><td>14.6 &#177; 0.3</td><td>0.531</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>385</td><td>19.8 &#177; 3.0</td><td>19.8 &#177; 3.4</td><td>19.7 &#177; 2.3</td><td>19.9 &#177; 3.1</td><td>0.940</td></tr><tr><td>Parental education level n (%)</td><td>341</td><td></td><td></td><td></td><td></td><td>0.793</td></tr><tr><td colspan="2"> Elementary/vocational school</td><td>132 (38.7)</td><td>41 (39.4)</td><td>47 (40.5)</td><td>44 (36.4)</td><td></td></tr><tr><td> College/university</td><td></td><td>209 (61.3)</td><td>63 (60.6)</td><td>69 (59.5)</td><td>77 (63.6)</td><td></td></tr><tr><td>Family income in NOK<sup>b</sup> n (%)</td><td>338</td><td></td><td></td><td></td><td></td><td>0.201</td></tr><tr><td>&lt; 200,000&#8211;749,999</td><td></td><td>70 (20.7)</td><td>21 (20.4)</td><td>17 (14.8)</td><td>32 (26.7)</td><td></td></tr><tr><td> 750,000&#8211;1,249,999</td><td></td><td>171 (50.6)</td><td>50 (48.5)</td><td>66 (57.4)</td><td>55 (45.8)</td><td></td></tr><tr><td> 1,250,000- &gt; 2,000,000</td><td></td><td>97 (28.7)</td><td>32 (31.1)</td><td>32 (27.8)</td><td>33 (27.5)</td><td></td></tr><tr><td>Immigrant<sup>c</sup> n (%)</td><td>341</td><td>7 (2.1)</td><td>2 (1.6)</td><td>2 (1.7)</td><td>3 (2.5)</td><td>0.914</td></tr><tr><td colspan="7">Nutritional status</td></tr><tr><td>LA, 18:2n-6 (%)</td><td>415</td><td>10.8 &#177; 1.3</td><td>10.8 &#177; 1.4</td><td>10.8 &#177; 1.2</td><td>10.9 &#177; 1.3</td><td>0.707</td></tr><tr><td>AA, 20:4n-6 (%)</td><td>415</td><td>15.6 &#177; 1.5</td><td>15.6 &#177; 1.4</td><td>15.6 &#177; 1.6</td><td>15.6 &#177; 1.5</td><td>0.958</td></tr><tr><td>EPA, 20:5n-3 (%)</td><td>415</td><td>0.9 &#177; 0.4</td><td>0.9 &#177; 0.3</td><td>0.9 &#177; 0.4</td><td>0.9 &#177; 0.4</td><td>0.960</td></tr><tr><td>DPA, 22:5n-3 (%)</td><td>415</td><td>2.4 &#177; 0.3</td><td>2.4 &#177; 0.3</td><td>2.4 &#177; 0.3</td><td>2.3 &#177; 0.3</td><td>0.110</td></tr><tr><td>DHA, 22:6n-3 (%)</td><td>415</td><td>4.9 &#177; 1.1</td><td>4.9 &#177; 1.0</td><td>5.0 &#177; 1.2</td><td>4.8 &#177; 1.0</td><td>0.171</td></tr><tr><td>Omega-3 index<sup>d</sup></td><td>415</td><td>5.8 &#177; 1.3</td><td>5.8 &#177; 1.2</td><td>5.9 &#177; 1.4</td><td>5.7 &#177; 1.3</td><td>0.304</td></tr><tr><td>&#8804; 8 n (%)</td><td></td><td>395 (95.2)</td><td>122 (95.3)</td><td>135 (93.1)</td><td>138 (97.2)</td><td>0.271</td></tr><tr><td>s-25(OH)D (nmol/L)</td><td>424</td><td>48.8 &#177; 17.4</td><td>49.1 &#177; 17.1</td><td>49.7 &#177; 17.8</td><td>48.3 &#177; 17.4</td><td>0.671</td></tr><tr><td>&lt; 50 nmol/L n (%)<sup>e</sup></td><td></td><td>229 (54.0)</td><td>72 (54.5)</td><td>76 (52.1)</td><td>81 (55.5)</td><td>0.832</td></tr><tr><td>s-Ferritin (&#956;g/l)</td><td>412</td><td>40.7 &#177; 23.1</td><td>40.9 &#177; 22.4</td><td>41.2 &#177; 24.5</td><td>40.4 &#177; 22.3</td><td>0.953</td></tr><tr><td> &lt;15 &#956;g/l n (%)<sup>e</sup></td><td></td><td>40 (9.7)</td><td>12 (9.4)</td><td>13 (9.2)</td><td>15 (10.6)</td><td>0.912</td></tr><tr><td>UIC (&#956;g/L)</td><td>415</td><td>122.6 &#177; 63.7</td><td>122.6 &#177; 71.3</td><td>122.9 &#177; 59.3</td><td>125.0 &#177; 66.7</td><td>0.693</td></tr><tr><td>&lt; 100 &#956;g/l<sup>e</sup></td><td></td><td>164 (39.5)</td><td>55 (42.6)</td><td>49 (34.3)</td><td>60 (42.0)</td><td>0.282</td></tr><tr><td>Dietary intake</td><td>414</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Fish for dinner<sup>f</sup></td><td></td><td>1.5 (0.9)</td><td>1.5 (1.0)</td><td>1.4 (0.9)</td><td>1.5 (0.9)</td><td>0.780</td></tr><tr><td>Herring/mackerel/salmon for dinner<sup>f</sup></td><td></td><td>1.0 (0.9)</td><td>1.0 (1.0)</td><td>0.9 (0.9)</td><td>1.0 (1.0)</td><td>0.852</td></tr><tr><td>Fish as bread spread<sup>f</sup></td><td></td><td>0.6 (1.0)</td><td>0.7 (1.0)</td><td>0.6 (1.0)</td><td>0.6 (0.9)</td><td>0.620</td></tr><tr><td>Fish oil supplements (n (%))<sup>g</sup></td><td>413</td><td></td><td></td><td></td><td></td><td>0.659</td></tr><tr><td> Never</td><td></td><td>220 (53.3)</td><td>60 (46.9)</td><td>81 (56.3)</td><td>79 (56.0)</td><td></td></tr><tr><td> 1&#8211;3 times/month</td><td></td><td>53 (12.8)</td><td>18 (14.1)</td><td>18 (12.5)</td><td>17 (12.1)</td><td></td></tr><tr><td> 1&#8211;3 times/week</td><td></td><td>45 (10.9)</td><td>19 (14.8)</td><td>14 (9.7)</td><td>12 (8.5)</td><td></td></tr><tr><td> 4&#8211;6 times/week</td><td></td><td>20 (4.8)</td><td>6 (4.7)</td><td>5 (3.5)</td><td>9 (6.4)</td><td></td></tr><tr><td> Every day</td><td></td><td>75 (18.2)</td><td>25 (19.5)</td><td>26 (18.1)</td><td>24 (17.0)</td><td></td></tr></table>
b2430183fc12c24991569c9f7b70293262dff2de5d309b85ae40c66966cd4b44.png
complex
<table><tr><td></td><td colspan="3">Screening set</td><td colspan="3">Validation set</td><td colspan="3">Merge set</td></tr><tr><td>SNP</td><td>Controls (<i>n</i> = 100)</td><td>LCs (<i>n</i> = 100)</td><td>OR (95% CI/<i>P</i><sub>trend</sub>)<sup>a</sup></td><td>Controls (<i>n</i> = 751)</td><td>LCs (<i>n</i> = 284)</td><td>OR (95% CI/<i>P</i><sub>trend</sub>)<sup>a</sup></td><td>Controls (<i>n</i> = 851)</td><td>LCs (<i>n</i> = 384)</td><td>OR (95% CI/<i>P</i><sub>trend</sub>)<sup>a</sup></td></tr><tr><td>rs8021276</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> AA</td><td>72</td><td>43</td><td>Reference</td><td>543</td><td>120</td><td>Reference</td><td>615</td><td>163</td><td>Reference</td></tr><tr><td> AG</td><td>24</td><td>35</td><td>2.97 (1.43&#8211;6.16/3.52 &#215; 10<sup>-3</sup>)</td><td>178</td><td>100</td><td>2.45 (1.75&#8211;3.42/1.417 &#215; 10<sup>-7</sup>)</td><td>202</td><td>135</td><td>2.48 (1.84&#8211;3.33/2.00 &#215; 10<sup>-9</sup>)</td></tr><tr><td> GG</td><td>4</td><td>22</td><td>11.92 (3.42&#8211;41.55/9.97 &#215; 10<sup>-5</sup>)</td><td>30</td><td>64</td><td>6.54 (3.85&#8211;11.10/3.49 &#215; 10<sup>-12</sup>)</td><td>34</td><td>86</td><td>6.98 (4.35&#8211;11.22/9.27 &#215; 10<sup>-16</sup>)</td></tr><tr><td> AG/GG</td><td>28</td><td>57</td><td>4.16 (2.11&#8211;8.18/3.62 &#215; 10<sup>-5</sup>)</td><td>208</td><td>164</td><td>3.09 (2.27&#8211;4.19/5.33 &#215; 10<sup>-13</sup>)</td><td>236</td><td>221</td><td>3.17 (2.42&#8211;4.16/8.08 &#215; 10<sup>-17</sup>)</td></tr><tr><td>rs7158733</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> GG</td><td>57</td><td>32</td><td>Reference</td><td>345</td><td>112</td><td>Reference</td><td>402</td><td>144</td><td>Reference</td></tr><tr><td> GT</td><td>30</td><td>35</td><td>3.59 (1.62&#8211;7.99/1.72 &#215; 10<sup>-3</sup>)</td><td>242</td><td>97</td><td>1.25 (0.89&#8211;1.75/0.21)</td><td>272</td><td>132</td><td>1.41 (1.014&#8211;1.91/0.03)</td></tr><tr><td> TT</td><td>13</td><td>33</td><td>6.59 (2.57&#8211;16.88/8.57 &#215; 10<sup>-5</sup>)</td><td>164</td><td>75</td><td>1.38 (0.95&#8211;2.00/0.10)</td><td>177</td><td>108</td><td>1.70 (1.22&#8211;2.37/1.78 &#215; 10<sup>-3</sup>)</td></tr><tr><td> GT/TT</td><td>43</td><td>68</td><td>4.50 (2.18&#8211;9.31/4.98 &#215; 10<sup>-5</sup>)</td><td>406</td><td>172</td><td>1.30 (0.96&#8211;1.75/0.09)</td><td>449</td><td>240</td><td>1.52 (1.17&#8211;1.99/2.03 &#215; 10<sup>-3</sup>)</td></tr><tr><td>rs10146249</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> CC</td><td>46</td><td>20</td><td>Reference</td><td>292</td><td>93</td><td>Reference</td><td>338</td><td>113</td><td>Reference</td></tr><tr><td> CA</td><td>41</td><td>48</td><td>3.08 (1.47&#8211;6.43/2.76 &#215; 10<sup>-3</sup>)</td><td>288</td><td>141</td><td>1.72 (1.23&#8211;2.40/1.40 &#215; 10<sup>-3</sup>)</td><td>329</td><td>189</td><td>1.96 (1.45&#8211;2.64/1.26 &#215; 10<sup>-4</sup>)</td></tr><tr><td> AA</td><td>13</td><td>32</td><td>5.77 (2.31&#8211;14.37/1.59 &#215; 10<sup>-4</sup>)</td><td>171</td><td>50</td><td>1.20 (0.78&#8211;1.83/0.41)</td><td>184</td><td>82</td><td>1.67 (1.16&#8211;2.41/5.80 &#215; 10<sup>-3</sup>)</td></tr><tr><td> CA/AA</td><td>54</td><td>80</td><td>3.74 (1.87&#8211;7.49/1.86 &#215; 10<sup>-4</sup>)</td><td>459</td><td>191</td><td>1.54 (1.13&#8211;2.09/6.24 &#215; 10<sup>-3</sup>)</td><td>513</td><td>271</td><td>1.86 (1.41&#8211;2.46/1.58 &#215; 10<sup>-3</sup>)</td></tr></table>
699b288b7d78103c5d2f907d114a0cb9adcf5d4d89ef4448222d36bed0cc618c.png
simple
<table><tr><td>Microorganisms</td><td>PN-EO</td><td>CHD<sup>a</sup></td><td>1<sup>b</sup></td><td>2<sup>b</sup></td><td>3<sup>b</sup></td><td>4<sup>b</sup></td><td>1 + 2 + 3 + 4<sup>c</sup></td></tr><tr><td><i>E. faecalis </i></td><td>250.0</td><td>14.8</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td></tr><tr><td><i>S. salivarius </i></td><td>250.0</td><td>7.4</td><td>4000</td><td>4000</td><td>4000</td><td>4000</td><td>4000</td></tr><tr><td><i>S. mutans </i></td><td>3.9</td><td>1.8</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>1000</td></tr><tr><td><i>S. mitis </i></td><td>31.3</td><td>14.8</td><td>4000</td><td>4000</td><td>4000</td><td>4000</td><td>4000</td></tr><tr><td><i>S. sobrinus </i></td><td>62.5</td><td>1.8</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>4000</td></tr><tr><td><i>S. sanguinis </i></td><td>62.5</td><td>7.4</td><td>4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td><td>&gt;4000</td></tr><tr><td><i>L. casei </i></td><td>31.3</td><td>3.7</td><td>4000</td><td>4000</td><td>4000</td><td>4000</td><td>500</td></tr></table>
c2d2d423ea4f53563763187f5136e82bc26366325d7e7d789758b81e7930689c.png
simple
<table><tr><td>Isolates</td><td>Body site</td><td><i>spa</i> type</td><td>SCC<i>mec</i></td><td>ST<sup>a</sup></td><td>PFT<sup>b</sup></td></tr><tr><td>27 N</td><td>nasal</td><td>t002</td><td>II</td><td>ST105</td><td>A1</td></tr><tr><td>08 N</td><td>nasal</td><td>t311</td><td>II</td><td>ST105</td><td>B1</td></tr><tr><td>P65N</td><td>nasal</td><td>t002</td><td>II</td><td>ST105</td><td>C</td></tr><tr><td>98I</td><td>groin</td><td>t14789</td><td>IVa</td><td>ST1176</td><td>D1</td></tr><tr><td>62 N</td><td>nasal</td><td>t149</td><td>I</td><td>ST5</td><td>E1</td></tr><tr><td>P32N</td><td>nasal</td><td>t37</td><td>III</td><td>ST239</td><td>F1</td></tr><tr><td>78 N</td><td>nasal</td><td>t110</td><td>I</td><td>ST105</td><td>G</td></tr><tr><td>111 N</td><td>nasal</td><td>t002</td><td>II</td><td>ST105</td><td>H</td></tr><tr><td>59 N</td><td>nasal</td><td>t149</td><td>IVa</td><td>ST1510</td><td>I</td></tr></table>
747fbc8b1e0e0b6ede078df6879c0289d2c3bcfe7abd9e98c049eac4683f7178.png
simple
<table><tr><td>Year</td><td>Trade Specialization Index (TSI)</td></tr><tr><td>2001</td><td>-0.940</td></tr><tr><td>2006</td><td>-0.898</td></tr><tr><td>2010</td><td>-0.844</td></tr></table>
e8a0b04e86da95995bbaea3872a73b48911ba3a00fced139fb87a6e5fd0b7550.png
complex
<table><tr><td rowspan="2">Features </td><td colspan="3"> DNA configurations </td></tr><tr><td> A </td><td> B </td><td> Z </td></tr><tr><td>Helix orientation </td><td> Right-handed </td><td>Right-handed </td><td>Left-handed</td></tr><tr><td>DNA diameter </td><td> 2.55 </td><td> 2.37 </td><td> 1.84</td></tr><tr><td>bp diameter </td><td> 1.0 </td><td>1.0 </td><td> 0.6</td></tr><tr><td>bp axial step </td><td> 0.23 </td><td> 0.33 </td><td> 0.38 </td></tr><tr><td>Helix pitch </td><td> 2.46 </td><td> 3.2 </td><td> 3.0 </td></tr><tr><td>bp/helix turn </td><td> 10.7 </td><td> 10 </td><td> 12 </td></tr><tr><td>bp/nucleosome </td><td> 286 </td><td> 198 </td><td> 172</td></tr><tr><td>Helix axial shift </td><td> 0.76 </td><td> 1.2 </td><td> 0.77</td></tr><tr><td>Target angular aperture </td><td> 87&#176;</td><td> 73&#176;</td><td> 60&#176;</td></tr><tr><td>Target height </td><td> 0.119 </td><td> 0.183 </td><td> 0.249</td></tr><tr><td>Total number of bp </td><td>7.72 &#215; 10<sup>8</sup></td><td>5.35 &#215; 10<sup>8</sup></td><td>4.64 &#215; 10<sup>8</sup></td></tr><tr><td>Target volume (nm<sup>3</sup>) </td><td> 0.12 </td><td> 0.13 </td><td> 0.10</td></tr></table>
02cca9587f84d174fe4d9e3d87c47f28c6f180c420871357250888f766dff9e2.png
simple
<table><tr><td>GOLD stage *</td><td>Number of patients (%)</td></tr><tr><td>Stage I</td><td>18 (17.0%)</td></tr><tr><td>Stage II</td><td>42 (39.6%)</td></tr><tr><td>Stage III</td><td>28 (26.4%)</td></tr><tr><td>Stage IV</td><td>18 (17.0%)</td></tr><tr><td>Total LAA score <sup>&#8224;</sup></td><td>Patient number (%)</td></tr><tr><td>7-12</td><td>46 (43.4%)</td></tr><tr><td>13-18</td><td>24 (22.6%)</td></tr><tr><td>19-24</td><td>36 (34.0%)</td></tr></table>
db404ddfc2c4d9545d1c7d5b2755850208955814b9584cb2bb9ff8f9d153735a.png
complex
<table><tr><td>Kano Model</td><td colspan="2">Refined Kano Model</td></tr><tr><td>Quality Attribute</td><td>High Important Attributes</td><td>Low Important Attribute</td></tr><tr><td>Attractive quality</td><td>High attractive quality</td><td>Low attractive quality</td></tr><tr><td>One-dimensional quality</td><td>High value-added quality</td><td>Low value-added quality</td></tr><tr><td>Must-be quality</td><td>Critical quality</td><td>Necessary quality</td></tr><tr><td>Indifferent quality</td><td>Potential quality</td><td>Care-free quality</td></tr></table>
c7409ca474048d95fd821fbcb39e1003c34188ba916c029dfce624c5b2acd353.png
complex
<table><tr><td>Molecule</td><td>Actions/effects</td><td>Reference</td></tr><tr><td rowspan="5">Sulfur dioxide</td><td>Possible long-term cardiac abnormality</td><td>Pishgoo et al. (15)</td></tr><tr><td>Cardiac and mitochondrial dysfunction (rats)</td><td>Qin et al. (1)</td></tr><tr><td>Increase heart susceptibility to oxidative stress</td><td>Zaky et al. (16)</td></tr><tr><td>Inhibits the proapoptotic effect of isopropylarterenol on myocardial tissue through a bcl-2/cytc/caspase-9/caspase-3 pathway</td><td>Jin et al. (11)</td></tr><tr><td>Aggravates myocardial I/R injury</td><td>Zhang et al. (17)</td></tr><tr><td>Sulfur dioxide</td><td rowspan="2">Ameliorated systemic hypertension and pulmonary hypertension prevented the development of atherosclerosis and protected against myocardial ischemia-reperfusion (I/R) injury and isoproterenol-induced myocardial injury</td><td rowspan="2">Huang et al. (18)</td></tr><tr><td>Sulfites</td></tr><tr><td rowspan="2">Sulfur mustard</td><td>Modification of the ratio prooxidant/antioxidant</td><td rowspan="2">Shohrati et al. (19)</td></tr><tr><td>Reduction of serum GSH, increase of serum malondialdehyde (MDA)</td></tr><tr><td rowspan="4">Sulfites</td><td>Deleterious effects through the mitochondrial Fe<sup>3+</sup> cyt <i>c</i>-mediated ROS</td><td>Velayutham et al. (20)</td></tr><tr><td>Reduced the length and volume of the ventricular capillaries (rats)</td><td>Noorafshan et al. (21)</td></tr><tr><td>With sulfite oxidase contributes in NO signaling</td><td>Wang et al. (22)</td></tr><tr><td>They can affect voltage-gated sodium (Na<sup>+</sup>) channels (VGSC) in a concentration-dependent manner in isolated rat ventricular myocytes. Protective action of catechins</td><td>Wei and Meng (23)</td></tr></table>
0483e9140e3401aaa08d8c21b866db3b25da6de8c2bedd6ff0e35c9fafa23158.png
complex
<table><tr><td></td><td colspan="2">ST use</td><td></td><td></td><td colspan="4">RR/OR</td></tr><tr><td>Source<sup>a</sup></td><td>Type<sup>b</sup></td><td>Exposure<sup>c</sup></td><td>Smoking</td><td>Sex</td><td>Id.</td><td>Cases<sup>d</sup></td><td>Estimate (95%CI)</td><td>Adjustment factors<sup>e</sup></td></tr><tr><td>Case-control studies</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Wynder <i>et al</i>. 1957 [40]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>Chew</td><td>Ever</td><td>Any</td><td>M</td><td>1</td><td>NA</td><td>no association<sup>f</sup></td><td>none</td></tr><tr><td>Vincent and Marchetta 1963 [45]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>Snuff</td><td>Use</td><td>Any</td><td>M</td><td>2</td><td>5</td><td>1.81 (0.33&#8211;9.97)</td><td>none</td></tr><tr><td>Williams and Horm 1977 [55]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>ST</td><td>Ever</td><td>Any</td><td>M</td><td>3</td><td>16</td><td>2.01 (1.15&#8211;3.51)<sup>g</sup></td><td>age, race, smok</td></tr><tr><td>Wynder and Stellman 1977 [56]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>Chew</td><td>Ever</td><td>Any</td><td>M</td><td>4</td><td>46</td><td>1.35 (0.96&#8211;1.89)<sup>g</sup></td><td>none</td></tr><tr><td></td><td>Snuff</td><td></td><td></td><td></td><td>5</td><td>15</td><td>1.46 (0.82&#8211;2.57)<sup>g</sup></td><td>none</td></tr><tr><td></td><td>ST</td><td></td><td></td><td></td><td>6</td><td>61</td><td>1.40 (1.04&#8211;1.89)<sup>h</sup></td><td>none</td></tr><tr><td>Engzell <i>et al</i>. 1978 [57]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- nasal cancer</td><td>Snuff</td><td>Use</td><td>Any</td><td>M</td><td>7</td><td>NA</td><td>no association</td><td>none</td></tr><tr><td>Brinton <i>et al</i>. 1984 [64]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- nasal cancer</td><td>Chew</td><td>Use</td><td>Any</td><td>M+F</td><td>8</td><td>15</td><td>0.74 (0.40&#8211;1.50)</td><td>sex</td></tr><tr><td></td><td>Snuff</td><td></td><td></td><td></td><td>9</td><td>23</td><td>1.47 (0.80&#8211;2.80)</td><td></td></tr><tr><td></td><td>ST</td><td></td><td></td><td></td><td>10</td><td>38</td><td>1.08 (0.68&#8211;1.70)<sup>h</sup></td><td>none</td></tr><tr><td>Stockwell and Lyman 1986 [70]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- nasal cancer</td><td>ST</td><td>Ever</td><td>Any</td><td>M+F</td><td>11</td><td>1</td><td>2.93 (0.40&#8211;21.66)<sup>g</sup></td><td>none</td></tr><tr><td>- larynx cancer</td><td>ST</td><td>Ever</td><td>Any</td><td>M+F</td><td>12</td><td>6</td><td>2.02 (0.84&#8211;4.86)<sup>g</sup></td><td>none</td></tr><tr><td>Young <i>et al</i>. 1986 [71]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>ST</td><td>Ever</td><td>Any</td><td>M</td><td>13</td><td>NA</td><td>no association</td><td>none</td></tr><tr><td>Lewin <i>et al</i>. 1998 [102]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>- larynx cancer</td><td>Snuff</td><td>Current</td><td>Any</td><td>M</td><td>14</td><td>15</td><td>1.00 (0.50&#8211;1.90)</td><td>age, alc, res, smok</td></tr><tr><td></td><td></td><td>Former</td><td></td><td></td><td>15</td><td>9</td><td>0.80 (0.40&#8211;1.70)</td><td></td></tr><tr><td></td><td></td><td>Ever</td><td></td><td></td><td>16</td><td>24</td><td>0.90 (0.50&#8211;1.50)</td><td></td></tr></table>
fbca45c40334a79d2f6bbc9d538bb09a57eae3c53d7b4722304f25973873813d.png
simple
<table><tr><td>Variable</td><td>Mean</td><td>ICC</td><td>95% CI for ICC</td><td>Deff</td><td>n<sub>a</sub></td></tr><tr><td>Age (years)</td><td>26.1</td><td>0.018</td><td>0.004-0.033</td><td>5.3</td><td>265</td></tr><tr><td>Month stopped working</td><td>6.9</td><td>0.015</td><td>&lt;0.001-0.032</td><td>2.6</td><td>99</td></tr><tr><td>Workload (hours daily)</td><td>8.0</td><td>0.040</td><td>0.007-0.072</td><td>6.9</td><td>98</td></tr><tr><td>Pre-pregnancy weight (Kg)</td><td>62.1</td><td>0.021</td><td>0.005-0.038</td><td>6.6</td><td>250</td></tr><tr><td>Height (m)</td><td>1.6</td><td>0.041</td><td>0.011-0.071</td><td>9.8</td><td>238</td></tr><tr><td>Final weight (Kg)</td><td>73.2</td><td>0.022</td><td>0.005-0.040</td><td>6.4</td><td>237</td></tr><tr><td>Weight gain in pregnancy (Kg)</td><td>10.9</td><td>0.012</td><td>0.001-0.023</td><td>4.5</td><td>229</td></tr><tr><td>Initial Body Mass Index (Kg/m<sup>2</sup>)</td><td>24.4</td><td>0.012</td><td>0.001-0.024</td><td>4.5</td><td>230</td></tr><tr><td>Final Body Mass Index (Kg/m<sup>2</sup>)</td><td>28.7</td><td>0.016</td><td>0.002-0.030</td><td>5.5</td><td>220</td></tr><tr><td>Number of pregnancies</td><td>2.4</td><td>0.006</td><td>&lt;0.001-0.013</td><td>2.8</td><td>265</td></tr><tr><td>Number of vaginal deliveries</td><td>0.8</td><td>0.005</td><td>&lt;0.001-0.011</td><td>2.5</td><td>265</td></tr><tr><td>Number of cesarean sections</td><td>0.3</td><td>0.014</td><td>0.002-0.025</td><td>4.7</td><td>265</td></tr><tr><td>Number of abortions</td><td>0.3</td><td>0.006</td><td>&lt;0.001-0.013</td><td>2.3</td><td>265</td></tr><tr><td>Number of uterine curettage</td><td>0.2</td><td>0.008</td><td>&lt;0.001-0.015</td><td>2.9</td><td>264</td></tr></table>
70792b318ab5706d8df2f3e94e4257b2fbb3fb75d241663769cc0c686577f31f.png
simple
<table><tr><td>GroupNo.</td><td>Description</td><td>Body site where<i>S. aureus </i>detectedin Parsonnet 2005study<sup>a</sup></td><td>Ab present inParsonnet 2005study<sup>b</sup></td><td>No. of subjectsenrolled<sup>c</sup></td><td>No. of subjectscompleting allvisits</td></tr><tr><td>1</td><td>Carriers of SA TSST-1(+)</td><td>Vagina</td><td>Yes or No</td><td>14</td><td>11</td></tr><tr><td>2</td><td>Carriers of SA TSST-1(+)</td><td>Nose or anus</td><td>Yes</td><td>78</td><td>64</td></tr><tr><td>3</td><td>Carriers of SA TSST-1(-)</td><td>Any site</td><td>Yes</td><td>69</td><td>49</td></tr><tr><td>4</td><td>Non-carriers</td><td>None</td><td>Yes</td><td>75</td><td>58</td></tr><tr><td>5</td><td>Negative Ab control(Carriers or Non-carriers)</td><td>Any site</td><td>No</td><td>75</td><td>61</td></tr></table>
673dec0b21cc7ac315cd3da224600e08ff223583df40be88762f7ab00012e1bf.png
complex
<table><tr><td colspan="8">Gay/Lesbian</td></tr><tr><td> </td><td colspan="2">Model 1 (adjusted for socio-demographic characteristics)<sup>a</sup></td><td colspan="2">Model 2 (controlling for depressive symptoms)<sup>b</sup></td><td>% reduction in association controlling for PHQ-9</td><td colspan="2">Sobel test for significance of mediator</td></tr><tr><td>Outcome</td><td>OR*</td><td>(95% CI)</td><td>OR*</td><td>(95% CI)</td><td> </td><td>Z Value</td><td>P-Value</td></tr><tr><td>Current Smoker</td><td>1.843</td><td>(1.17, 2.92)</td><td>1.812</td><td>(1.14, 2.88)</td><td>1.68</td><td>1.846</td><td>0.064</td></tr><tr><td>BMI (Overweight/Obese)</td><td>1.128</td><td>(0.78, 1.64)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Lifetime History of Drug Use (Excluding Marijuana)</td><td>1.786</td><td>(1.10, 2.91)</td><td>1.766</td><td>(1.09, 2.87)</td><td>1.12</td><td>1.4863</td><td>0.137</td></tr><tr><td>Lifetime History of Marijuana Use</td><td>1.753</td><td>(1.09, 2.82)</td><td>1.746</td><td>(1.09, 2.81)</td><td>0.40</td><td>1.50534</td><td>0.132</td></tr><tr><td>Risky Drinking (5 or more drinks) in Past 12 months</td><td>1.01</td><td>(0.61, 1.69)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Lifetime Period of Risky Drinking</td><td>1.271</td><td>(0.76, 2.12)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="8">Bisexual</td></tr><tr><td> </td><td colspan="2">Model 1 (adjusted for socio-demographic characteristics)<sup>a</sup></td><td colspan="2">Model 2 (controlling for depressive symptoms)<sup>b</sup></td><td>% reduction in association controlling for PHQ-9</td><td colspan="2">Sobel test for significance of mediator</td></tr><tr><td>Outcome</td><td>OR*</td><td>(95% CI)</td><td>OR*</td><td>(95% CI)</td><td> </td><td>Z Value</td><td>P-Value</td></tr><tr><td>Current Smoker</td><td>2.124</td><td>(1.65, 2.73)</td><td>2.044</td><td>(1.59, 2.63)</td><td>3.77</td><td>3.04054</td><td>0.0023</td></tr><tr><td>BMI (Overweight/Obese)</td><td>0.897</td><td>(0.61, 1.31)</td><td> </td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Lifetime History of Drug Use (Excluding Marijuana)</td><td>3.381</td><td>(2.24, 5.10)</td><td>3.301</td><td>(2.20, 4.96)</td><td>2.37</td><td>1.93298</td><td>0.0532</td></tr><tr><td>Lifetime History of Marijuana Use</td><td>2.928</td><td>(2.05, 4.19)</td><td>2.901</td><td>(2.02, 4.16)</td><td>0.92</td><td>3.44351</td><td>&lt;0.001</td></tr><tr><td>Risky Drinking (5 or more drinks) in Past 12 months</td><td>1.499</td><td>(1.05, 2.15)</td><td colspan="2">Cannot Estimate</td><td> </td><td> </td><td> </td></tr><tr><td>Lifetime Period of Risky Drinking</td><td>2.901</td><td>(1.67, 5.04)</td><td colspan="2">Cannot Estimate</td><td> </td><td> </td><td> </td></tr></table>
d5ebf277e4faa67abbf435c4f6525af2d4a55f64080878158d8f341b8d83f75a.png
simple
<table><tr><td>Scenario</td><td>MP Windows (s)</td><td>PRN</td></tr><tr><td>1</td><td>8&#8211;16</td><td>27</td></tr><tr><td></td><td>21&#8211;25</td><td>11, 22</td></tr><tr><td></td><td>30&#8211;35</td><td>16</td></tr><tr><td></td><td>40&#8211;45</td><td>1, 4, 21, 27</td></tr><tr><td>2</td><td>20&#8211;80</td><td>1, 4, 21, 27</td></tr></table>
5a4b024750b9fce610dbaf6a474890cc0ff2a05968f5e4d1465750052563a8c8.png
simple
<table><tr><td></td><td>AUC</td><td>95%CI</td><td>z statistic</td><td><i>P</i> value (Area=0.5)</td><td>Associated criterion</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>With or without WBRT(0:no/1:yes)</td><td>0.650&#177;0.0717</td><td>0.551-0.741</td><td>2.098</td><td>0.0359</td><td>&gt;0</td><td>33.33</td><td>96.74</td></tr><tr><td>Fraction(f)</td><td>0.712&#177;0.0637</td><td>0.615-0.797</td><td>3.335</td><td>0.0009</td><td>&lt;=2</td><td>66.67</td><td>66.30</td></tr><tr><td>BED(cGy)</td><td>0.892&#177;0.0335</td><td>0.816-0.945</td><td>11.710</td><td>&lt;0.0001</td><td>&gt;7410</td><td>91.67</td><td>84.78</td></tr></table>
6f05a94c381dd0cfdf8b8123935eec690b4ed43e708282312049b94a10d071db.png
complex
<table><tr><td rowspan="2">Diagnostic Stage</td><td rowspan="2">Diagnostic Modality</td><td colspan="2">Sensitivity (%)</td></tr><tr><td>Central</td><td>Peripheral</td></tr><tr><td rowspan="10">Initial Diagnosis</td><td>Sputum cytology</td><td>71</td><td>49</td></tr><tr><td>Bronchoscopy</td><td>88</td><td>78</td></tr><tr><td> Washings</td><td>47</td><td>43</td></tr><tr><td> Brushings</td><td>56</td><td>54</td></tr><tr><td> Biopsy</td><td>74</td><td>57</td></tr><tr><td>Radiologically guided transthoracic biopsy</td><td>-</td><td>90</td></tr><tr><td>Radial probe EBUS</td><td>-</td><td>73</td></tr><tr><td>Electromagnetic navigation</td><td>-</td><td>68</td></tr><tr><td>Cryobiopsy</td><td>95</td><td>74</td></tr><tr><td>Linear EBUS TBNA</td><td>82</td><td>-</td></tr><tr><td rowspan="5">Mediastinal Staging</td><td>Bronchoscopic TBNA</td><td colspan="2">78</td></tr><tr><td>Linear EBUS TBNA</td><td colspan="2">89</td></tr><tr><td>EUS</td><td colspan="2">89</td></tr><tr><td>EUS + EBUS</td><td colspan="2">91</td></tr><tr><td>Video assisted surgical mediastinoscopy</td><td colspan="2">89</td></tr></table>
1f9aa3d2e47247b8d7b774cfd1c54a4aaf038d806d1599c3f36281a3047e3fbf.png
simple
<table><tr><td>MMP</td><td>ANOVA</td><td>Post Test Results</td></tr><tr><td>pMMP-9</td><td>p = 0.0817</td><td>No significant differences.</td></tr><tr><td>aMMP-9</td><td>p = 0.0944</td><td>No significant differences.</td></tr><tr><td>pMMP-2</td><td>p = 0.0010</td><td>pH 5.6 (24 h) &lt; Positive Control (24 h) (p &lt; 0.05)</td></tr><tr><td></td><td></td><td>pH 9 (24 h) &lt; Positive Control (24 h) (p &lt; 0.01)</td></tr><tr><td></td><td></td><td>Negative Control (72 h) &lt; Positive Control (24 h) (p &lt; 0.001)</td></tr><tr><td></td><td></td><td>Positive Control (72 h) &lt; Positive Control (24 h) (p &lt; 0.05)</td></tr><tr><td></td><td></td><td>pH 4 (72 h) &lt; Positive Control (24 h) (p &lt; 0.05)</td></tr><tr><td></td><td></td><td>pH 5.6 (72 h) &lt; Positive Control (24 h) (p &lt; 0.05)</td></tr><tr><td></td><td></td><td>Negative Control (72 h) &lt; pH 4 (24 h) (p &lt; 0.05)</td></tr><tr><td>aMMP-2</td><td>p = 0.0019</td><td>pH 9 (24 h) &lt; Positive Control (24 h) (p &lt; 0.01)</td></tr><tr><td></td><td></td><td>pH 9 (24 h) &lt; pH 4 (24 h) (p &lt; 0.05)</td></tr><tr><td></td><td></td><td>Negative Control (72 h) &lt; Positive Control (24 h) (p &lt; 0.01)</td></tr><tr><td></td><td></td><td>Negative Control (72 h) &lt; pH 4 (24 h) (p &lt; 0.05)</td></tr></table>
f6749a2da9a0448da1fc440b8d82cea0d5ba077e9c527aac82154b3ecbef0649.png
complex
<table><tr><td></td><td colspan="4">Health consumer</td></tr><tr><td>Health professional</td><td><i>Integration</i></td><td><i>Assimilation</i></td><td><i>Separation</i></td><td><i>Individualism (Marginalization)</i></td></tr><tr><td><i>Integration</i></td><td>Consensual</td><td>Problematic</td><td>Conflictual</td><td>Problematic</td></tr><tr><td><i>Assimilation</i></td><td>Problematic</td><td>Consensual</td><td>Conflictual</td><td>Problematic</td></tr><tr><td><i>Separation</i></td><td>Conflictual</td><td>Conflictual</td><td>Conflictual</td><td>Conflictual</td></tr><tr><td><i>Individualism</i></td><td>Conflictual</td><td>Conflictual</td><td>Conflictual</td><td>Conflictual</td></tr></table>
2a9ff13ea6f3ef91ac75a55ad3c4130285d9f954d149e6c677c8f26dd7aef60d.png
simple
<table><tr><td>Immuno-staining</td><td>DLBCL component positive</td><td>LP cells positive</td><td>Reduced expression in DLBCL component</td><td>Enhanced expression in DLBCL component</td><td>Identical expression in DLBCL and NLPHL component</td><td>Identical expression in DLBCL and NLPHL in simultaneous cases</td></tr><tr><td>Bcl6</td><td>33/33 (100%)</td><td>33/33 (100%)</td><td>3%</td><td>0%</td><td>97%</td><td>96%</td></tr><tr><td>CD79a</td><td>33/33 (100%)</td><td>33/33 (100%)</td><td>0%</td><td>33%</td><td>67%</td><td>62%</td></tr><tr><td>CD19</td><td>32/33 (97%)</td><td>25/32 (78%)</td><td>3%</td><td>66%</td><td>31%</td><td>32%</td></tr><tr><td>CD75</td><td>31/33 (94%)</td><td>32/33 (97%)</td><td>12%</td><td>9%</td><td>79%</td><td>81%</td></tr><tr><td>EMA</td><td>24/33 (73%)</td><td>27/33 (82%)</td><td>18%</td><td>6%</td><td>76%</td><td>85%</td></tr><tr><td>J-chain</td><td>24/33 (73%)</td><td>27/33 (82%)</td><td>27%</td><td>3%</td><td>70%</td><td>77%</td></tr><tr><td>Bcl2*</td><td>20/32 (63%)</td><td>27/33 (82%)</td><td>0%</td><td>38%</td><td>63%</td><td>69%</td></tr><tr><td>MUM1</td><td>21/33 (63%)</td><td>24/32 (72%)</td><td>13%</td><td>13%</td><td>75%</td><td>77%</td></tr><tr><td>JAK2</td><td>12/30 (40%)</td><td>4/27 (15%)</td><td>0%</td><td>23%</td><td>77%</td><td>82%</td></tr><tr><td>CD10</td><td>12/33 (36%)</td><td>2/33 (6%)</td><td>0%</td><td>33%</td><td>67%</td><td>69%</td></tr><tr><td>p-STAT6</td><td>9/30 (30%)</td><td>8/26 (31%)</td><td>9%</td><td>5%</td><td>86%</td><td>89%</td></tr><tr><td>CD30</td><td>7/33 (21%)</td><td>7/33 (21%)</td><td>6%</td><td>6%</td><td>88%</td><td>92%</td></tr><tr><td>CD15</td><td>4/33 (12%)</td><td>2/33 (6%)</td><td>0%</td><td>12%</td><td>88%</td><td>85%</td></tr><tr><td>IgD</td><td>4/33 (12%)</td><td>5/33 (15%)</td><td>3%</td><td>0%</td><td>97%</td><td>96%</td></tr></table>
7d6ca66862355d89a1912db9f80f3bfef5ad847c4b26cc7a9094bec087167f96.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">PCO</td></tr><tr><td>X</td><td>Y</td><td>Z</td></tr><tr><td>C31</td><td>&#8722;5</td><td>0</td><td>100</td></tr><tr><td>C32</td><td>&#8722;4.5</td><td>&#8722;30</td><td>250</td></tr><tr><td>C33</td><td>&#8722;20</td><td>0</td><td>150</td></tr><tr><td>C34</td><td>&#8722;20</td><td>0</td><td>150</td></tr></table>
70f0898f08d37724d9f40ddec206c85ce19eebff912614cc6ff5a48b6a4b7d4f.png
complex
<table><tr><td><i>Name</i></td><td><i>Position</i></td><td><i>Length</i></td><td><i>Orientation</i></td><td><i>Distance</i></td><td><i>Located on</i></td><td><i>Accession</i></td></tr><tr><td>001-G11-CCfw</td><td>70,072</td><td>669</td><td>fw</td><td rowspan="2">37,428</td><td>SSCR</td><td>FI107918</td></tr><tr><td>001-G11-CCrv</td><td>107,500</td><td>778</td><td>rv</td><td>LSCR</td><td>FI107577</td></tr><tr><td>002-M15-CCfw</td><td>115,079</td><td>852</td><td>fw</td><td rowspan="2">42,542</td><td>SSCR</td><td>KG642400</td></tr><tr><td>002-M15-CCrv</td><td>7899</td><td>780</td><td>rv</td><td>LSCR</td><td>KG642401</td></tr><tr><td>198-M21-ccrv</td><td>111,193</td><td>579</td><td>fw</td><td rowspan="2">39,080</td><td>SSCR</td><td>JY420463</td></tr><tr><td>198-M21-pIfw</td><td>551</td><td>617</td><td>rv</td><td>LSCR</td><td>JY420464</td></tr></table>
32dd7770578349911740cc667971d5db75c0383cce96e0b85a8b02a913419efe.png
complex
<table><tr><td>Variable</td><td>Value</td></tr><tr><td> Age (years)</td><td>63 (58&#8211;73)</td></tr><tr><td> Sex ratio (male/female)</td><td>16/9</td></tr><tr><td> Body mass index (kg/m<sup>2</sup>)</td><td>26 (22&#8211;27)</td></tr><tr><td> Euroscore 2 (%)</td><td>5 (3&#8211;8)</td></tr><tr><td> Left ventricular ejection fraction (%)</td><td>60 (60&#8211;66)</td></tr><tr><td> Preoperative serum creatinine (&#956;mol/l)</td><td>76 (59&#8211;90)</td></tr><tr><td> Glomerular filtration rate (ml/min/1.73 m<sup>2</sup>)</td><td>82 (75&#8211;91)</td></tr><tr><td colspan="2">Comorbidities (<i>n</i>, %)</td></tr><tr><td> Hypertension</td><td>15 (60)</td></tr><tr><td> Chronic obstructive pulmonary disease</td><td>2 (8)</td></tr><tr><td> Dyslipidemia</td><td>11 (45)</td></tr><tr><td> Smokers</td><td>6 (24)</td></tr><tr><td colspan="2">Type of surgery (<i>n</i>, %)</td></tr><tr><td> Coronary surgery</td><td>8 (32)</td></tr><tr><td> Valve surgery</td><td>12 (48)</td></tr><tr><td> Combined surgery</td><td>2 (8)</td></tr><tr><td> Other cardiac surgery</td><td>3 (12)</td></tr><tr><td> Thoracic surgery</td><td>4 (16)</td></tr><tr><td colspan="2">Chronic medications (<i>n</i>, %)</td></tr><tr><td> Beta blockers</td><td>10 (40)</td></tr><tr><td> Renin angiotensin system inhibitors</td><td>12 (48)</td></tr><tr><td> Statins</td><td>11 (44)</td></tr><tr><td> Antiplatelet agents</td><td>9 (36)</td></tr><tr><td> Calcium channel blockers</td><td>5 (20)</td></tr><tr><td> Nitrates</td><td>2 (8)</td></tr><tr><td colspan="2">Vasoactive support</td></tr><tr><td> Norepinephrine at baseline (&#956;g/kg/min)</td><td rowspan="2">0.03 &#177; 0.10</td></tr><tr><td>During POAF</td></tr><tr><td> Kaliemia (mmol/l)</td><td>4.1 &#177; 0.4</td></tr><tr><td> Hemoglobin (g/dl)</td><td>10.8 &#177; 1.6</td></tr><tr><td> SpO<sub>2</sub> (%)</td><td>96.0 &#177; 1.8</td></tr></table>
84168a97ecdae2e0141631a0a87e25c54f3edeb5d8b00233d762f8e63b8c1c7b.png
complex
<table><tr><td> </td><td colspan="3">Prevention protocol</td><td colspan="3">Treatment protocol</td></tr><tr><td></td><td rowspan="2">DIO</td><td><i>L. laricina</i></td><td><i>L. laricina</i></td><td rowspan="2">DIO</td><td><i>L. laricina</i></td><td><i>L. laricina</i></td></tr><tr><td> </td><td>125 mg/kg</td><td>250 mg/kg</td><td>125 mg/kg</td><td>250 mg/kg</td></tr><tr><td>Retroperitoneal fat pad (g)</td><td>1.34 &#177; 0.05</td><td>1.26 &#177; 0.04</td><td>1.14 &#177; 0.05*</td><td>1.51 &#177; 0.08</td><td>1.35 &#177; 0.24</td><td>1.44 &#177; 0.04</td></tr><tr><td>Epididymal fat pad (g)</td><td>2.40 &#177; 1.00</td><td>2.56 &#177; 0.08</td><td>2.56 &#177; 0.07</td><td>1.21 &#177; 0.03</td><td>1.32 &#177; 0.18</td><td>1.85 &#177; 0.12*</td></tr><tr><td>Brown fat pad (g)</td><td>0.30 &#177; 0.03</td><td>0.33 &#177; 0.01</td><td>0.28 &#177; 0.02</td><td>0.44 &#177; 0.01</td><td>0.37 &#177; 0.06</td><td>0.42 &#177; 0.02</td></tr><tr><td>Liver weight (g)</td><td>1.77 &#177; 0.09</td><td>1.85 &#177; 0.05</td><td>1.80 &#177; 0.07</td><td>2.62 &#177; 0.15</td><td>2.44 &#177; 0.38</td><td>2.57 &#177; 0.12</td></tr><tr><td>Liver index</td><td>410 &#177; 2</td><td>429 &#177; 1</td><td>437 &#177; 1</td><td>551 &#177; 3</td><td>539 &#177; 5</td><td>555 &#177; 2</td></tr></table>
d0725a04fdbd6ae3eacaf69eb65d054decd07288d62b814b541c93465c0182f6.png
complex
<table><tr><td> </td><td> </td><td colspan="4">Classification accuracy(%)</td></tr><tr><td>Participant</td><td> </td><td>SELDA (M)</td><td>SELDA (C)</td><td>SEQDA(M)</td><td>SEQDA(C)</td></tr><tr><td>P1</td><td>AR</td><td>96.98</td><td>96.39</td><td>95.52</td><td>96.26</td></tr><tr><td> </td><td>FC</td><td>96.48</td><td>96.10</td><td>97.56</td><td>99.18</td></tr><tr><td>P2</td><td>AR</td><td>93.56</td><td>93.14</td><td>88.78</td><td>92.84</td></tr><tr><td> </td><td>FC</td><td>96.28</td><td>95.19</td><td>95.69</td><td>97.45</td></tr><tr><td>P3</td><td>AR</td><td>97.32</td><td>96.20</td><td>98.59</td><td>99.44</td></tr><tr><td> </td><td>FC</td><td>98.87</td><td>98.04</td><td>98.60</td><td>99.51</td></tr><tr><td>P4</td><td>AR</td><td>92.95</td><td>92.15</td><td>92.03</td><td>92.63</td></tr><tr><td> </td><td>FC</td><td>92.18</td><td>92.31</td><td>93.87</td><td>94.27</td></tr><tr><td>P5</td><td>AR</td><td>92.37</td><td>89.78</td><td>91.25</td><td>93.58</td></tr><tr><td> </td><td>FC</td><td>93.97</td><td>92.80</td><td>95.07</td><td>97.90</td></tr><tr><td>P6</td><td>AR</td><td>96.61</td><td>94.85</td><td>95.83</td><td>97.00</td></tr><tr><td> </td><td>FC</td><td>96.10</td><td>95.46</td><td>97.06</td><td>97.91</td></tr><tr><td>P7</td><td>AR</td><td>93.72</td><td>91.64</td><td>85.45</td><td>88.76</td></tr><tr><td> </td><td>FC</td><td>90.16</td><td>89.37</td><td>93.09</td><td>94.59</td></tr><tr><td>P8</td><td>AR</td><td>93.97</td><td>93.14</td><td>97.55</td><td>98.03</td></tr><tr><td> </td><td>FC</td><td>95.87</td><td>95.49</td><td>98.11</td><td>97.70</td></tr><tr><td>P9</td><td>AR</td><td>97.58</td><td>97.48</td><td>96.78</td><td>97.14</td></tr><tr><td> </td><td>FC</td><td>97.78</td><td>97.80</td><td>98.24</td><td>99.00</td></tr><tr><td>P10</td><td>AR</td><td>96.18</td><td>95.72</td><td>95.98</td><td>97.59</td></tr><tr><td> </td><td>FC</td><td>95.33</td><td>94.93</td><td>96.53</td><td>97.13</td></tr><tr><td>Mean</td><td>AR</td><td>95.12</td><td>94.05</td><td>93.87</td><td>95.33</td></tr><tr><td> </td><td>FC</td><td>95.30</td><td>94.75</td><td>96.38</td><td>97.46</td></tr></table>
7837ed6c7c46f1b3d3a6bc2c227172d4c61ddab86c9cecb29264e6d9e54cd38c.png
complex
<table><tr><td></td><td></td><td></td><td>F25</td><td>F57</td><td>Ethanol &#215; Fish Oil</td></tr><tr><td rowspan="2">Final body weight (g)</td><td>C</td><td>425.2 &#177; 4.4 <sup>c</sup></td><td>440.2 &#177; 4.7 <sup>a</sup></td><td>437.0 &#177; 10.7 <sup>b</sup></td><td>0.74</td></tr><tr><td>E</td><td>392.0 &#177; 11.9 *</td><td>379.3 &#177; 12.9</td><td>398.7 &#177; 6.0</td><td></td></tr><tr><td rowspan="2">Relative liver weight (%) <sup>3</sup></td><td>C</td><td>2.2 &#177; 0 <sup>b</sup></td><td>2.3 &#177; 0 <sup>b</sup></td><td>2.5 &#177; 0 <sup>a</sup></td><td>0.4533</td></tr><tr><td>E</td><td>2.9 &#177; 0 *</td><td>3.1 &#177; 0.1</td><td>3.2 &#177; 0.2</td><td></td></tr><tr><td rowspan="2">Plasma ALT activity (U/L)</td><td>C</td><td>33.7 &#177; 1.9 <sup>b</sup></td><td>39.7 &#177; 6.9 <sup>a,b</sup></td><td>41.8 &#177; 6.7 <sup>a</sup></td><td>0.1781</td></tr><tr><td>E</td><td>78.0 &#177; 15.0 *</td><td>81.2 &#177; 21.4</td><td>66.2 &#177; 13.4</td><td></td></tr><tr><td rowspan="2">Plasma AST activity (U/L)</td><td>C</td><td>75.8 &#177; 5.0 <sup>b</sup></td><td>77.2 &#177; 1.2 <sup>b</sup></td><td>91.5 &#177; 3.2 <sup>a</sup></td><td>0.0003</td></tr><tr><td>E</td><td>151.5 &#177; 10.0 *<sup>,e</sup></td><td>122.0 &#177; 9.8 <sup>f</sup></td><td>131.2 &#177; 16.8 <sup>f</sup></td><td></td></tr><tr><td rowspan="2">Hepatic TGs (mg TGs/g liver)</td><td>C</td><td>9.05 &#177; 0.64</td><td>10.00 &#177; 0.68</td><td>12.26 &#177; 1.25</td><td>&lt;0.0001</td></tr><tr><td>E</td><td>15.51 &#177; 0.42 *<sup>,e</sup></td><td>11.61 &#177; 1.06 <sup>f</sup></td><td>8.93 &#177; 0.52 <sup>g</sup></td><td></td></tr><tr><td rowspan="2">Hepatic TC (mg TC/g liver)</td><td>C</td><td>13.10 &#177; 0.70 <sup>b</sup></td><td>14.60 &#177; 1.00 <sup>a,b</sup></td><td>17.10 &#177; 1.10 <sup>a</sup></td><td>0.8515</td></tr><tr><td>E</td><td>17.90 &#177; 0.90 *</td><td>19.00 &#177; 1.30</td><td>20.50 &#177; 1.40</td><td></td></tr><tr><td rowspan="2">Plasma adiponectin (&#956;g/mL)</td><td>C</td><td>12.2 &#177; 1.0 <sup>a</sup></td><td>13.9 &#177; 0.9 <sup>a,b</sup></td><td>16.5 &#177; 2.0 <sup>b</sup></td><td>0.947</td></tr><tr><td>E</td><td>5.1 &#177; 1.3 *<sup>,f</sup></td><td>7.4 &#177; 1.3 <sup>e,f</sup></td><td>10.3 &#177; 1.5 <sup>e</sup></td><td></td></tr></table>
e113f4dab9bbab281edc81379398b9a939078976090128989eeb225a8c579c6a.png
complex
<table><tr><td>Substance name</td><td>Mechanism of action</td><td>Clinical trial, design and results</td><td>Reference</td></tr><tr><td>TAK-242 (Resatorvid)</td><td>Binds covalently to Cys747 of TLR4-TIR domain and blocks TLR4/TIRAP and TLR4/TRAM interactions</td><td>Randomized, double-blind, placebo-controlled phase 2 trial (274 patients). Failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure.</td><td>[124]</td></tr><tr><td rowspan="3">Eritoran (E5564)</td><td rowspan="3">Lipid A mimic, binds to MD-2</td><td>Phase 2, double-blind, placebo-controlled, ascending-dose study (152 patients). Eritoran was well tolerated but did not attenuated systemic inflammation significantly.</td><td>[127]</td></tr><tr><td>Randomized, double-blind, placebo-controlled, multinational phase 3 trial (1961 patient). Treatment did not improve 28-day survival.</td><td>[131]</td></tr><tr><td>Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial (293 patients). Eritoran was well tolerated but the mortality was not decreased significantly.</td><td>[132]</td></tr></table>
60072c273ce961c402b8dbf86d7c3b5605e235a1e4b76cb8e5a979b899b8b642.png
complex
<table><tr><td> </td><td> </td><td>P-value</td><td>Lower 95% CI</td><td>Upper 95% CI</td></tr><tr><td rowspan="2">2hPG</td><td>Crude</td><td>&lt;.001</td><td>8.553</td><td>9.238</td></tr><tr><td>Adjusted</td><td>&lt;.001</td><td>8.546</td><td>9.241</td></tr><tr><td>FPG</td><td>Crude</td><td>&lt;.001</td><td>6.164</td><td>6.473</td></tr><tr><td> </td><td>Adjusted</td><td>&lt;.001</td><td>6.162</td><td>6.476</td></tr><tr><td rowspan="2">HbAlc</td><td>Crude</td><td>.001</td><td>6.123</td><td>6.346</td></tr><tr><td>Adjusted</td><td>.002</td><td>6.124</td><td>6.342</td></tr></table>
d86626aaf2af8dfd016eacf9c179d4c4da2dcfd084b3b397e99b972a0d920c43.png
simple
<table><tr><td></td><td>All patients</td><td>Patients with OS &gt;50 months</td><td>Patients with OS &lt;50 months</td><td><i>P</i>value</td></tr><tr><td>ORR (%)*</td><td>44.9</td><td>82.6</td><td>17.9</td><td>&lt;0.00001</td></tr><tr><td>CBR (%)*</td><td>63.3</td><td>100</td><td>35.7</td><td>&lt;0.00001</td></tr><tr><td>TTF*</td><td>10</td><td>26</td><td>5</td><td>0</td></tr><tr><td>TTP*</td><td>18</td><td>34</td><td>5</td><td>0</td></tr><tr><td>OS*</td><td>38</td><td>68</td><td>17</td><td>&lt;0.00001</td></tr><tr><td>OS from diagnosis of MBC</td><td>52</td><td>113</td><td>20</td><td>&lt;0.00001</td></tr><tr><td>Number Of chemotherapy regimens*</td><td>1 (0-3)</td><td>1 (0-3)</td><td>1 (0-3)</td><td>0.66</td></tr><tr><td>Number of chemotherapy regimens for BC</td><td>3 (1-7)</td><td>4 (1-7)</td><td>4 (1-6)</td><td>0.36</td></tr><tr><td>Number of chemotherapy regimens for MBC</td><td>3 (1-7)</td><td>3 (1-7)</td><td>3 (1-5)</td><td>0.2</td></tr></table>
9dbbc55f9bfee07f6786a346d8cebc136822cd9791d34f770890dda9823e40aa.png
complex
<table><tr><td> </td><td>PD (<i>n</i> = 14)</td><td>CON (<i>n</i> = 17)</td><td rowspan="2"><i>P</i> value</td></tr><tr><td> </td><td>Means &#177; SD</td><td>Means &#177; SD</td></tr><tr><td>Age (years)</td><td>62.79 &#177; 4.59</td><td>61.35 &#177; 4.27</td><td>0.376 </td></tr><tr><td>Gender<sup>*</sup></td><td>11 M/3 F</td><td>13 M/4 F</td><td>0.889 </td></tr><tr><td>Disease duration (years) </td><td>2.46 &#177; 1.43</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>UPDRS score</td><td> </td><td> </td><td> </td></tr><tr><td> Part I&#8212;mood/cognition </td><td>2.93 &#177; 1.14</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td> Part II&#8212;activities of daily living </td><td>9.93 &#177; 2.27</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td> Part III&#8212;motor examination </td><td>21.79 &#177; 5.66</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td> Part IV&#8212;complications of therapy </td><td>0</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>MMSE score</td><td>23.93 &#177; 2.13</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>VAS</td><td>4.77 &#177; 1.30</td><td>5.69 &#177; 1.25</td><td>0.064 </td></tr><tr><td>WST</td><td>37.01 &#177; 1.44</td><td>35.74 &#177; 1.39</td><td>0.022 </td></tr><tr><td>HPT</td><td>47.74 &#177; 2.09</td><td>45.33 &#177; 3.44</td><td>0.042 </td></tr></table>
c802de7c14b49674ed7ec8557157108f54fdcf418738582df6a94d69be94f1da.png
simple
<table><tr><td>Age group</td><td>Cyano.</td><td>N</td><td>Expo. to RBC (%)</td><td>RBC in CPB (%)</td><td>Expo. to FFP (%)</td><td>FFP in CPB (%)</td><td>Expo. to PLT (%)</td></tr><tr><td>&lt; 1 mo.</td><td>1</td><td>8</td><td>6 (75)</td><td>4 (50)</td><td>2 (25)</td><td>8 (100)</td><td>0 (0)</td></tr><tr><td> </td><td>0</td><td>21</td><td>19 (90)</td><td>18 (86)</td><td>12 (57)</td><td>21 (100)</td><td>5 (24)</td></tr><tr><td>1 to 6 mo.</td><td>1</td><td>21</td><td>15 (71)</td><td>8 (38)</td><td>2 (9)</td><td>2 (9)</td><td>1 (5)</td></tr><tr><td> </td><td>0</td><td>24</td><td>19 (79)</td><td>21 (87)</td><td>1 (4)</td><td>0 (0)</td><td>1 (4)</td></tr><tr><td>6 to 12 mo.</td><td>1</td><td>10</td><td>2 (20)</td><td>1 (10)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td> </td><td>0</td><td>15</td><td>11 (73)</td><td>5 (33)</td><td>0 (0)</td><td>1 (7)</td><td>0 (0)</td></tr><tr><td>1 to 3 yr.</td><td>1</td><td>13</td><td>4 (31)</td><td>2 (15)</td><td>1 (8)</td><td>1 (8)</td><td>0 (0)</td></tr><tr><td> </td><td>0</td><td>25</td><td>13 (52)</td><td>4 (16)</td><td>0 (0)</td><td>1 (4)</td><td>0 (0)</td></tr><tr><td>&gt; 3 yr.</td><td>1</td><td>12</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td> </td><td>0</td><td>33</td><td>1 (3)</td><td>1 (3)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr></table>
6edc9b8d31fd8dbb4ac4569e8cfee1edf6c89a9e13c1771592634540284ddf62.png
complex
<table><tr><td></td><td colspan="2">SERPINB9</td><td colspan="2">CD83</td><td colspan="2">CD9</td></tr><tr><td></td><td>Pool</td><td>Indiv</td><td>Pool</td><td>Indiv</td><td>Pool</td><td>Indiv</td></tr><tr><td>Control</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>MS</td><td>0.5</td><td>2.47</td><td>1.1</td><td>0.58</td><td>1.23</td><td>3.5</td></tr></table>
bedadce8e2ed93b962016a8ed5f048c6662da5b225d0553c8ac5102b227b3e02.png
simple
<table><tr><td>QoL Domains</td><td>Mesor</td><td>Amplitude</td><td>Circadian Quotient</td><td>Rhythm Quotient</td><td>24-hr Correlation</td><td>Night-day Sleep Balance</td></tr><tr><td>EORTC Symptom Items</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Fatigue</td><td></td><td></td><td>-0.4</td><td>-0.41</td><td></td><td>-0.52</td></tr><tr><td>Pain</td><td></td><td></td><td></td><td>-0.39</td><td></td><td></td></tr><tr><td>Loss of Appetite</td><td></td><td></td><td></td><td></td><td></td><td>-0.47</td></tr><tr><td>EORTC Functional Domains</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Social</td><td></td><td></td><td></td><td>.34</td><td></td><td></td></tr><tr><td>Role</td><td></td><td></td><td></td><td></td><td></td><td>0.56</td></tr><tr><td>Cognitive</td><td></td><td></td><td></td><td></td><td></td><td>0.45</td></tr><tr><td>EORTC Global Health item</td><td></td><td></td><td></td><td></td><td>0.53</td><td></td></tr><tr><td>Ferrans-Powers QLI Domains</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Health/Function</td><td>0.44</td><td>0.51</td><td></td><td></td><td>0.45</td><td>0.39</td></tr><tr><td>Social/Economic</td><td></td><td>0.38</td><td>0.39</td><td></td><td></td><td>0.40</td></tr><tr><td>Psychological Spiritual</td><td></td><td>.45</td><td></td><td>0.4</td><td></td><td>0.45</td></tr><tr><td>Family</td><td></td><td>0.45</td><td></td><td></td><td></td><td></td></tr></table>
a3b3504201f2c87484c7af2870c19383b9d6051128aee5cd91cc654fd3bd8903.png
simple
<table><tr><td>Case</td><td>Signs/symptoms</td><td>Treatment</td><td>R</td></tr><tr><td>1</td><td>Anorexia, weight loss, fasting hypoglycemia, and mental aberrations</td><td>IVH, Di</td><td>[12]</td></tr><tr><td>2</td><td>Weakness, anorexia, orthostatic dizziness, failure to lactate, and weight loss</td><td>BB, C</td><td>[13]</td></tr><tr><td>3</td><td>Myalgia, anorexia, nausea, vomiting, weight loss, and failure to lactate</td><td>IVH, C </td><td>[14]</td></tr><tr><td>4</td><td>Lethargy, anorexia, vomiting, and weight loss</td><td>IVH, C, AT, RAI</td><td>[15]</td></tr><tr><td>5</td><td>Fatigue, weakness, nausea, vomiting, myalgia, arthralgia, and weight loss</td><td>C</td><td>[16]</td></tr><tr><td>6</td><td>Lethargy, myalgia, arthralgia, myopathy, nausea, vomiting, anorexia, weight loss, and failure to lactate</td><td>C, AT</td><td>[17]</td></tr><tr><td>7</td><td>Confusion, tachycardia, and dehydration</td><td>C, RAI</td><td>[17]</td></tr><tr><td>8</td><td>Disturbed mental state, severe nausea, vomiting, increased thirst, polyuria, and weight loss</td><td>AT, C, DDAVP</td><td>[4]</td></tr><tr><td>9</td><td>Anorexia, diarrhea, night sweats, myalgia, and weight loss</td><td>IVH, BP, AT, C</td><td>[18]</td></tr><tr><td>10</td><td>Headache, anorexia, weakness, fever, tachycardia, mental changes, and failure to lactate</td><td>C, IVH, KI, AT, BB </td><td>[19]</td></tr><tr><td>11</td><td>Nausea, vomiting, fever, and lethargy</td><td>C</td><td>[7]</td></tr><tr><td>12</td><td>Anorexia, nausea, vomiting, and severe dehydration</td><td>C, IVH</td><td>[20]</td></tr><tr><td>13</td><td>Vomiting and diarrhea</td><td>IVH, BB, C</td><td>[21]</td></tr><tr><td>PC</td><td>Vomiting, nausea, constipation, and weight loss</td><td>IVH, C, Di, BP, AT, BB </td><td> </td></tr></table>
43c2813198eb0aa32bb80a89b7f63804a3779310c1fd3af516beec5cea0f270f.png
simple
<table><tr><td></td><td>miR-96 (per million)</td><td>miR-182 (per million)</td><td>miR-183 (per million)</td></tr><tr><td>HER2-enriched (n = 34)</td><td>55.0 &#177; 46.9<sup>*</sup></td><td>49308.2 &#177; 31807.6</td><td>24494.0 &#177; 16871.2<sup>*</sup></td></tr><tr><td>Basal (n = 105)</td><td>42.3 &#177; 30.6</td><td>38971.0 &#177; 24170.6<sup>**</sup></td><td>21991.9 &#177; 16491.6<sup>*</sup></td></tr><tr><td>Luminal A (n = 406)</td><td>40.4 &#177; 35.5</td><td>50347.2 &#177; 34351.2</td><td>17668.1 &#177; 13604.2</td></tr><tr><td>Luminal B (n = 109)</td><td>38.0 &#177; 25.5</td><td>43312.6 &#177; 27928.1</td><td>17779.5 &#177; 13563.3</td></tr></table>
de1cd4fddc6e9d3caa6e5dff867ea01a200d27548501acbbad0cc5cd8af945c8.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2">Community-based organization Naloxone distribution</td><td rowspan="2">Traditional prescription</td><td colspan="4">Pharmacy-based Naloxone models</td></tr><tr><td>CPA</td><td>Standing medication order</td><td>Protocol order</td><td>Pharmacist prescribing</td></tr><tr><td>Who issues prescription?</td><td>Prescriber via standing order</td><td>Prescriber</td><td>Non-pharmacist prescriber</td><td>Non-pharmacist prescriber</td><td>Licensing board</td><td>Pharmacist</td></tr><tr><td>Medical professionals required</td><td>Varies by state: prescriber, state/local health department</td><td>Prescriber + pharmacist</td><td>Prescriber + pharmacist</td><td>Prescriber + pharmacist</td><td>Pharmacist</td><td>Pharmacist</td></tr><tr><td>Potential recipients</td><td>Individuals served by the community-based organization</td><td>Patients of the prescriber</td><td>Varies by state</td><td>Anyone meeting criteria specified by prescriber</td><td>Anyone meeting criteria specified by licensing board</td><td>Anyone for whom medication is indicated</td></tr><tr><td rowspan="2">Target overdose risk population served</td><td rowspan="2">People who use drugs (prescription opioids, heroin) who access the community-based organization*</td><td>People who use drugs who are in treatment/visit a prescriber*</td><td>People who use drugs (prescription opioids, heroin) who visit a pharmacy*</td><td>People who use drugs (prescription opioids, heroin) who visit a pharmacy*</td><td>People who use drugs (prescription opioids, heroin) who visit a pharmacy*</td><td>People who use drugs (prescription opioids, heroin) who visit a pharmacy*</td></tr><tr><td>Patients prescribed opioids who are at risk of overdose*</td><td>Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*</td><td>Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*</td><td>Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*</td><td>Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*</td></tr><tr><td>Geographic reach</td><td>Limited to where community-based organizations are located and operate</td><td>Limited to where the prescriber practices</td><td>Any participating pharmacy within the state</td><td>Any participating pharmacy within the state</td><td>Any participating pharmacy within the state</td><td>Limited to where the pharmacist practices</td></tr></table>
bfa7941d50b2bfa09ea59019bf9e49dda7cb4b5e469bb417b9350a07c59a8cbd.png
complex
<table><tr><td rowspan="2">Group (<i>n</i>)</td><td rowspan="2">M/F,<i>n</i>(missing data)</td><td rowspan="2">Age at death, yr (mean &#177; SD)</td><td colspan="3">Sections available,<i>n</i></td></tr><tr><td>Frontal</td><td>Temporal</td><td>Hippocampal</td></tr><tr><td>Controls (32)</td><td>14/18</td><td>72.0 &#177; 21.0</td><td>19</td><td>32</td><td>31</td></tr><tr><td>AD (46)</td><td>23/23</td><td>72.0 &#177; 6.0</td><td>46</td><td>41</td><td>41</td></tr><tr><td>MND (25)</td><td>20/5</td><td>64.3 &#177; 12.0</td><td>17</td><td>25</td><td>24</td></tr><tr><td>FTLD (72)</td><td>41/31</td><td>65.6 &#177; 9.1</td><td>71</td><td>66</td><td>60</td></tr><tr><td> FTLD-tau (31)</td><td>14/14 (3)</td><td>67.2 &#177; 9.6</td><td>31</td><td>25</td><td>25</td></tr><tr><td><i>MAPT</i> (5)</td><td>2/3</td><td>62.2 &#177; 5.4</td><td>5</td><td>4</td><td>4</td></tr><tr><td>Pick (26)</td><td>12/11 (3)</td><td>68.3 &#177; 10.1</td><td>26</td><td>21</td><td>21</td></tr><tr><td> FTLD-TDP (41)</td><td>26/15</td><td>64.7 &#177; 8.7</td><td>40</td><td>41</td><td>35</td></tr><tr><td>Type A (17)</td><td>8/9</td><td>68.7 &#177; 4.2</td><td>17</td><td>17</td><td>14</td></tr><tr><td>Type B (14)</td><td>12/2</td><td>58.3 &#177; 9.0</td><td>13</td><td>14</td><td>12</td></tr><tr><td>Type C (10)</td><td>6/4</td><td>66.5 &#177; 9.4</td><td>10</td><td>10</td><td>9</td></tr></table>
ba3fe273bf307ea927487572b943005ab1e0705346494847a687ff7b20062341.png
simple
<table><tr><td></td><td>Patients<i>n</i></td><td>Tested forvitamin Dlevels (%)</td><td>Deficientor severelydeficient<sup>a</sup> (%)</td><td>Minimum level ofvitamin D for bonehealth<sup>b</sup> (%)</td><td>Vitamin D at&gt; 75 nmol/L</td></tr><tr><td>Male</td><td>14</td><td>8 (57)</td><td>6 (75)</td><td>2 (25)</td><td>0 (0)</td></tr><tr><td>Female</td><td>42</td><td>19 (45.2)</td><td>15 (79)</td><td>4 (21)</td><td>0 (0)</td></tr><tr><td>White</td><td>39</td><td>18 (46.1)</td><td>13 (72.2)</td><td>5 (27.8)</td><td>0 (0)</td></tr><tr><td>BME</td><td>17</td><td>9 (52.9)</td><td>9 (100)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>Total</td><td>56</td><td>27 (48)</td><td>22 (81.5)</td><td>5 (18.5)</td><td>0 (0)</td></tr></table>
b61b3f7ba9c10d05749fb9ac3ce96b9d1a86e74e9623587997bd15d5fde4523c.png
simple
<table><tr><td>Term</td><td>Count</td><td><i>P</i>-value</td><td>Genes</td></tr><tr><td>Regulation of transcription, DNA-dependent</td><td>105</td><td>4.82E&#8211;06</td><td><i>REST, RORA, ZNF254, HOXC6, TDGF3, GATA6, TDGF1, OLIG2, MLL3, PITX2, NODAL, EMX2, ZNF814, EOMES, SUZ12, HES5, SOX7, LIN28A, NR2C2, ARX, FOXH1, LHX9, DNMT3A, SALL4, FOXA2, NR6A1, PAX3, GLI2, POU5F1, HEY2, ZNF720, SOX10, NANOG, DMRT3, OTX2, RUNX1T1, SPEN, HAND1, ISL1, POU5F1B, ATRX, RBAK, THRAP3, PBX2</i></td></tr><tr><td>Embryonic morphogenesis</td><td>26</td><td>3.44E&#8211;04</td><td><i>RBP4, FOXA2, PAX3, GLI2, TDGF3, SPRY2, HAND1, PRKRA, TDGF1, CEP290, NODAL, EOMES, PCDH8, CFC1, DKK1, SALL4, GNAQ, HOXB6, LRP6, PTCH1, MAB21L2, PBX2</i></td></tr><tr><td>Lung development</td><td>11</td><td>0.004697</td><td><i>SPRY2, RBP4, FOXA2, PDGFA, GATA6, DHCR7, NODAL, VEGFA, GLI2, FOXP1, KDR</i></td></tr><tr><td>Regulation of neurogenesis</td><td>13</td><td>0.026608</td><td><i>PHOX2B, NBN, BMP2, FOXA2, REST, ISL1, GLI2, RUFY3, HES5, CCND2, NUMB, NEFM, ASPM</i></td></tr><tr><td>Forebrain development</td><td>16</td><td>7.60E&#8211;04</td><td><i>OTX2, EMX2, GLI2, ISL1, AHSG, ARX, SALL3, ATRX, FEZF2, DKK1, GNAQ, NUMB, PAFAH1B1, LRP8, RELN, ASPM</i></td></tr><tr><td>Neuron differentiation</td><td>32</td><td>8.12E&#8211;04</td><td><i>FGFR1, FOXA2, ONECUT2, GRIN3A, PAX3, RORA, GLI2, PTEN, CXCL12, KLHL1, ARX, KAL1, NUMB, CEP290, OLIG1, PAFAH1B1, OLIG2, RET, BHLHE22, OTX2, EMX2, LIFR, ISL1, CDKN1C, SALL3, FEZF2, EPHA4, ADM, GNAQ, HES5, VEGFA, RELN</i></td></tr><tr><td>Cerebral cortex development</td><td>6</td><td>0.008017</td><td><i>ARX, EMX2, LRP8, PAFAH1B1, RELN, AHSG</i></td></tr><tr><td>Telencephalon development</td><td>7</td><td>0.038287</td><td><i>ARX, SALL3, EMX2, LRP8, PAFAH1B1, RELN, AHSG</i></td></tr></table>